|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/12/22 ¤U¤È 01:11:24²Ä 2920 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j 21¤é¦¤W6ÂI59¤À¶K¤å 1§ÜÅé®Ä»ù»P ¨Æ¥ó¼Æ 30 32 11 4 ¬O¦p¦óºâ¥X¨Óªº ? ( 50 21 ¥i¥H²z¸Ñ ) 2 ¹w¦ô¤U±¤T²Õ MOS ¬ù¦h¤ÖÓ¤ë? IgG >= 1:160 112¤H (50% ) 4 year survival 78.1% IgG >= 1:320 84¤H (38% ) 4 year survival 85.9% IgG >= 1:640 50¤H (22% ) 4 year survival 91.8% |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/12/21 ¤W¤È 11:37:14²Ä 2919 ½g¦^À³
|
¥ô¤j ¥H¼í®õ³o¼Ëªº eps¡A´«¨ì¤£¦P²£·~ªºªÑ²¼¡A¥«³õµ¹ªº»ùȳ£·|¤£¤@¼Ë ¦Ó¥xÆWÁÙ¦b¾Ç²ß¦p¦óµû»ù¥Í§ÞªÑ¡A¤£¥i§_»{¡Anªø´Á§ë¸ê¯E¹©¡A¤j·§³£n¦³·í¥ý¯Pªº·Ç³Æ |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/12/21 ¤W¤È 11:21:45²Ä 2918 ½g¦^À³
|
¦A¦¸·PÁ²q·Q¤j.CliFF¤jªº¸Ô²Ó¸ê°T |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/12/21 ¤W¤È 11:15:56²Ä 2917 ½g¦^À³
|
¥J²Ó¬Ý¬Ý¼í®õ¶°¹ÎªºªÑ²¼.¦^ÀY¬Ý¬Ý¯E¹©§AÌ´Nª¾¹D¥¼¨Óªº¤U³õ·|¦p¦ó ¼í®õ¥þ³Ìªñ£¸¦¸²{¼W70¤¸.³Ìªñ¨â¦~³£ÁȤK¤¸.¥Ø«e¤¤Q´X¤¸ ¯E¹©£¸¤ò¨SÁÈÁÙ¦³¨â¦Ê¦h.ÁÙ¤£«OÃÒ¥¼¨Ó¨â¦~¯àÁÈ¿ú.. ·í¯E¹©¶^¯}ÃöÁä»ùªº®ÉÔ.¥«³õ§â¥Lªº¯«¸Ü·b¯}¤F.¨«¤U¯«¾Â«á.½Ð¥æ¥X¦¨ÁZ ¤j¹Ú½Ö¥ý¿ô.§Úª¾¹D§Ú³Ñ¾l¨S¦³´î½Xªº³æ¤l.À³¸Ó·|«ÜºG..ÁÙ¦n¤£¦h ½Ð§O¦b¥Î±Ï¤Hªº¡§ÃÄ¡§..¨Ó®`§ë¸ê¤H |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2016/12/20 ¤U¤È 09:49:02²Ä 2916 ½g¦^À³
|
dear ALL º¥ý§ÚÌ¥²¶·¥ýÅý¦Û¤v¦³Áû²M´·.¤£³QªÑ»ù¼vÅTªº¤ß ¤Úµá¯S»¡¹L:»ù®æ¬O§A©Ò¥I¥Xªº.¦Ó»ùȬO§A©Ò·|±o¨ìªº §A§Ú³£ª¾¹D¯E¹©ªº»ùȦb¨º¨à ¦ýªÑ»ù¶^Á`·|Åý¤H¥¢¥h¤F²z´¼ ªÑ»ùº¦Á`·|Åý¤H¥Rº¡¼ÖÆ[ ¤j¤T´Á¬O¥²nªº¸g¾ú¹Lµ{(¤£·|¬O¤p¤T´Á) ¦ý¬O ¯u¥¿Åý¯E¹©¨ú±oÃÄÃÒªº¬OÁ{§É¤G´Áªºos.¤ÎBTD ¸ò§Ö³t³qÃöªº¨ú±o ³o¨Ç¨Æ±¡¦³¥i¯à¦b10´XӤ뤧«á´Nµo¥Í¤F¤£·|«Ü¤[ µM¦Ó ¬°¦ó¦³¤H¤´µM´±©ñªÅ©O? þª¾¨rÆN´±¦b¹ï¤â¾Ö¦³60%ªÑÅv®É©ñªÅ©O? þþ¤§²Â¨rÆN´±©O¡K.¤S¤£¬O§ä¦º»¡ §Ú§@¹Ú¹Ú¨ì¦³ÓÂi±¤W®aÂi±¤U«ùªÑ¶W¹L50%ªºªÑªF ¦]¬°±N¨Ó±ÂÅv«á¤jªÑªF¥²¶·nÄÀªÑ ¥L·íµM¤£·Q¯E¹©¹³¥x¿n¹q ÂE®ü³o¼Ë³Q¥~¸ê§â«ù ¥Lªº¤H®æ¯S½è¦Ü¤Ö³£·Qºû«ù¤@Ó¥i¥H§Ü¿Åªºª¬ªp ©ó¬O±z»¡ªº±¡ªpµo¥Í¤F....250¶^¨ì200°¨¤W®³¥X20»õ ¯E¹©«oÅý¥L¶VÀ£¶V§C n¬~¥XÄw½X §Y¨Ï230¶R±o¥H«á1000½æ¥XÁÈ»ù®t¤]¬°¼Æ¤£¤Ö nª¾¹D¨Ã¤£¬O¨CÓ¤H³£¦³±i©¾¿Ñªº¥¿¬£ ¸ò³¢¸³ªº¥¿È §Ú̱¹ï¹Dªº¬O¤@Ó±M¨«ªk«ßÃä½tªº¸gÀçªÌ ²{¦bªÑ²¼½æ±¼ªº¤@©w·|«á®¬ ¨ì®É§Q¦h®ø®§ ©Î¦¬ºô®É¶¡¤@¨ì ¦o¨CÅ¥µ¹§A¨ÓÓ¸õªÅº¦°± ¤U³æ20±i¥i¯à¥u¶Rªº¨ì¨â±i ©Ò¥H §ÚÌ¥²¶·n¦³¤@Áû¿W¥ß°·¥þ«ä¦Òªº¯à¤O ¯E¹©¦b±z¤ß¥Ø¤¤ªº»ùȬO¦h¤Ö? §Ú·Q700-800¬O¶]¤£±¼ªº 200¦h¤¸ªº¶W¶^ªÑ»ù¯àºû«ù¦h¤[? ¤p§Ì¥¿·Ç³Æ¦bÄw¤@µ§¿ú¶i³õ¾ß«K©y~¨ìþ¸Ì¥h§ä¨º»ò«K©yªº¯E¹©»ù®æ©O? ¾ß«K©y ²{¦b¬O®ÉÔ ¤£µM§O³Q¨rÆN¾ß¨«¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/19 ¤U¤È 08:02:12²Ä 2915 ½g¦^À³
|
¹ï¤£°_ ¸É¥R¤@¤U ¿ÕµØÅܧ󪺳sµ² https://clinicaltrials.gov/archive/NCT02460224/2016_06_02/changes Åܧó«áªº±Ôz https://clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&rank=1 Criteria Inclusion Criteria: Phase I part: - Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists Phase II part: .Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups: .Group 1: NSCLC .Group 2: Melanoma .Group 3: Renal cancer .Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 .Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution¡¦s guidelines. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/19 ¤U¤È 07:46:09²Ä 2914 ½g¦^À³
|
¥ÑCliff ¤j®¦¼w ªº´£¥Ü Åý¤p§Ì±o¥H»{ÃѨä¥Lªº§K¬ÌÀˬdÂI TIM-3 ¤Î LAG-3 TESARO ¤½¥q´¿¤½§G¤@¥÷¦³ÃöPD-1; TIM-3;LAG-3 ¹«Åé¸ÕÅ窺²n¤Û¿O¤ù³ø§i https://www2.anaptysbio.com/wp-content/uploads/2015/09/AACRApr2015.pdf ²Ê²¤¦aÂI¥X : Áp¦X¤ñÓ§O¦n , ¦Ó( PD-1§í¨î¾¯+ LAG-3§í¨î¾¯ ) ªº®ÄªG ¤S¤ñ ( PD-1§í¨î¾¯+ TIM-3§í¨î¾¯ ) ¨Ó±o¨Î ©Ò¥H¤p§Ì´N¥H¸û¨ÎªºLAG-3§K¬ÌÀˬdÂI§í¨î¾¯¨Ó»¡©ú ½Ð°Ñ¦Òhttp://cancerres.aacrjournals.org/content/72/4/917 ³o¥÷³ø§i ¤w¦p«ez , ¦b¹«Åé¤WLAG-3ªº³æÃĮĪG , ¨Ã¤£·|¤ñPD-1 §í¨î¾¯¨Ó±o¦³®Ä ¦ý¬OY©MPD-1§í¨î¾¯Áp¦X , ¦b´I©óCD8+ TILªº¸~½F¤W ( ½Ðª`·N³oÓ±ø¥ó , ¦b¤HÅéÀù²ÓM¤Wªºªí²{µ{«× , ¤p§ÌÁÙ¨S§ä¨ì¬ÛÃö¸ê®Æ , ³o¬O¸Óµ¥§K¬ÌÀøªk¤ÏÀ³»P§_ªºÄpµ²(?) ) ¹ï¨âºØ¸~½F®ÄªG«Ü¦n , µM¹ï¥t¤@ºØÀù²ÓM«h§¹¥þµL®Ä ( ¹êÅç¥u¥Î¤TºØÀù¯g²ÓM®èªº¦Ñ¹« ) ¤£¹LY¾¯¶q¹L°ª , ¥i¯à¦s¦³§K¬Ì·¼Éªº°ÝÃD ? ¦Ó¦b¤HÅéÁ{§É¤W , ´N¤âÃ䪺¸ê®Æ , ¥HBMS ¶]³Ì§Ö , ¿ÕµØºò°l¦b«á , ¨ä¥LÁÙ¦³¤¤¤p«¬Ãļt¤]¦b°µ ( 1 ) BMS ªº NCT 01968109 2013/10/31 ¶}©l©Û¶Ò , ¥»¨Ó¥u¬Ý¦w¥þ©Ê.¾¯¶q , «o©ó¨â¦~«á2015/10/21 , ±NSecondary_outcome¼W¥[BOR/ORR/DCR¡Kµ¥¦h¶µÆ[¹îÀø®Äªº«ü¼Ð https://clinicaltrials.gov/archive/NCT01968109/2015_10_21/changes ³o¥i¯àªí¥Ü : ±q¦w¥þ©Ê¶i¶¥¨ì¦³®Ä©Ê©Ò°µªº½Õ¾ã? ¦ý¤À²Õ¸Ì±¨S¦³©Û¶ÒBC±wªÌ ( ¦ó¥H¨S¦³ ) ( 2 ) ¿ÕµØ ªº NCT02460224 2015/11/09¶}©l©Û¶Ò , 2016/06/26 ±N쥻¤À¬°10²Õªº¤£¦P¾AÀ³¯g±wªÌ , ÁY´î¬°NSCLC / Melanoma / Renal cancer ¤T²Õ ³o©Î¤]ªí¥Ü : ¦bLAG-3 Áp¦X PD-1 ªºªvÀø¤W , ¥i¯à³o¤TºØÀù¯gÀø®Ä¸û¨Î , ¦Ó³Q¾ÜÀuÄ~ÄòÁ{§É? ¤]¨S¦³BC ( ¦ó¦] ) ¥H¤W¨âÓ¨Ò¤l , ·Pı¤W³£¦üÁ{§É°µ¨ì¬Y¶¥¬q , ¨Ìª¬ªp©Ò°µªº½Õ¾ã§ó°Ê? ¯E¹©833¦b 2016/12/01©Ò°µªºÅܧó ¬O§_¤]¦p¤p©_¤j¤j©Ò±À´ú ¬O¤½¥q¬Ý¨ì§ÜÅé®Ä»ù.Àø®Äµ¥¼Æ¾Ú«á , ¹Á¸Õªº¶i¶¥¤§§@? °²¦p¬O³o¼Ë , ¤p§Ì´Á«Ý833¯à§ó¤W¤@¼h¼Ó , ¬°¯E¹©¦b°ê»ÚÄvª§¤¤ª§±o¤@®u¤§¦a , 888¤]¬O ¯E¹©ªºGH¾÷¨î»P¤H¤£¦P , Áö¦³Ävª§¦ý¤]¥iÁp¦X¬°¤§, ¤Æ¼Ä¬°¤Í , ³o©Î¬O¯E¹©ªº³Ì¤jÀu¶Õ------ ¤p§ÌªºÃ¨¤ß¦k·Q ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/12/19 ¤U¤È 07:32:37²Ä 2913 ½g¦^À³
|
·PÁ²q·Q¤j¤À¨É |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/19 ¤U¤È 06:38:32²Ä 2912 ½g¦^À³
|
¦Û±q Theratope¬Ì]¡]STN-KLH¡^¤T´ÁÁ{§É¥¢±Ñ«á ¦A¬Ý¤@¦¸¥¦ªº³ø§i¡Ahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228158/#!po=40.3846 ¥¦ªº¤¤¦ì§ÜÅéºw«×¥i¹F10,240¡]IgM)¡F20,480¡]IgG¡^ ¬Û¹ïªº¡A822 »P¥¦¦³¦P¼Ëªº¸üÅé©M¦õ¾¯¡A«o¥u¦³160 ¡A¬Û®t¹F64¤Î128¿ ¤HÅé´N¬O³o»ò©_§®¡A¤£¸ÕÅç´N¤£ª¾µ²ªG¡AÃø¥H®M¥Î Theratope¦³±j¤j§ÜÅé¡A«o¦]§Ü줣·í¦Ó¥¢±Ñ 822 ¦³«Ü´Îªº§ÜìGH¡A¬Û¹ï¦a¡A§ÜÅé²£¥X¤£Y¤H¡AÁÙ¦bµ¥OS ¤£ª¾833 ¯à§_¦³¥X¦âªºªí²{¡H¡I ¶È¨Ñ°Ñ¦Ò¡AÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/12/19 ¤W¤È 12:01:24²Ä 2911 ½g¦^À³
|
1°²¤éŪ¨ì¤@½gÃö©ó¦p¦óµû¦ô¥Í§Þ¤½¥qªº¤å³¹¡A¬Û«H¤j®a¤@©w«Ü·P¿³½ì¡A^¤å¤£¬O«Ü¦nªº¯E¤Í¤£¥Î¾á¤ß¡A¨Ï¥ÎGoogle½Ķ¤@©w¬Ý±oÀ´ How to do qualitative analysis on biotech companies. ¤@±¾\Ū¤@±«ä¦Ò¯E¹©¬O§_²Å¦X¤å³¹ªº½×z¡A ³o¼Ë´N¤£·|³Q»X½ª¯u¬Û ¡C 2¯E¹©¦bµ¥«Ý¤@Óbest timing ¦A¥X¤â¨q¦Ù¦×¡A§â¯E¹©¬Ýªº¤ÓªÅ¤j¥i¤£¥²¡C |
|
|
·|û¡GEmelianenk10143395 µoªí®É¶¡:2016/12/18 ¤U¤È 05:14:29²Ä 2910 ½g¦^À³
|
²³¤j¤j¦w ¤p§Ì¦³´XÓ¤p°ÝÃD½Ð±Ð (1) ¸Ñª¼ªºdata¬O28Ó¤ëor32Ӥ몺©O? (2) ©Ò¿×ªº28Ó¤ë(or 32Ó¤ë)¬O«ü²Ä¤@Ó¨ü¸ÕªÌor 60%ªº¨ü¸ÕªÌ? (3) 2015/10 data lock«á, ¤½¥qª¾¹D¥Ø«eªºPFS or OSªº¼Æ¾Ú¶Ü? (4) ´N¥Ø«eªº¼Æ¾Ú, ¦³¿ìªk§PŪpfsµLªk¹F¼Ð, ¬O¦]¬°¨ü¸ÕªÌªºIgG<160 or ¦¬®×±ø¥ó©Ò¼vÅT©O(NED,CR.PR,SD)? ·PÁ²³¤j¤j |
|
|
·|û¡GµL¹Ð10141268 µoªí®É¶¡:2016/12/15 ¤U¤È 10:45:07²Ä 2909 ½g¦^À³
|
¥Í©R¦³Ó¥X¤f¤]¦n |
|
|
·|û¡G¦³¹Ú³Ì¬ü10141895 µoªí®É¶¡:2016/12/15 ¤U¤È 10:28:15²Ä 2908 ½g¦^À³
|
¤£À´³o¨Çn¤HÃöª©ªº¤ßºA¡Aˤ£¦p½æ¤@½æºâ¤F¡A·Ð´o´N¤£¨£¡I³o¨Ç±M·~ªº¤j¤j¡A¦³¨C¤Ñ¦b¨ºÃä³Û¦h©MªÅ¶Ü¡HˬO¦³¤ß¤H¬G·N¦b¨ºÃä³yÁÁ¥Í¨Æ¡A±µµÛ´N¦³¤H»DÂû°_»R¡C¹É¹É |
|
|
·|û¡GAnna10139604 µoªí®É¶¡:2016/12/15 ¤U¤È 09:47:37²Ä 2907 ½g¦^À³
|
¸Û¼°¦a«Øijª©¥D¡AÃö¤F¯E¹©ªº©Ò¦³ª©§a¡I§Ú¬Û«H¤£¤Ö¤H³£¦bÃöª`¦¹ª©¡A¦¨¬°¦³¤ß¤H¤W¤U¨ä¤âªº«´¾÷¡C¤p©f¥Ñ°J¦a·PÁÂ¥xÁÞ¤j¡Bcliff¤j¡B¤Ñ©R¤j¡B²q·Q¤jµ¥⋯¦U¦ì¥O§Ú´L·qªº«e½úÌ´£¨ÑªºÄ_¶Q¸ê®Æ¡A§Ú·Q«áÄò´NÅý¤j®a¦Û¦æ°µ¥\½Ò¦Û¦æ§ë¸ê§a⋯⋯¡A¯u¥¿·Q§ë¸êªº£¸©wÀ´¡B£¸©w·|¦Û¤v°lÂܪº¡A¤j®a¦U¾Ì¥»¨Æ§a⋯⋯ |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/12/15 ¤U¤È 09:29:16²Ä 2906 ½g¦^À³
|
250 ~ 321 ³o¤@°Ï, ´²¤á¼W¥[«Ü¦h, ¦pªGnÅý³o¤@°Ï´²¤á®M¨ì¦³·P ¥Ø¼Ð»ù¤£´N¬O 1 ¦rÀY? |
|
|
·|û¡Gsw375285510142190 µoªí®É¶¡:2016/12/15 ¤U¤È 08:36:41²Ä 2905 ½g¦^À³
|
·|³o¼ËºC©Ê¶^ ¸ò³oÃäµo¨¥¦h¤Ö¦³ÂIÃö«Y§a ·d±o´²¤á®M¤@°ï¤]¬~¤£°®²b ¤t´¶nÀ£§C°ª»ùÃÄ,³o¼Ë¹ïÀùÃĪÑ(°ª»ù¸s²Ä¤@¦W)©ú©ú¬O§QªÅ ³£¯àÅܦ¨§Q¦h.... |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/12/15 ¤U¤È 05:44:59²Ä 2904 ½g¦^À³
|
n°_¶D´N§ÖÂI°_¶D¡A¤£n§é¿i§O¤H |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/12/15 ¤U¤È 05:18:18²Ä 2903 ½g¦^À³
|
·Ó³o¼Ë»¡¡A¤£¯} 250 ÁÙ¨S¿ìªk¬~¥X¯u¥¿ªº¯BÃB§r |
|
|
·|û¡Gsuperjoe10141522 µoªí®É¶¡:2016/12/15 ¤U¤È 04:55:40²Ä 2902 ½g¦^À³
|
¥u¬O¦³Å¥»¡À˹î©x°_¶Dªº®ø®§? ¦ýªÑ»ù¤]¨S¶^¦h¤Ö, ³oºØºC©Ê¶^ªk¹ï´²¤á¨Ó»¡,¯u¬O³ÌÃøÀ³¥Iªº,½æ¤]¤£¬O,¶R¤]¤£¬O ¦ÒÅç¦pªG¶^¯}250, ½T¤S¨S°±·l¥¨¶q,¨º´N·ò·Ð¤F! |
|
|
·|û¡G¤p¯E°g10137673 µoªí®É¶¡:2016/12/15 ¤U¤È 04:39:38²Ä 2901 ½g¦^À³
|
½Ð°Ý¤µ¤Ñ«æ±þ¨º¤@¬q¬O¦³Å¥»¡À˹î©x°_¶D¶Ü¡AÁÂÁ¡C |
|
|
·|û¡Gsw375285510142190 µoªí®É¶¡:2016/12/15 ¤U¤È 04:31:29²Ä 2900 ½g¦^À³
|
¬Ý¤F³oª© §Úª¾¹D¬°¦ó¥ý«e¦³¤HnÃöª©¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/12/14 ¤W¤È 01:14:45²Ä 2899 ½g¦^À³
|
¾Ç²ß¿W¥ß«ä¦Ò ¬Ý§O¤H¬Ý¤£¨ìªº¦a¤è PFS 33 Ó¤ëÁÙ¤£°÷ÅåÆv¶Ü? ¤w°±ÃÄ2¦~¤FC ! ¦pªGÄ~Äò¬I¥´·|«ç¼Ë? ¶PÀù¥PFS ¬ù6Ó¤ë OBI822ªºbenchmark ¬O9Ó¤ë, ¦³²£¥Í§ÜÅ骺PFS ¬ù11.1 -17.6 Ó¤ë (822 PFS ¤]¦³®Ä ¤w¶W¹Lbenchmark) OS §ó¥O¤H´Á«Ý °_¨Ó¤W´Z©Ò¬Ý¨ì¹j¾Àª©ªº°Q½× ¥H¤W²³æ¦^À³ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/9 ¤U¤È 06:19:16²Ä 2898 ½g¦^À³
|
«z¡I Cliff ¤j®¦¼w ³o»ò²Ó¿°¡B±M·~ªº¤º®e ¥u¦³±z¤~·|ª¾¹Dphase 1 ªº±M·~«× ¤]¥u¦³±z¦³¯à¤O½×z ¤pªº¸ò±zªº¯Z¡A³£«Ü¦Y¤O¤F¡A¦ó½×¥ý¹w²ß ±z¶}ªº®Ñ³æ¡A¤pªº¥u¯à«j¤O¬°¤§¤F ÁÂÁ±zªº«ü¾É ¸U¤À·PÁ¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/12/9 ¤U¤È 03:25:11²Ä 2897 ½g¦^À³
|
²q·Q¤j¤j ¤µ¤Ñâ±áªº¶K¤åµ¹±zªº¦^µª¤º®e¤Ó½§²L¡A«á¨Ó±o¨ì¤@¨Ç½×z¡A°ß®£½§²Lªº¤º®e»~¾É¤F±z¡A©Ò¥H¥ý½Ðª©¥D§R¤F¡]µ¹ÄP¤¸¥Sªº¦^µª¤º®e«h¬O¥¿½TµL»~ªº¡A¥L¤w¬Ý¨ì¤F¡AÀ³¸Ó¤£¥Î¦A¸É¶K¤F§a¡H¡^ 833¤@´Á¸ÕÅç§ó§ï¤@¨Ç¤º®eì¦]¬°¦ó¡A©Î³\¦p¤p©_¤jªº±À½×¡A§Ú¤£½T©w¡C§Ú¥u¯à´£¨Ñ¤wª¾ªº³¡¤À¡Aºç¤¤·L¨¥¤j¸qn¾a«¥Ì¦Û¤v¨Ó¥Î¥\¡A§Ú¥uµo²{³o¬O«Ü±M·~ªº¡A§Ú¤Ó¤p¬ÝPhase I¤F¡A¤~³s©]§R¤å¡A©Ò¥Hµ¹³ßÅw¬ã¨sªº±z¡A´£¨Ñ¸ê®Æµ¹±z¥ý¬ã¨s¬ã¨s¡A§Ú¤]ÁÙ¨SŪ¡Aµ¥¦£¹L³o¤@¶g¡A12/20¥H«á¤p§Ì¦A¤W¨Ó¦V±z½Ð¯q¡C ÃöÁä¦r¡G ¨å«¬3+3³]p¡]www.tma.tw/ltk/100540404.pdf ¡^ ¡Ø18 for dose escalation phase ¡Ø40 for cohort expansion phase ¬°¤F¸ÕÅç¥Øªº¦Óקï¡A¤£¬O¦Ò¶qªvÀø±Ú¸s¤j¤p¡C «Øij¥ýŪ¤@¤U¡G¡]Ū¹LAbstract & Introduction´N·|¤ñ¸ûÀ´¤F¡^ 2014May13¡]¥ýŪ«e¨¥ªº³¡¤À¡I¡^ Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience (jnci.oxfordjournals.org/content/106/7/dju163.full.pdf+html) 2013 Alexia Iasonos-Design Considerations for Dose-Expansion Cohorts in Phase I Trials ½Ð±qSci-Hub¥h½Õ¥Xì¤å¡CAlexia Iasonos¬OMSKCCªº±M®a¡C ³Ì«á¦A¬Ý³oÓ´N·|«éµM¤j®©¡A¤@´Á¦¬®×¡Ö300¤H¡AºÆ¤F¡HÁÙ¬O¦Û§ä³Â·Ð¡H Anti PD-1 clinical trial¡G A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov/ct2/show/NCT02715284) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/9 ¤U¤È 02:18:41²Ä 2896 ½g¦^À³
|
¤p©_¤j¤j¡A¦n«Óªº±À·Q¡I ¤p§Ì³Ì´Ü¨Ø±zÅÞ¿è±À²zªº¯à¤O ¯à¥HESMOªº¸ê®Æ¡A³sµ²833ªº¥i¯à°ª®Ä»ù¡A±À½×¥X¤½¥q¦³·N¬D¾Ôªº·N¦V °t¦X¤t´¶¹Î¶¤¤§»¡ ¦ü¥G¬O«Ü¦X©óÅ޿誺±À´ú ¦Ü©ó¹ê±¡¬°¦ó ©Î¥u¯àµ¥«Ý¤½¥qªº¤½¥¬ ¤]³\¦Ñ¤j·|¥ý¤ÀªR¦±§é¡A¤]»¡¤£©w ©êºp¤F¡A¤p§Ì³ßÅw²q·Q¡A¼vÅT¤F±z ¤£¹L¡Aµ²¦X¤j®a¶°«ä¼s¸qªº±À·Q ½ü¹ø©Î¦b¨ä¤¤¨o¡H¡I ÁÂÁ±zºë±mªº±À·Q¡A³oÓ³sµ²¬O¤p§Ì·Q³£¨S·Q¨ìªº µ¹¤F¤p§Ì«Ü¦nªº¤@½Ò¡C ¦A¦¸ÁÂÁ±z¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/12/9 ¤U¤È 01:01:59²Ä 2895 ½g¦^À³
|
²q·Q¤j¡A 833ªº¦¬®×¯Ç¤J±ø¥ó©ó12/1°µ¤F§ó§ï¡A ¤p§Ì²q·Q¤½¥q¬O¤£¬O±q822ªºÁ{§É¼Æ¾Ú¤Î833³o¤@¦~¨Ó¦¬®×¥´°wªº±wªÌ¨¤Wµo²{¤F¤@¨Ç¦³§â´¤ªºªF¦è¡A©Ò¥H°µ¤F§ó§ï¡H 822±o¨ìªºµ²½×¬O¦³§ÜÅ馳Àø®Ä¡A§ÜÅé¶V°ªÀø®Ä¶V¦n¡C¦ý¬O¹ï©ó«DCR,PR,SDªº±wªÌ¥i¯à¨S¦³Àø®Ä(OS¹Ï¤W16Ó¤ë¥H«e¹êÅç²Õ»P¹ï·Ó²Õ¦±½u¨S¦³¥ô¦ó®t²§¡A³o¨Ç¥i¯à¬O¬Ý°_¨ÓCR,PR,SD¦ý¹ê»Ú¤W¸~½F¤@ÂI¤]¤£stableªº±wªÌ)¡C 833³o¤@¦~¨ÓÁöµM©Ò¦¬ªº±wªÌÆ[¹î¤´¦b¶i¦æ¤¤¡A¨ì¥Ø«e¬°¤îÆ[¹î¨ìªºª¬ªp¬O§_§C°Æ§@¥Î»P¹w´Á¤@P¡A©Ò¥H¥i¥H¤jÁx©¹¥i¯à¨Å骬ªp§ó®tªº«DCR,PR,SD±wªÌ®¼¶i¡H¦w¥þ©Ê¬Û·í©ñ¤ß¡H 822¦b¨ÅÀù¤W§Y¨Ï¬O°ª§ÜÅ騺¤@²Õ¡A¦b16Ó¤ë¥H«e¤]µo¥Í¤F13Өƥó¡A»P§C§ÜÅé²Õ¦b16Ó¤ë¥H«eµo¥Í¤F18Өƥó®t²§¤£¤j¡A18-13=5ªº®t²§¥i¯à¬O¦]¤À²Õ³y¦¨ªº²Îp®t²§¤ñ¦]Àø®Ä³y¦¨ªº®t²§¦³§ó¦nªº¸ÑÄÀ¡C¦Ü©ó16Ó¤ë¥H«e¹êÅç²Õ¾ãÅé¨Æ¥óµo¥Í²v(13+18=31)/224=13.8%»P¹ï·Ó²Õ¦b16Ó¤ë¥H«eªº¨Æ¥óµo¥Í²v17/124=13.7%´X¥G¤@¼Ë¡C¦]¦¹¤p§Ì쥻¥H¬°822¦b«DCR,PR,SD±wªÌ¨¤W¬OµL¯à¬°¤Oªº¡C¦ýESMO¤½¥¬ªº§ë¼v¤ùÅã¥Ü¡A°ª§ÜÅé²Õ¦bIgG®Ä»ù¤j©ó320»P¤j©ó640¨º¤G²Õ¦³·¥ÅãµÛªº§C¨Æ¥óµo¥Í²v¡AÃø¹D§ÜÅé®Ä»ùn°ª¨ì³oÓµ{«×¤~¥i¥H¹ï¥I«DCR,PR,SD±wªÌ¨¤Wªº¸~½F¡H 833¥H§ó°ªªºIgG¬°¶D¨D¡A¬O§_¤Ö¼Æªº¤w¦¬®×±wªÌ¨¤WÆ[¹î¨ì¤F¹w´Áªº¼Æ¾Ú(°ª®Ä»ù)¡A¦]¦¹¥i¯à¦b«DCR,PR,SD±wªÌ¨¤W¤]¯à±a¨ÓÀø®Ä¡H ¤½¥q¬Ý±o¨ì©Ò¦³ªº¼Æ¾Ú¡A§ÚÌ¥u¯à±q¤½¥qªº°Ê§@¨Ó²q¤½¥q¬Ý¨ìªº¼Æ¾Ú¡A¤p§Ì¨ü±z¼vÅT¡Aº¥º¥¦a¤]³ßÅwªF²q¦è²q¡A¥H¤W¥þÄݶòq¡A³Ì«áÁÙ¬O¥H¤½¥q¤½§iªº¬°·Ç¡C ÁÂÁ±z¡I |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/12/9 ¤W¤È 07:44:51²Ä 2894 ½g¦^À³
|
¦U¦ì¤j¦¦w ·PÁÂcliff¤j¸ÔºÉ¸Ñ»¡ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/9 ¤W¤È 07:31:31²Ä 2893 ½g¦^À³
|
Cliff ¤j®¦¼w¯u¬O¦ò¤ß¨Óªº ¦³°Ý¥²µª¡A¦³¨D¥²À³§r¡I ¸g¥Ñ±zªº¸ÔºÉ¸Ñ»¡¡A¤p§Ì©ú¥Õ¤F¨Æ±¡ªº¨ÓÀs¥h¯ß ÁÂÁ±z¡I ¥»¨Ó¤pªº¬O³o¼Ë·Qªº ¤½¥q¬O¬°¤F¦]À³¤t´¶¹Î¶¤¥i¯à±À¥Xªº¬I¬F³Wµe¡A©Ò°µªº±Ú¸sÂX¥R¡A¼W¥[ªº¤H¼Æ¨Ã¶W¹Lìq¤H¼Æªº¤@¿¦³¾l ¥Ñ517´Á°]°TÂù¶g¥Zªº³ø¾É ¡u¡u ¤t´¶Äv¿ï¹Î¶¤¦b11¤ë11¤é´£¨Ñ°·±dÂåÀø³Wµe¡G¡u§ï²¬ü°ê¹«~º[ÃĪ«ºÞ²z§½¡]FDA¡^¡A§óÃöª`¯f±wªº»Ý¨D»P³Ð·sÂåÀø²£«~¡v¡A ¨Ã¥¼´£¥X§ó¦h²Ó¸`»PÀu¥ý¶¶§Ç¡C¤t´¶¥i¯àÂX¤jright to try¡]¸Õ¥ÎÅv¡^ªº¾A¥Î¡A³oÓªk®×±NÅý¥½´Á¯f±w±o¥H¸Õ¥Î¤w³q¹L¦w¥þÀËÅ窺¹êÅ礤·sÃÄ¡C °ÆÁ`²Î´^´µ¡]Mike Pence¡^±À°Ê¦¹ªk¬Û·í¿n·¥ ¡v¡v ¤½¥q¦b³oÓ®ÉÂI§ó°Ê¡A¦³µÛ®É¶¡¤Wªº¥©¦X©MÅÞ¿è ¥B·s¼Wªº¹êÅç±Ú¸s©Î§ó²Å¦X¡u¥½´Á¯f±w¡vªº´yz¡A ¼W¥[°´¦hªº¤H¼Æ¡A°£¤F¬Ý¦w¥þ©Ê¥~¡A©Î³\ÁÙ¦³Æ[¹îªì¨BÀø®Äªº·N¨ý¡H Y¤@¤Á¦³¬Ü¥Ø¡A©Î¥i´`¦¹¤Á¤J¬ü°ê¥«³õ? ¦P®É822ªº OSY¦³¹F¼Ð¡A¤SÀò¥xÆWÃÄÃÒ¡A¤]¥i¨Ì¦¹¶i¤J¬ü°ê¥«³õ? ¦Ü©ó¯à¤£¯à¬ü¹Ú¦¨¯u¡A´N¬ÝÃĮġB¬ü°êªk³Wµo®i¡AÁÙ¦³¤½¥qªº§V¤O¤F J«ä¶Ã·Qªº³sµ²¡A«¢¡I¤p§Ì´N§â¥¦§ô¤§°ª»Õ§a¡I ¦A¦¸·PÁ±zªº«ü¾É ·P®¦ ¡I |
|
|
·|û¡G¤p¯E°g10137673 µoªí®É¶¡:2016/12/8 ¤U¤È 04:28:52²Ä 2892 ½g¦^À³
|
¤t´¶¥i¯àÂX¤jright to try¡]¸Õ¥ÎÅv¡^ªº¾A¥Î¡A³oÓªk®×±NÅý¥½´Á¯f±w±o¥H¸Õ¥Î¤w³q¹L¦w¥þÀËÅ窺¹êÅ礤·sÃÄ¡C°ÆÁ`²Î´^´µ¡]Mike Pence¡^±À°Ê¦¹ªk¬Û·í¿n·¥¡A¾Ú³ø¸ü¡Aright to try¦b¬ü°ê31¦{±À¦æ¬Û·í¦³¦¨®Ä¡F¥u¬O¡A¦¹Á|®£Åý¦{¬F©²Åv¤Oâ¾rFDA¤§¤W¡C¦P®É¡A¤t´¶©IÆ~¡AÀ³©ñ¼e¤w¦b°ê¥~®Ö㪺ÃĪ«¶i¬ü°ê¾P°â¡C³o¨Ç³£µ¥¦P«d®zFDAªººÞ²zÅv¡C¦¹¥~¡A®z¤Æ«áªºFDA¡A¹ï³\¦h¤w®Ö㪺ÃĪ«¦b¥é³æ¼Ð¥Ü¥~¨Ï¥Î¡]off-label use¡^ÁÙ¦³ªk¥iºÞ¶Ü¡H¥~¬É¼~Án¥|°_¡C¤µ¦~ªì¡AFDA¤~¦V°ê·|n¨D´£°ª8%¹wºâ¡A«Ø¥ß·s¹«~¦w¥þºÊ·þ¨t²Î¡B§ïµ½ÃĪ«µû¦ô¡A¥H¤Î¤ä«ùÀù¯gµn¤ë¡]Moonshot¡^pµe¡F¤£¹L¡A¥~¬É¾á¤ß¡A¤t´¶¤W¥ô±N§R´îFDA¹wºâ¡C¤t´¶ªí¥Ü±N¾ã¹yFDA¡Aº¥ý¬O´î¤ÆÁcº¾³W©w¡AÁ|¾Ç¦WÃĬ°¨Ò¡A¥Ø«e¶W¹L¥|¤d¶µÃĪ«µ¥«Ý®Öã¡A¥¼¨Ó±N¥[³t¼f®Ö¡C¤t´¶·Q³z¹L¥«³õÄvª§¾÷¨î¨Ó½Õ°ÃÄ»ù¡A¤£¦P©ó§Æ©Ô¿¶»EµJ¦b¤Ö¼Æ¤£¦X²zªº°ªÃÄ»ù¡C¡C¥H¤W¸ê®Æ¨ú¦Û°]°T¡C¦pÄݹê¡A¹ï¯E¹©¬O§Q¦h¡C |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/12/8 ¤U¤È 03:33:12²Ä 2891 ½g¦^À³
|
½Ð±Ðcliff¤j¤Î¦U¦ì¤j ¬Ý¨ì³o½g¤å³¹»¡¦b¦Ñ¹«¹êÅ礤.833²£¥Íªº§ÜÅé¬O³Ì°ªªº.¤ñ822ÁÙ°ª.¯u¹ê©Ê¦p¦ó.¬O¥NªíÃÄ®Ä¶Ü ¡iÁÞ¤À¤l§Üì¸~½F¬Ì]-©ñ²´¥@¬É¡j ±q¤G¤Q¤@¥@¬ö¶}©l¡AÀù¯g¬Ì]ªº¶}µo¤w¸gÁÚ¤J²Ä¤GÓ¤Q¦~¡A¸g¾ú¤F¤@¶}©lªº«H¤ßº¡º¡©M²z·Q¡A«á¨ÓªºÀù¯g¬Ì]¤½¥q¦p Cancervax¡BXcyte ¦]¬ÛÄ~¥¢±Ñ¦Ó³Q¾ã¨Ö¡A¨Ï±o¥þ¥@¬É³vº¥¹ïÀù¯g¬Ì]§Þ³N¥¢¥h«H¤ß¡CµM¦Óªñ¦~¨Ó¡A³oÓ»â°ìªº¬ÛÃö¬ã¨s¤S«·s¿U°_Àù¯g¬Ì]¥i¯à¶}µo¦¨¥\ªº·s§Æ±æ¡A2010 ¦~¬ü°ê Dendreon ¤½¥qªº Provenge ÃĪ«¡A³q¹L FDA ®Öã¥Î©óªvÀø«e¦C¸¢Àù¡A¥D°Ê¦¡§K¬ÌÀøªkªº¸~½F¬Ì]©Î³\±N¦¨¯u¡C¦Ó¥xÆWªº¦³Ãö¬ã¨s¤]¤£¸¨¤H«á¡A²Ä¤@¥NÀù¯gÁÞ¤À¤l¬Ì] GH-KLH/QS21¡]OBI-822¡^ ¤w¸g¶¶§Q¦a¶i¤J¤F²Ä¤T´ÁÁ{§É¸ÕÅç¡A¬ÛÃö¸ÕÅçµ²ªG³Ì§Ö¦b 2015 ¦~´N·|¥XÄl¡I³o¶µ¬ð¯}©Êªº³Ð·s¬ã¨s¬O¥Ñ¥xÆW¤¤¥¡¬ã¨s°|°|ªø¯Î±Ò´fªº¬ã¨s¹Î¶¤¶i¦æ¡A¥ḺNÀù¯g¬Ì]ªº¶}µoµÛ«©ó°w¹ïÀù²ÓMªí±ªº¹èÁÞ¤À¤l§Üì¡ÐGlobo H.¡C Globo H¡]GH¡^¬O¤@ºØ¥Ñ6Ó³æÁާΦ¨ªº¹èÁÞ¤À¤l¡A¦b¦hºØÀù¯g²ÓM¤W¯S²§ªí²{¡A¯S§O¬O¦b¤W¥Ö¡]epithelium¡^²ÓMÀù¡A¦p¡G¨ÅÀù¡BªÍÀùµ¥¡C¥Ñ©óÁÞÃþ¤À¤l¨Ã¤£¬O¤@ºØÀu¨}ªº§Üì¡AµLªk¦³®Ä¤Þµo§K¬Ì¤ÏÀ³¡A©Ò¥H¬Ì]¤¤ÁٻݦA¥[¤W¯à²£¥Í¨}¦n§K¬Ì¤ÏÀ³ªº¸üÅé³J¥Õ¡]carrier protein¡^©M¨ë¿E§K¬Ì²ÓM¬¡¤Æªº¦õ¾¯¡]adjuvants¡^¡C¬°¤F¬D¿ï¥X³Ì¨Îªº¸üÅé³J¥Õ¡A¤¤¬ã°|¹Î¶¤¦X¦¨¤F 4 ºØ±µ¦X¤£¦P³J¥Õªº GH ¬Ì]¡A³o¨Ç¸üÅé³J¥Õ¥]¬A¥Õ³ïÃþ¬r¯À¡]diphtheria toxoid, DT¡^¡BÆ_¤Õ´U¨©¦åÂůÀ¡]keyhole limpet hemocyanin, KLH¡^¡B¯}¶Ë·Ãþ¬r¯À¡]tetanus toxoid, TT¡^©M¤û¦å²M¥Õ³J¥Õ¡]bovine serum albumin, BSA¡^¡A¨Ã·f°t¤F6ºØ¤£¦P¦õ¾¯¡]C1, 7DW8-5, C34, C17, AlPO4, MF59¡^¡Aª`¤J¨ì¹êÅç¦Ñ¹«Å餺´ú¸Õ¨ä¤Þµoªº§K¬Ì¤ÏÀ³®ÄªG¡C¹êÅçµ²ªGÅã¥Ü·f°t¥Õ³ï¬r¯À©M C34 ¦õ¾¯ªº GH-DT/C34 ¬Ì]¡A¯à²£¥Í³Ì°ª¶qªº GH-specific IgG¡A¥Ø«e¸Ó¬ã¨s¹Î¶¤¤w¸g±N³oÓÃĪ«§Þ³NÂಾµ¹¥Í§Þ¤½¥q¡A¶}µo¦¨¬°²Ä¤G¥NÁÞ¤À¤l¬Ì]¡]OBI-833¡^¡A¤é«e¤w³q¹L¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¤HÅéÁ{§É¸ÕÅç¼f¬d¡]IND¡^¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/8 ¤U¤È 02:20:15²Ä 2890 ½g¦^À³
|
ÁÂÁÂCliff¤j®¦¼w¥t¤@Æ[ÂIªºåªR ¨º¤Ñ¤p§Ì¼g¤Ó§Ö¡AÀ³¼g¬°¸û«e½uªvÀø¡A¤~¦X¹ê±¡ ¤S¨Ì±zªº¬Ýªk¨Ó±À´ú ¬O§_¬O¤½¥q«á¨Óµoı±Ú¸s²[»\¤£©P©µ¡A¦Ó§@ªº¸É±j ¦Ó«D¤p§Ì©Ò²q´úªº ---¡]¬O¦]ÃĮĤ£¿ùªº§ó¤W¤@¼h¼Ó¡^ °²Y¬O³o¼Ë¡A¤½¥q¥¼§K¤Ó»¹¤F ÁÂÁ±zªº«ü¥¿ ªY½à±zªº¤j¤å¡AÁ`¦³º¡º¡ªº¦¬Ã¬ ¦A¦¸·PÁ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/12/8 ¤U¤È 01:49:14²Ä 2889 ½g¦^À³
|
833ªº¦¬®×¯Ç¤J±ø¥ó©ó12/1°µ¤F§ó§ï¡G ¡G¡u¦Ü¤Ö¸g¹L¥ô¤@ºØ²{¦³§ÜÀùªvÀøÃĪ««á¹F¨ìSD¡BPR©ÎCRªºµLªkªv¡ªºÂಾ©ÊÀù¯g±wªÌ¡v ·s¡G¡u¦Ü¤Ö¹ï¥ô¤@ºØ²{¦³§ÜÀùªvÀøÃĪ«µL®Ä¡A¥B¹ï¼Ð·ÇÀøªkµL®Ä©ÎÃø¥H§Ô¨üªº´_µo©ÎÂಾ©ÊÀù¯g±wªÌ¡v¡A °ò¥»¤W§Ú¤£Ä±±o³o¼Ëªº§ó§ï¬Oªí¥Ün©¹¡u²Ä¤@½uªvÀø¡vªº¤è¦V¨«¡C ¦]¬°¥¦ªº¦¬®×±Æ°£±ø¥óªº²Ä¤@¶µ´N»¡¡G¡u¥¼¸g¼Ð·Çªº¤ÆÀø¡B¶Pº¸»XÀøªk©Î¼Ð¹vªvÀøªº¥½´Á/Âಾ©ÊÀù¯g±wªÌ¡C¡v¬O¤£³Q¦¬®×ªº¡C¡]Patients who have not received standard chemotherapy, hormonal or targeted therapy for their underlying advanced/metastatic cancer.¡^¡C ¥²¶·¥ý¸g²{¦³ÀøªkªvÀø«áµL®ÄªÌ¤~¯Ç¤J¥»¸ÕÅç¡A©Ò¥H¤£¬O·í§@²Ä¤@½uªvÀø¡C ¤£¹L«ÂI¬O¡A³o¼Ëªº¤@´Á¸ÕÅç¹ï¶Hªº¨îÀ³¤£·|¼vÅT833¥¼¨ÓÃÄÃÒ¾AÀ³¯gªº±Ú¸s¡A¤]´N¬O»¡¡A¤£¦]¤@´Á¦¬®×¹ï¶H³QÁY¦b«á½uªvÀø¡A´Nªí¥Ü±N¨Óªº¤G¡B¤T´Á³£n³QÁY¦b³oÓ±Ú¸s¡C¦]¬°833ªº°t¤è¦b¤HÅé¸ÕÅç¤WÄÝ©ó¥þ·s²Õ¦X¡A¦]¬°¡uÛ²z¡v¦Ò¶q¡A³Qn¨D¦bª`«¡u¦w¥þ©Ê¡vµû¦ôªº¤HÅé¤@´Á¸ÕÅçn¥H¹ï²{¦³ÀøªkµL®Ä©ÎµLªk§Ô¨üªÌ¬°¥D¨Ã«D¬ð¤a©Î¤£¦X²z¡F¤Ï¹L¨Ó»¡¡A¤@¥¹°µ§¹¤@´Á¸ÕÅç«á¡A¦w¥þ©ÊYÀò±o»{¦P¡A«áÄòªº¤G¡B¤T´Á¸ÕÅçn³W¹º¬Æ»ò±Ú¸s¨ÓÄò°µ¸ÕÅç¡A´N¯à¥Ñ¤½¥q¦Û¤v³W¹º¡C¥H²{¦³ªº¤@´Ápµe¨Ó¹w´ú¡A¤£µL¥¢¯u¤§¸·¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/8 ¤W¤È 08:39:39²Ä 2888 ½g¦^À³
|
¥xÁÞ¤j¤j ¤p§Ì¤]«Ü¤£³ßÅw§Ú³oºØөʧr ÁÂÁ±zªº¶}¾É |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/12/8 ¤W¤È 12:56:38²Ä 2887 ½g¦^À³
|
²³¤j¤j±ß¦w: 1 Lin¤j»¡ªº¹ïOBI833¤w¦¬®×§¹¦¨ ( 6¤ëªÑªF·|´N¤w¹w§i 36¤À30¬í) ( ¯E¹©·s»D¤¤¤ß11¤ë23¤é¤]´£¨ì) ¥H¤U¬°Ó¤H¬Ýªk ¶È¨Ñ°Ñ¦Ò : 1 OBI833¤w¦¬®×§¹¦¨26¦W¨ü¸Õ¤~¦³¯à¤O¦A¦¬32¦W¶i¦æ¤£¦P¨ü¸Õ±ø¥ó¤U²£¥Í§ÜÅ鱡§Î¤ñ¸û 2 OBI833§¹¥þÁ{§Éªº³t«×·|¤ñOBI822§Ö«Ü¦h(°²¦p²£¥Í§ÜÅ骺®É¶¡¤ñ¸ûµu,IgG IgM §ÜÅé¤ñ¸û±j, °ª®Ä»ù¤ñ²v¤ñ¸û¦h ) 3 OBI833¦h¦¬32¦W¶i¦æ¤£¦P¨ü¸Õ±ø¥ó¤U²£¥Í§ÜÅ鱡§Î¤ñ¸û,¬°¤U¤@¨Bªº¤è¦V´£¨Ñ§ó¤jªº°j±ÛªÅ¶¡, OBI833 ¥´10°w¥uªá6Ó¤ë ,¨¬¨¬¤ñ822 ¤Ö¤TÓ¤ë, ¦pªG³Q¬ü°êFDAµo²{¨ä¼ç¤O,¦b¬ü°êÀù¯g®g¤ëpµeªº¥úÀô¤U, Àò±o¬ð¯}©ÊªvÀø®Öã§Ú¤@ÂI¤]¤£·N¥~ 4 ¨ÅÀùOBI822¤T´ÁÁ{§É©ÒÀò±oªºÄ_¶Q¸ê®ÆÅý¥¼¨Ó822 833 888 ¨ä¥LÀù¯gªº¬ãµo´£¨Ñ¤F¦p¿O¶ð¯ëªº¤è¦V«ü¤Þ, ÅýÁ{§É³]p §ó©P©µ¦¨¥\¾÷·|§ó¤j 5 ¹w¦ô©ú¦~Q1¯E¹©ªºpipeline ¹M¦a¶}ªá ³o¬O¯E¹©»ùÈ´£¨ì³Ì°ªªº®ÉÔ ²q·Q¤j: ťť´N¦n ,¤»³£¦Y¨ì¹¡¤¤µ¥»ù¦ì¦Ü¤Ön500°_¸õ,1000¥H¤W¤ñ¤ñ¬Ò¬O, ¤¤¤s°Ï¦³¤@®a¬üX¶º©±°ªÀɪº¦Y¨ì¹¡1500¦Ü2000 ¥~¥[10%ªA°È¶O. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/7 ¤W¤È 08:42:43²Ä 2886 ½g¦^À³
|
·PÁ¤ѩR¤jºëªöªº¸ÑŪ ¤p§Ìªº²q´ú ¤½¥q·|§ïÅܤJ¿ï¼Ð·Ç À³¸Ó¬O¬Ý¨ìCR/PR/SD±wªÌªºÀø®Ä ¦Ó¿n·¥¥XÀ» ¼W¥[32¤H¨ä¥LÀøµ{¥¢±Ñ©Î¤£@¨üªº±wªÌ ¬D¾Ô¤@½uªvÀø ¤½¥qªº¨IÀq Åý¤H¤£±Ë ¥DnÁÙ¬O¦b©x¥q¥¼µ²§r? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/7 ¤W¤È 07:38:59²Ä 2885 ½g¦^À³
|
³o·|¬O¤@Ó«GÂI¶Ü¡H ¤½¥q¦b2016/12/01 §â쥻»ÝnCR,PR,SDªº¤J¿ï¼Ð·Ç®³±¼¤F §ï¥H¡uSubjects with recurrent or metastatic incurable disease that failed to respond to at least one line of anticancer standard therapy and for which standard treatment is no longer effective or tolerable. ¡v¨ú¥N https://clinicaltrials.gov/archive/NCT02310464/2016_12_01/changes ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/12/6 ¤U¤È 08:08:55²Ä 2884 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j³ÌªñÁÙ¦³¤@ÓS·|ij,¯E¹©¬O§_·|°Ñ»P???Y·|¬O§_¦pªÑªF·|»¡ªº¥¼¨Ó¥b¦~¤º·|±N©Ò¦³ÃĮĤ½¶}?? |
|
|
·|û¡G±¡¸q10143273 µoªí®É¶¡:2016/12/6 ¤U¤È 04:57:49²Ä 2883 ½g¦^À³
|
¬°¤°»ò¤¤¸Î¤ÎÃĵØÃij£§Ö¨ú¨ìÃÄÃÒ¤F¡AªÑ»ù¤´¦p¦¹§C°g¡HÃø¹D¥¼¨Ó«e´º¤£¬Ý¦n¶Ü¡H¯E¹©¥¼¨Ó¤T´Á³q¹L¡A¥«³õ¬O§_¤]¬O§N¤ÏÀ³¡H |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/12/6 ¤W¤È 10:15:50²Ä 2882 ½g¦^À³
|
ÁÂÁ¤ѩR¤j¤@ª½¦b¶Â©]´H¥VÂI¿U¤@µ··x·N ¤p§Ì¦b¦¹¦V±z·P®¦. ¤§«e¦³³ö¨ì©ú¦~¦³«Ü¦hÁ{§É¦P®É¶i¦æ ªá¿úªº³t«×À³¸Ó«Ü§Ö ©Ò¥H¤p§Ì¤]»{¦P©ú¦~À³¸Ó·|¼W¸ê©Î¨p¶Ò ¥u¬O²{¦b¥Í§Þ¸ê¥»¥«³õ§N²M §Ú©È§xÃø«« ¥H¤W¤@ÂI·Qªk¸ò±z¥æ¬y ÁÂÁÂ. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/6 ¤W¤È 09:56:45²Ä 2881 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¸ÑŪ ¥Ñ¸ÕÅç¾úµ{ 2015/11/3 ±N©Û¶Òªº±wªÌ§ó§ï¬°²¾Âà©Ê±wªÌ https://clinicaltrials.gov/archive/NCT02310464/2015_11_03/changes 2016/01/05 ±Nª¬ªp§ï¬°©Û¶Ò¤¤ https://clinicaltrials.gov/archive/NCT02310464/2016_01_05/changes 2016/11/30 ±N¹w©w¦¬®×¤H¼Æ ¥Ñ26¤H ¼W¬°58¤H https://clinicaltrials.gov/archive/NCT02310464/2016_11_30/changes ³o¼W¥[ªº¤H¼Æ ¬OÀ³Âå®v©Î±wªÌn¨D? ÁÙ¬OÂX¤j¼Ë¥»¼Æ¥HÀ³²Îp©Ò»Ý? ¡§ evaluations will also include immunological response, tumor markers and clinical endpoints such as disease or progression free survival (RECIST 1.1).¡¨ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/12/6 ¤W¤È 07:41:50²Ä 2880 ½g¦^À³
|
³o¥NªíµÛ¤°»ò·N¸q¡H½Ð°Ý¦³¤j¤jª¾±¡¶Ü¡H https://clinicaltrials.gov/archive/NCT02310464/2016_11_30/changes |
|
|
·|û¡G¤p½¼¦Ì10143503 µoªí®É¶¡:2016/12/5 ¤U¤È 03:10:56²Ä 2879 ½g¦^À³
|
·PÁ¤ѩR¤j»P´¡ªá¤G¤j´£¨Ñªº¸ê°T! |
|
|
·|û¡G´¡ªá¤G10142127 µoªí®É¶¡:2016/12/5 ¤W¤È 01:13:45²Ä 2878 ½g¦^À³
|
clinicaltrials.gov/ct2/show/study/NCT01516307 |
|
|
·|û¡G´¡ªá¤G10142127 µoªí®É¶¡:2016/12/5 ¤W¤È 01:09:38²Ä 2877 ½g¦^À³
|
ClinicalTrials.gov A service of the U.S. National Institutes of Health Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects 2016-09-12 updated Status Active, not recruiting Start date 2011-12 Last follow-up date 2017-02 (Anticipated) Primary completion date 2016-12 (Anticipated) 2016-12-5 updated Overall Survival (OS) [ Time Frame: 5 years ] [ Designated as safety issue: No ] Enrollment: 349 Study Start Date: December 2011 Estimated Study Completion Date: February 2017 Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) |
|
|
·|û¡GKO10139074 µoªí®É¶¡:2016/11/30 ¤U¤È 09:25:42²Ä 2876 ½g¦^À³
|
2016.11.30 ¯E¹©ÀòTIPSµûŲA¯ÅªÖ©w ¥xÆW¯E¹©¥Í§Þ (4174)29¤é³q¹L¸gÀÙ³¡¤u·~§½¥xÆW´¼¼z°]²£ºÞ²z³W½d¡]TIPS¡^ ¬d®Ö¤p²Õ¹ê¦a¼f¬d¡A¨Ì¨äÅçÃÒªº±M§Q¡B°Ó¼Ð¡BÀç·~¯µ±Kµ¥½d³ò¡A³q¹LTIPSªº A¯ÅÅçÃÒ¡A¹ï¯E¹©´¼¼z°]²£ºÞ²z¬°¤@¤jªÖ©w¡C TIPS«Y¸gÀÙ³¡¤u·~§½©Ò©e°U°õ¦æªº¡u±À°Ê¥ø·~«Ø¸m´¼¼z°]²£ºÞ²z¨î«×pµe¡v¡A §Æ±æÂǦ¹¹ê²{¡u¥þ±´¶¤Î§Ú°ê¼t°Ó¡B°]¹Îªk¤H¡B¬ã¨s¾÷ºc´¼¼z°]²£ºÞ²z¨î«×¡v Ä@´º¡A¨Ã«Ø¥ß¤½¥¡B¤½¥¿ªºÅçÃÒ¾÷¨î¡A¥HÃÒ©ú¥ø·~´¼¼z°]²£«OÅ@¤ÎºÞ²z¯à¤O¡A «P¶i¥ø·~¹B¥Î´¼¼z°]²£³Ð³yÀç¹B®Ä¯q¡C ¦¹¦¸TIPS¬d®Ö¤p²Õ°w¹ï¯E¹©¡u´¼¼z°]²£ºÞ²z¼f¬d¡v¡B¡u´¼¼z°]²£¸ê·½ºÞ²z¡v ¤Î¡u´¼¼z°]²£¨ú±o/«OÅ@/ºûÅ@¡vµ¥¶µ¥Ø¶i¦æ¬d®Ö«á¡Aµ¹¤©A¯Åµû»ù¡C¯E¹©±j½Õ ¡A´¼¼z°]²£¤§±M§QºÞ²z»P¥¬§½¡A¬O·sÃĬãµo¤½¥q«nÄvª§¤O«ü¼Ð¡A¥¼¨Ó¤½¥q±N §ó¶É¥þ¤OºûÅ@»Pºë¶i¤½¥q´¼¼z°]²£«OÅ@»PºÞ²z¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/24 ¤U¤È 10:36:12²Ä 2875 ½g¦^À³
|
¯E¹©¿D¬w±M§Q¤å¥ó http://pericles.ipaustralia.gov.au/ols/auspat/pdfSource.do?fileQuery=yu%89%86%5E%8B%96%8E%91%86%85G%87%8A%8D%86%8F%82%8E%86%5EbvSQRUSQTZXXbRSQRVQXQZO%91%85%87G%90%97%86%93%5E%8B%96%8E%91%86%85 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/23 ¤U¤È 07:37:39²Ä 2874 ½g¦^À³
|
¯E¹©OBI-833·s±M§Q¥Ó½Ð Àò¥x¿D®Öã³q¹L http://udn.com/news/story/6/2125248 ... ¯E¹©ªí¥Ü¡AOBI-833¬O¯E¹©¦b¬ãµo§ÜÀùÃĪ«¸gÅç°ò¦¤U¡A¦A±µ¦A¼F¡A¥Ñ¤¤¬ã°|§ÞÂà¡A¶}µo¥HGlobo H¬°§Ü쪺·s¥D°Ê¦¡§K¬ÌÀøªk²£«~¡A ©ó2014¦~12¤ë¤Î2015¦~7¤ë¤À§O¥Ñ¬ü°ê¤Î¥xÆW¹«~ÃĪ«ºÞ²z¸p³q¹L¤@´ÁÁ{§É¸ÕÅçpµe¡A¥¿¿n·¥®i¶}GÀù¡BªÍÀù¡B¨ÅÀù¤Î¤j¸zª½¸zÀùµ¥¯f¤H¦¬®×¡A ¹wp¦~©³§Y±N§¹¦¨¡C ·sÀò±oªºOBI-833±M§Q«Y«ü¥H¥Õ³ïÃþ¬r¯À¡]DT¡^¬°³J¥Õ½è¸üÅé¡A¦b»P¸Ó¬Ì]¼Ð»x§ÜìGlobo HÃì±µ®É¡A¯E¹©¤w¥i¬ð¯}¤åÄm¤W©Ò¸üªº§Þ³N¨î¡A ¥iÃì±µªºGlobo H§ó¦h¡A¹B¥Î¦¹§Þ³N¡A¥i¹F¦¨°ªºÒ¤ô¤Æ¦Xª«±K«×¬Ì]¡C ¡]ºK¦Û¤¤¥¡ªÀ) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/22 ¤U¤È 08:37:31²Ä 2873 ½g¦^À³
|
¹ï¤£°_¡I§ó¥¿¤@¤U ¤p§Ì«e¤åSKLCC¬°MSKCC¤§»~ ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/22 ¤U¤È 02:37:22²Ä 2872 ½g¦^À³
|
Cliff ¤j®¦¼w ¤p§Ì°O±o±z´£¹L SKLCCªº¦hªG¾ð¬Ì]¡Aµ²ªºªG¤l¤£¦h ³oÓ¦h¤FSSEA-4ªºÂù»ù¬Ì], ·|¤£·|²£¥Í¸û¦hªºSSEA-4§ÜÅé¡AÀ³¬OÓ«ÂI §_«hGH-DT/C34 ¤]³\´N¨¬°÷¤F¡H³oÓµª®×©Î¦³«Ý±N¨Ó¹êÅç½T»{¡H ¤p§ÌJ«ä¶Ã·Qªº |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/11/22 ¤U¤È 02:07:20²Ä 2871 ½g¦^À³
|
Cliff ¤j ¦pªG¯u±Ó·P¡A§@ªÌ¥i¥H¿ï¾Ü¤£¤½¶}¯È¥»½×¤å©Î©µ«á¤½¶} |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/11/22 ¤U¤È 01:38:44²Ä 2870 ½g¦^À³
|
³æµoÁÞ§Ü줣°÷¬Ý¡C ÂùÅT¯¥¡GGlobo H+SSEA-4¡×Globo H-DT-SSEA-4¡]handle.ncl.edu.tw/11296/ndltd/52962836747162936411¡^ 1.¥uÀ]¤º¾\Ū¡C¨Æ¯A±Ó·P¡H 2. SSEA-3©O¡H 3. ¡K¡K¡K¡K |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/11/22 ¤U¤È 12:21:28²Ä 2869 ½g¦^À³
|
¥H¤U¤º®e´¿¦b¥»ª©page.14¡u2015/4/15 ¤U¤È 07:25:21²Ä 220 ½g¦^À³¡v¶K¹L¡A¸ê®Æ¨Ó·½¬O¡G ¡u104¦~3¤ë16¤é¡u²{ª÷¼W¸êµo¦æ·sªÑ¿ì²z¤WÂd«e¤½¶}©Ó¾Pº[ªÑ²¼ªì¦¸¤WÂd¥Î(»ù®æ½T©wª©)¡v¤½¶}»¡©ú®Ñ¡APDF page161/697ªí®æùØ¡C¡]doc.twse.com.tw/pdf/201503_4174_B04_20161122_113821.pdf ¡^¡v¡C ´£¨ì·í¦~¡]2012¦~?¡^¥»¨Ó·QÅ¥¨ú¥þ²yÀù¯g±M®aªº«Øij¡A°w¹ï¥Ø«eµLÃÄ¥iÂ大¤T³±©Ê¨ÅÀù¡A¦V¬ü°êFDA¥Ó½Ð¶i¤J¥þ²yÁ{§É¤T´Á¸ÕÅç¡A¦ý«á¨Ó¤½¥q»{¬°»Ý¼f·Vµû¦ô¨Ã¡u¼W¥[¤@¶µÁ{§É«e¬ã¨s¶µ¥Ø¡v¡A°£»Ýµ¥«Ý¸Ó¶µ¬ì¾Ç¼Æ¾Ú§¹¦¨¥~¡A¦A¥[¤W822¸Ñª¼µ²ªG»P±M®a¦@¦P³]p¨Ã±Ò°Ê¥þ²yÁ{§É¤T´Á¸ÕÅçpµe¡C ¤½¶}»¡©ú®Ñì¤å¦p¤U¡G ¡uOBI-822 Global Pivotal¡]¥þ²yÁ{§É¤T´Á·Ç³Æ¡^¡v ì³W¹º±¡§Î¡G ¡uOBI-822¨ÅÀùªº¥þ²yÁ{§É¤T´Á¸ÕÅç¸g¥þ²yÀù¯g±M®a«Øij¡A°w¹ï¥Ø«eµLÃÄ¥iÂ大¤T³±©Ê¨ÅÀù¡A¸g¬ü°êFDA»{¥i¦w¥þµL¸·«á¡A¹wp¥i¾¨³t¶i¤J¥þ²yÁ{§É¤T´Á¸ÕÅç¡A¬Gì¹wp©ó103¦~¤U¥b¦~«×¶}©l°e¼f¡v¡C ¦ý¬O¨Æ¹ê¤W¨Ã¥¼§¹¦¨¦¹¶i«×¡A¸êª÷³Q«O¯d¤U¨Ó¡A®t²§ì¦]¡G ¡u¥»¤½¥q¬°´£°ª¥þ²yÁ{§É¤T´Á¸ÕÅ礧¦¨¥\¾÷·|¥H«O»ÙªÑªFÅv¯q¡A¦Û102¦~¶}©l»P¥þ²y¨ÅÀù±M®a¶}·|°Q½×¸Ó¶µÁ{§É³]p¡A´X«×»P¥þ²yª¾¦W±M®a°Q½×µ²ªG»{¬°¦b¿ï¾Ü¨ü¸ÕªÌ±Ú¸s¤è±»Ý¼f·Vµû¦ô¨Ã¼W¥[¤@¶µÁ{§É«e¬ã¨s¶µ¥Ø¡A°£»Ýµ¥¸Ó¶µ¬ì¾Ç¼Æ¾Ú§¹¦¨¥~¡A¥Ñ©ó·sÃÄOBI-822¦h°ê¦h¤¤¤ßÁ{§É¤G/¤T´Á¤§¦¬®×¶i«×¶W«e¡A¥»¤½¥q±N¦P®É°Ñ·Ó¸Ó¶µ¸ÕÅçµ²ªG»P±M®a¦@¦P³]p¨Ã±Ò°Ê¥þ²yÁ{§É¤T´Á¸ÕÅçpµe¥H¼W¥[¬ãµo¦¨¥\¾÷²v¡C¡v ¹L¤F¤@¦~¥b¨Ó¨ì²{¦b2016/11¡A 1. ¡u¼W¥[¤@¶µÁ{§É«e¬ã¨s¶µ¥Ø¡v¡A³o¶µªº¬ã¨s¶µ¥Ø¬O¡H¸Ó¶µ¬ì¾Ç¼Æ¾Ú©O¡H¦ü¥G±q¨Ó¨S¦³ªÑªF°Ý¹L³o¤@ÃD¡H 2. ¾Ú±x±N¥H¤T³±Àù¬°¤T´Á¸ÕÅ窺°_ÂI¡H¦ü¥G¶¤F¤@°é¤S¦^¨ì¤F³oӮפl¤W¡H |
|
|
·|û¡G¦³¹Ú³Ì¬ü10141895 µoªí®É¶¡:2016/11/21 ¤U¤È 02:53:25²Ä 2868 ½g¦^À³
|
·PÁ¤ѩR¤j¤À¨É§K¬ÌÀøªkºÖµ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/8 ¤W¤È 12:35:59²Ä 2867 ½g¦^À³
|
¯E¹©¥þ²y¤T´ÁÁ{§É³]p§Ú»{¬°¯E¹©¤£·|¥u±a¨â¤TÓ¤è®×¥h½Í¡A¤è®×«Ü¦h¤¸¤~¯àÅý¦Û¤v¥ß©ó¤£±Ñ¤§¦a¡A±q³Ì¦nªº¨ì³Ì®tªº¤è®×¤¤ÁÙ¦³«Ü¦h¥i¯à¤£¿ùªº¤è®×¡A¦b¦w¥þ¦³®Äªº«eÃD¤U¡A¥un¹ï¯S®í±Ú¸s¯f±w¦³¯q¡A¯àº¡¨¬¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¡A¬ü°êFDA·|¦³¼u©Êªº¨Ó³B²z |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/7 ¤U¤È 11:46:03²Ä 2866 ½g¦^À³
|
²³¤j¤j ¯E¹©¥þ²y¤T´ÁÁ{§É³]pÁÙ¨S¥XÄl¡A¯à³Q®Öã´Nªí¥Ü¬ü°êFDA»{¬°³]p¬O¦X²zªº¡A¯à±µ¨üªº¡A²Å¦X¯f±w§Q¯qªº¡A²{¦b¥Î°²³]©Êªº¤è®×¥h°Q½×¯E¹©¥þ²y¤T´Á¥i¯à·|»P¨Æ¹ê¤£²Å°Õ!¥H¤W«Øij¡C |
|
|
·|û¡GRudy10141433 µoªí®É¶¡:2016/11/7 ¤U¤È 11:16:41²Ä 2865 ½g¦^À³
|
¬Ý°_¨Ó³Ì²³æ¤S¨S¦³ª§Ä³ªº¿z¿ï¤èªk¡A¤j·§´N¦Ñ¥v¤j10/29¼gªº¤è®×¤G¡A¥ý¥´¤@°w¶q§ÜÅé¤F¡C ·|¤£·|¥ý¥Î§C¾¯¶q¥´¤@°w¸Õ¸Õ©O¡H ¥´Ó¥|°w¡AÁöµM¥i¥H¿ïªº§óºë·Ç¡A¦ý´N¦p¦P¤Ñ©R¤j©Ò»¡¡A¤é«á¦pªG¤W¥«¡A¤]n¬Û¦P¼Ð·Ç¿z¿ï¡A¹ï·sÃıÀ¼s¬OÓ¯ÊÂI¡C ¦Ó¥B¥Î PD ¨Ó·í¿z¿ï¼Ð·Çªº¸Ü¡AÁ`¬Oı±o©Ç©Çªº°Õ¡C |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/11/7 ¤U¤È 10:19:03²Ä 2864 ½g¦^À³
|
¤Ñ©R¤j: www.youtube.com/watch?v=UAtFMtAQDI0 |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/11/7 ¤U¤È 09:59:39²Ä 2863 ½g¦^À³
|
¤Ñ©R¤j ³o¼Ë¨S§ÜÅ骺´N»Ýn888 ¤½¥q³W¹ºÀ³¸Ó¬O³o¼Ëªº§a |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/11/7 ¤U¤È 09:38:47²Ä 2862 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¤T´ÁÀ³¸Ó¤£¬OÂùª¼´ú¸Õ¤F ¥´§¹¥|°w¦³¤ÏÀ³ªº¯d¤U¨Ó ³o¼Ë¦X²z¶Ü ½Ð¦U¦ì¤j¯««üÂI |
|
|
·|û¡GRudy10141433 µoªí®É¶¡:2016/11/7 ¤U¤È 08:55:14²Ä 2861 ½g¦^À³
|
¤Ñ©R¥S¤£¦n·N«ä¡A§Ú»~·|±zªº·N«ä¤F¡C §Ú¥H¬°¬O¥ý¿z¿ï¦A¤À²Õ¡A¤]´N¬O»¡©Ò¦³¤H³£¥´¥|°w¡A¿z¿ï³q¹L¥H«á¦A¤À¹êÅç²Õ¹ï·Ó²Õ¡C ³o¼Ë²Îp¤W´N¨S¦³°ÝÃD¡A¦ý¹ï·Ó²Õ¥´¤F¥|°w822¡A¤S²^¨O±¼¤@¨ÇÃa¾Ç¥Í¡A·íµM·|¼W¥[¤£¤ÖOS¡C ¦Ó¥B³o¼Ëªº¹êÅç·|±o¨ì¥H¤Uªºµ²½×¡GOBI-822¹ï©ó¨Ï¥ÎOBI-822¦³®Äªº¤H¬O¦³®Äªº....#$$%^@...... ¦Ü©ó±z»¡ªº¬O¤À²Õ¥H«á¡A¦A¦U¦Û¿z¿ï¯f¤H¡A³o¼Ë¬O¦³°ÝÃDªº¡C ¨Ò¦p¨ºÓ¥´§¹¤E°wªºPFS¼Æ¾Ú¡A§Ú¥»¨Ó¤]¥H¬°¦b²Îp¤W¬O¤@Ó¤½¥ªº¤ñ¸û¡AÁÙ¬O³Ìªñ¬Ý¤FT^T¥Sªº¤å³¹¤~ª¾¹D¡A³o¼ËÁÙ¬O¤£°÷ªº¡C Á|Ó¨Ò¡A¦pªG822¹ï¤Ö³¡¤À¤H¦³®`¡A¦P®É¤]¹ï¤@¨Ç¤H¦³¯q¡A³y¦¨PFS < 20¶g ©M PFS > 100¶g ªº¤H³£¼W¥[¡C ¨º³o¼Ëºâ¦³®Ä¶Ü¡H¯àµoÃÄÃҶܡH´N¤£¤@©w¤F¹À¡C ¥i¬O¥u²Îp¥´§¹¤E°wªº¤H¡A´N§â PFS < 20 ªº¤HÂo±¼¤F¡A¥u³Ñ¤U¨Ó¦n¬Ýªº¼Æ¾Ú¡A©Ò¥H»¡¬O¤£¤½¥ªº¡C ®¦®¦¡A¤S·Q¨ì¡A¨º³o¼Ë§Ú¤W±©Ò»¡ªº¡A¥ý¿z¿ï¦A¤À²Õ¤]ÁÙ¬O¦³ºÃ¼{¡C¹ï©ó¥´822¦³®`ªº¤H¡A·|¨S¦³¦Ò¼{¶i¥h¡C |
|
|
·|û¡GRudy10141433 µoªí®É¶¡:2016/11/7 ¤U¤È 04:25:26²Ä 2860 ½g¦^À³
|
¤Ñ©R¥S¡A ¹ï©ó¤w¸gª¾¹DOBIµL®Äªº¤H¨Ó»¡¡A¿z¿ï±¼Åý¯f¤H¥t§ä¥Í¸ô¡A³o§Ú¦P·N¡A¬O¨S°ÝÃDªº¡C §Úªº·N«ä¤£¬O³o¼Ë¡A§Ú¬O»¡§¹¦¨¿z¿ïªº¤èªk¡A¦pªG»Ýn¸g¾ú¤K¶g®É¶¡¡AÁÙ¦³¥ÎPD°µ¬°¥N»ùªº¸Ü¡A³o´N¤£¬O«Ü¦n¤F¡C ¥t¥~¤Ñ©R¥S±z»¡ªºMOS¼W¥[20Ó¤ë¡A¥þ¥@¬É¯f¤H·|·mµÛn¡A³o§Ú¤]¦P·N¡A³o¯uªº¬O«Ü¦nªº¼Æ¾Ú¡C ©Ò¥H§ÚÓ¤Hı±o¡A¤G´Áªº³oÓOS¼Æ¾Ú¡A´N¤w¸g«Ü¦n¤F¡C ¤T´Á¬D¹L¯f¤H¦A°µ¤@¦¸¡A¹ï·Ó²ÕOS¤@©w¤]·|©¹¤W´£¤É¡Aµ¥¨ì¼Æ¾Ú¦¨¼ô·|§ó¤[¡Aµ²ªG¤]¤£¨£±o·|¤ñ¤G´Á¦n«Ü¦h¡C |
|
|
·|û¡GRudy10141433 µoªí®É¶¡:2016/11/7 ¤U¤È 02:32:01²Ä 2859 ½g¦^À³
|
¤Ñ©R¥S±zªº¤èªk¦b²Îp¤W¬O¨S¦³°ÝÃDªº¡C ¦ý¹ê»Ú°µªk¤W¡A¹ï©óÀù¯g¥½´Á¯f±w¨Ó»¡¡Aµ¥¤K¶g¨SPD¤~¯à¶i¹êÅç¡A§Ú²qFDA¤£·|¦P·N¡A¤½¥q¤]À³¸Ó¤£·|³o¼Ë°µ¡C ªp¥B´Nºâ³o¼Ë°µ¯à®³¨ìÃÄÃÒ¡An¥´¥|°w°µ¯f±w¿z¿ïªºÃÄ¡A¦bÂå°|¤]«ÜÃø±À¡C ¤Ï¥¿¤½¥q¤w¸g°e¥ó¤F¡A°¨¤W´N¯àª¾¹Dµ²ªG¤F¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/7 ¤W¤È 11:44:12²Ä 2858 ½g¦^À³
|
ÁÂÁ T ¤j¤j²n¦ýºëªöªº¸ÑªR ·PÁ±z! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/11/7 ¤W¤È 11:26:58²Ä 2857 ½g¦^À³
|
§Ú·Qªk¤ñ¸û³æ¯Â¡A¬Ý¯Eôªº¼Æ¾Ú¡A¨ä¹ê§Úª`·Nªº´N¬O¤£n±¼¤Jpost-hocªº°g«ä¡A¤£¥i¸ÕÅç°µ¤@¥b¨Ì·Ó¤ÏÀ³µ²ªG¥h¤À²Õ! ¤µ¤Ñ¤W¤È¬Ý¤F¤@½g³ø§i¡A¦³ÂI²§¦±¦P¤u¤§¨ý! www.nejm.org/doi/full/10.1056/NEJMoa1611406#t=article ³q½g¤º®e´N¬O¥H¬Û¦P°_ÂI¥h¤ÀªR¡A§Y«Ksubgroup¤]¬O¥H¤@¶}©l¦¬®×®É´N¯à¤À²Õªº±¡ªp¤U¥h¤À²Õ¡C ©Ò¥H§Ú»{¬°Y¬O¥Hcancer cellªº GloboH ªí²{°µ¤À²Õ(+ ©Î - ´N¦n)¡A©Î³\¬O³o¦¸2´Áªº«GÂI¤Î±N¨Ó3´Áªº¤è¦V! ¤]ÁÂÁ©Ҧ³Ä@·N´£¨Ñ¸ê°T¤Î¬Ýªkªº¾Â¤Í! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/11/7 ¤W¤È 12:41:13²Ä 2856 ½g¦^À³
|
ÁÂÁÂT^Tªº¦^ÂÐ. ¡¨ §ë¸ên§Ù·V¤p¤ßDATAªº¨CÓÀô¸`¡¨ ¯u¬Oª÷¥É¨}¨¥, ¤]§Æ±æ¦b¨CÓÀô¸`data¥X²{®É, ¯à½Ð±z¤À¨É±zªº°ª¨£. ¦A¦¸·PÁÂ. |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/11/7 ¤W¤È 12:28:40²Ä 2855 ½g¦^À³
|
Walker ¤j ¥ø¹Ï±Àºt¤Ó¨S®Ä²v¤F n¬O§Ú´N¬£¶¡¿Ò¹L¥h¼ç¥ñ... §äÀb«ÈÀ°¦£... ¤£µM¦³¿ìªk«ü´§°Å±¼¹L¥h¬d¦©¸ê®Æ¤]¦æ |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/11/7 ¤W¤È 12:09:51²Ä 2854 ½g¦^À³
|
·x·x¤j¡A±z»¡¹ï¤F¡AISSCC ¬O¥b¾ÉÅé¬É°ê¤O®i¥Üªº³õ¦X¡AÁpµo¬ì»P¥x¿n¹q¦b¤W±µoªí¤F³\¦h¤åÄm¡A¦ý¡A³o¨Ç¤½¥q¦³µo«°T¶Ü¡H¨S¦³; ½×¤å¼g±o°÷²M·¡¶Ü¡H«ç»ò¥i¯à¡I¤T¬P¹q¤l¦³¦h¤Ö²´·ú¦b¬ÝµÛ¥L¡A¥ø¹Ï±Àºt¥XÃöÁäÂI ¸ê°T¤£¹ïºÙ¡H¤]³\¦³¤@ÂI¡A¦ý¸ê¥»¥«³õ¹ï³o¨â°¦ªÑ²¼¤w¦¨¼ô¨ì¹ï³oÓÅܼƤw¨S¦³¤£¹ïºÙ¤ÏÀ³ ´Á«Ý¯E¹©¦³¤@¤Ñ¤]¥i¥H¦p¦¹ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/6 ¤U¤È 09:42:16²Ä 2853 ½g¦^À³
|
T ¤j¤j ·PÁ±zªº¸ÑªR ¤p§Ì¹ï±z±M·~ª¾ÃѪº«ü¾É¡A»Ê·P¤¤º¡A¤p§ÌP³Ì°ª·q·N ±z©Ò´£¸ê°Tªº¸¨®t¡A¦V¨Ó¬OªÑ¥«ªº±`ºA¡A¦ý¬O¤S¦ó©` ¸ê®Æ¤§¤£»ô¡A¼vÅT§PÂ_¡A¤p§ÌÁaµM«Ü§V¤O²q·Q¡A¤]¥u¬O²q·Q ÁÂÁ±z ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/11/6 ¤U¤È 08:47:29²Ä 2852 ½g¦^À³
|
T¤j:¬O¥i¥H«Øij¤½¥q¯à§_°µ¨ì¦P¨B,¤£¹L¬JµM¤£²Å¦X«°T,¤]¬O¥i¥H¤£¥Î¤½¥¬ªº!¥xÆW¤j¦h¼Æ¤W¥«Âd¤½¥q³£¬O¦b©u«×ªk»¡·|©ÎªÑªF·|¤~·|´¦ÅS¦~«×©Î©u«×ªºÀç¹B.±µ³æ.§Þ³N¬ãµoµ¥¸ê°T,©Ò¥H¤£¤½¥¬¤]µL¤£§´! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/11/6 ¤U¤È 08:26:07²Ä 2851 ½g¦^À³
|
¦pªG¬O¨Ì´£¨Ñªº³sµ² S 26 & S 28 ½T¹ê¦p¦¹¡A¬O§Ú¨S¦¹°O¾Ð! ¦ý³o¼Ë¤ñ¸ûÁÙ¬O¥i¯à¸¨¤J©Ò¿× post-hocªº³´¨À¡A¦Ó¥B±Æ°£±¼ªº¯f¤H¼Æ´Xªñ5¦¨¡A¥u¯à»¡n«Ü¤p¤ß¸ÑŪ! «Ü©êºp¡A¨S¯à¤O¦^µª°²³]©Êªº°ÝÃD¡AÁÙ¬O¨Ì¨Æ¹ê°Q½×¸û¦n! 10/10 ESMO ; 10/26¤½¥q±N¼v¤ù©ñ¦bºô¶¤W! ³o¬q®É¶¡¦³¦h¤Ö¤H±µÄ²¨ì³o¨Ç·s¸ê®Æ¡A¬Û«H¤£¬O§A§Ú! ³o¼Ë¸ê°T¤£¹ïµ¥ªº®É¶¡®t¦X²z¶Ü? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/6 ¤U¤È 07:17:22²Ä 2850 ½g¦^À³
|
·PÁÂT¤j¤jªº«ü¾É ¤p§Ì¨º´±¬D¾Ô±z¡A±z«H¤â©à¨Óªº¸ÑªR¡A¤p§Ì®£©Ènªá¤W¦n¤[ªº®É¶¡¤~¯à®ø¤Æ ¤p§Ì¥u¬O¤ñ¸û¦³®É¶¡ªá¦b¤½¥q¤½§Gªº¸ê®Æ¤W¦Ó¤w ´N¦p¤»¤ë15¤é¤½¥qªº§ë¼v¤ù http://mops.twse.com.tw/nas/STR/417420160615M001.pdf slide 26 ©M 28 ¦s¬¡¹Ï¤¤¡A±q40 ¶g¥H«áªºnumber at risk´X¥G¤@¼Ë ¤p§Ì¤£²M·¡³o¼Ë¬O§_¥i¸ÑÄÀ¦¨¡A¥´§¹9°w¦h¬O¨â²Õ¤¤ª¬ªp³Ì¦nªº¡H ¥t¥~¡A¤p§Ì·Q¦A½Ð±Ð¤@Ó°ÝÃD ¨S¦³½T©wªºMOA·|³Q¥´ºj¡AµL±e¸mºÃ Y¤µ¤é°²³]ESMO¶ÀÂå®vslide 8 ªº OS ¦s¬¡¹Ï¡A¨äpȳ̫á¬O¤p©ó 0.001¡A¦ýMOA¤£©ú ³o¼Ëªºµ²ªG¡AÃĮķ|¤£·|³Q±µ¨ü¡H ¤p§Ì¤@ª½¦b§Æ±æ ¤½¥q³Ì¤jªº«GÂI¡A´N¬OOSµo¥Íªº¨Æ¥óÁ`¼Æ«æÁY¡A¬Æ©Î¤[¤[¤~µo¥Í¤@Ó¡A¥i¥H³yºÖ»Ýnªº¤H ÁÂÁ±z¡I ¹ï¤£¦íªº¬O¡A¤p§Ìè¤H¤@ª½»¡¹Ú ½ÐT¤j¤j©M¤j®aì½Ì ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/11/6 ¤U¤È 05:20:57²Ä 2849 ½g¦^À³
|
ÂyªÌ°ß±©¤j:¤£¦n·N«ä,§Ú¤Sn¦h¼L¦^À³¤F!XD 1.¿ï¦b¥þ²y±M®a»P¸~½FÂå¥Í»E¶°ªº¦a¤è¿ì¬ã°Q·|¸ò¦b¥xÆW¼sµo^¶¯©«¿ì¬ã°Q·|,þ¤@ºØÃn¥ú²v°ª?þ¤@ºØ®Ä¯q°ª?¬ì§Þ·~¨C¦~ªº·s²£«~¤£¤]³£¿ï¦b¼w°êCebit©Î¬ü°êCES®iµoªí¶Ü? 2.¬JµMÄÀ©ñªº¸ê®Æ¤£°÷,¤½¥q¥i¥Hµo«°T¶Ü?¸ê®Æ©ñ¦b¤½¥qºô¯¸Åý§A¬Ý«Ü¦X²z§a!¦³°½ÂöÜ? |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/11/6 ¤U¤È 04:30:27²Ä 2848 ½g¦^À³
|
ª©¤W°ª¤H«Ü¦h¡A¤p¤p©ñ¸v¤@¤U! §A¬O¹ïªº(Slide.9¨º±i¹Ï,§Úªº²z¸Ñ¬O¨º±i¬O¹êÅç²Õ¸ò¹ï³y²Õ¤À§O¦³¥´§¹¤E°wªº±wªÌ©Ò»s¦¨ªº¹Ï)! ¦ý¬J¬Oplacebo arm¡A§Ú·|°²³]¥´§¹9°w©M¾ãÅé¹ï·Ó²ÕµL®t²§¡A¤£µM´N¬O»¡placebo¤]¦³Àø®ÄÅo!(©Ò¿×¥´§¹9°w¬O¸û¦nªº»¡ªk¦bplacebo²Õ¤£¦¨¥ß¡A°£«D¤½¥q¼Æ¾Ú¦³§e²{¡A¬Æ©Î¥´§¹9°w¦bplacebo²Õ¬O¸û®tªº¥ç¤£¥i±Æ°£°Ú!) ¤G´Á©Ò¿×ªºproof of concept, ·íµM¤£¬O¶È¼Æ¾Ú P<0.05¡A¦pªG¯à§ä¨ì¦¸¤À²Õ¦³Àø®Ä(¦p«ez)¡A¤]¥i¥Ñphase 3±j¤ÆÃÒ¾Ú¡C¦ý¬On§ä¨ìMOA¸ÑÄÀµ²ªG(¦n&Ãa)¡A¦pªG¤£¯à¦Û¶ê¨ä»¡¡A§Y«Kµ²ªGP<0.05¤]·|³Q¥´ºj!·sÃĦbAD COMM³Q±ÀÂË¡A¦b³Ì«á¨S³QAPPROVEDªº¤]¤£¬O¨Sµo¥Í¹L¡A§ë¸ên§Ù·V¤p¤ßDATAªº¨CÓÀô¸`! ©Ò¥H¤½¥q»Ýn¸ê·½Äò°µ3´Á¡A¬Æ©ÎÁÙn1-2¦¸²{ª÷¼W¸ê¡A³o¤]¬O·íªì§Ú»{¬°¤£¸Ó¶R®wÂêѪºì¦]! §ÚÁÙ¬Oı±o³o¦¸ÄÀ©ñªº¸ê®Æ¤£°÷¡A¤]¤£¥²³z¹LESMO¿ì²z¡APanel discussion¯à´¡¤W¼Lªº¤HÁÙ¬OÂi±¤W¨º´X¦ì!¦b°ê¤º¿ì¬ã°Q·|Áܽаê»Ú±M®a´N°÷¤F¡AÁÙ¥i¥H¥[±j¥xÆWªº¯à¨£«×! ¤½¥q¬JµMªá¤j¿ú¿ì¤F·|¡A¸ê°T¤]¤Wºô¤F¡AÀ³¸Ó¥D°Ê¤½§i©Pª¾¡A¦Ó¤£¬O¥Ñºô¤Í¥h§ä¥X¨Ó!³oÂI§A¬Ý¤¤¸Î¡A TH.TOªº¬ã¨s³ø§i¥X¨Ó¤F¤½¥q¥ß¨è´N«°T¤F!¯E¹©ªº¸gÀç¹Î¶¤n¥[§â«l! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/6 ¤U¤È 03:23:47²Ä 2847 ½g¦^À³
|
ÁÂÁÂT¤j¤j¥H±M·~¨¤«×ªº¨ôµû ¤p§Ì¬Ý¤F´X¦¸ , ·Q¤F´X¦¸ , ¤]¦³´XÓºÃ°Ý , ·Q½Ð±ÐT¤j¤j©M¤j®a ?????????????????? s5 ¨È¬w¤H¦û¬ã¨s±Ú¸s¤ñ¨Ò¤Ó°ª,¬ü°êFDA¥²¦³ºÃ¼{ ????????????????????? ºÃ°Ý¤@: °²¦p¦b¬ü°ê©Û¦¬ªº71¤H , ¨ä½s¤J¹êÅç²ÕªºÃĮĤñ¨È¬wªÌ¦n , ¬O§_¥i¥Hµy¸ÑFDA ªº¥²¦³ºÃ¼{?! ?????????????????? s9 ¬D±¼¤F¤w¸gPROGRESSION¨S¥´§¹9°wªº¯f¤H¡C¥h©M¥þ³¡¹ï·Ó²Õ¤ñ¡A¤@¼Ë¦³¤£¤½¥ªº¦a¤è ???????????????????? ºÃ°Ý¤G: ¹xµ£¤j¤j¤wÂI¥X slide 9 ¬O¹êÅç²Õ»P¹ï·Ó²Õ§¡¿z¿ï¥X¥´§¹9°wªÌªºPFS¦s¬¡¹Ï ¤p§Ìªº·Pı , ³o¬O¨â²Õ¤¤¿z¿ï¥Xª¬ªp³Ì¦nªÌªº¤ñ¸û , ©Î¦³¥i°Ñ¤§³B , À³¤£¦Ü©ó¦³¤Ó¤jªºª§Ä³?! ????????????????? s15 ¦³ª§Ä³³B ¥´§¹9°w§ÜÅé°ª¡A¬OÃĪ«ªºÃö«Y¡AÁÙ¬O¥»¨Ó³o²Õ¯f¤H¥»¨Ó´N¬O·|°ª§ÜÅé(¦s¬¡¸û¤[¡APFS¸ûªø)¡A¤Ï¹L¨Ó»¡¡A¥´ªº¾¯¶q¶Vµu(¥Nªí·U¦PFS¡A¯f¤HÅé½èÄݧC§ÜÅé¡A¦s¬¡¶Vµu) ???????????????????? ºÃ°Ý¤T: ¤W¦C±ÔzÀ³¬°ºÃ°Ý¤Gªº½èºÃ©µ¦ù , YµL¤£¤½¥¤§³B , ¤W¦Cª§Ä³©Î¥i®ø«Ú?! ??????????????????? S17 Àù²ÓM¨S¦³globo H ªº¯f¤H¡AHR³ºµM±µªñ0.5¡A¦pªGP3¬D³oÓ±Ú¸s°µ¸ÕÅç¡A·|¤£·|¤j¤j¦¨¥\? ©Î¬O¬D3+¤]¦æ¡A ¦ý«ç»ò¸ÑÄÀ1+ªº¯f¤H«o¨S¦³Àø®Ä¡C¨ä¹ê³Ì«ápanel discussion¨ä¥LÂå®v¤ñ¸û¸Û¹ê¡A¹ïÀø®Ä³£ªí¥Ü¼Æ¾Ú¦³¡An¦A¬ã¨s!¤]±j½ÕP3«ç»ò¿ï¯f¤Hªº«n! ???????????????????????? ºÃ°Ý¥|: 822ªº³Ì¤jÀuÂI , ´N¬O¥H¤@¤ä¬Ì]¥i¯à²£¥Í¤TºØ¥Dn§ÜÅé , ¦Ó³o¤TºØ§ÜÅ駡¥i°w¹ïÀù²ÓMªº°t¹ï§Üìµ²¦X§ðÀ» ¨S¦³¸Ô²Óªº¤ÀªR²Îp¸ê®Æ , ¹ê¦bµL±q¤F¸Ñ¨ì©³¬O¦ó§@¥Î©Î¦]¯À¨ÏµM ¦³IgG¤ÎIgM¦U²£¥Í¤TºØ§ÜÅé , ±wªÌ¤¤³Ì¦h¦³6ºØªZ¾¹ , ¥i¸ê±þ¼Ä ¤p§Ìı±o¤½¥qÀ³¸Ó³Ìª¾¹D¨ä¤¤ì©e , ¥u¦³µ¥¤½¥qµo§G¦A¨Ó§P©w , ©Î¸û©ú®Ô? ?????????????????? s17 Globo H Ceramide act as immune check point molecule -> inhibit proliferation of T-cell & B-cell s23 Globo H enable tumors to evade the immune system and acts as angiogenics factor ©Ò¥H¹ï¥»¨¨S¿ìªk²£¥Í§ÜÅé±Ú¸s¡Aµ¹¥LGlobo-H·|¤£·|¤Ï¦Ó¦³®`? ????????????????????? ºÃ°Ý¤: ³oÓÆ[ÂI , ¥H«e¤j®a¦h©Ò°Q½× ´N²{¦b¬Ý¨ìªº¸ê®Æ Y¯Â¥HPFS ¦s¬¡¹Ï , ©Î¤ñ¸û·|¦³¦¹¶µºÃ¼{ªºªÅ¶¡ µMY·f°t OS ¦s¬¡¹Ï¨Ó¬Ý , À³´N¤£·|¦³³oºØºÃ¼{·P?! ¤p§Ì¬O¤@ӯʥFÂåÃĬÛÃö±M·~ªºª¾ÃѪ¼ °ÝÃD©Î¥¢¤§°¾»á¥i¯º , ¦³½Ð¤j®a«ü¥¿ ¤]½Ð T ¤j¤j®ü²[ , ¨Ã±`¨Ó«ü¾É ÁÂÁ±z! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/11/6 ¤W¤È 11:42:15²Ä 2846 ½g¦^À³
|
ÁÂÁÂT^Tªº¤À¨É. ¤U±³o¬q©Î³\¬O¬°¦ó<1:160ªº¤À²Õ¼Æ¾Ú®z©ó¹ï·Ó²Õªº«n¦]¯À¤§¤@. ÁÂÁ±zªº«ü¤Þ. ...................... ³¯°|¤h s17 Globo H Ceramide act as immune check point molecule -> inhibit proliferation of T-cell & B-cell s23 Globo H enable tumors to evade the immune system and acts as angiogenics factor ©Ò¥H¹ï¥»¨¨S¿ìªk²£¥Í§ÜÅé±Ú¸s¡Aµ¹¥LGlobo-H·|¤£·|¤Ï¦Ó¦³®`? ¡K¡K¡K¡K¡K.. ¦p¯E¤Í¤p¹xµ£©Ò¨¥, «D±`´Á«Ý¬Ý±zªº¤å³¹, ¹ï§Ú̳oºØ©|¦b¾Ç²ß¤¤ªº«á¾Ç, ¸g±`²£¥Í¨£¾ð¤£¨£ªLªºÂÕ«ä. «Ü¦hªº²z¸Ñ¤]¬O¾aª©¤W«e½ú@¤ß«ü¾É¤è¯à¾Ç²ß¤@¤G. ¬Û«H«Ü¦h¼ç¤ôªº¯E¤Í¹ï±zªº«W¸¨³¯z, ª½¨¥¤£¿Ð³£²`·P¨ü¯q¨}¦h. §Æ±æ±z¯à«ùÄò¦b¦Ê¦£¤§¾l¤À¨É±zªº¨£¸Ñ. ¥t¥~½Ð±Ð, ¦b¤G´Á¤¤©Ò¿×ªºproof of concept, ¤@©wn¨Ì¾Ú¼Æ¾Ú P<0.05 ¶Ü? °²³]ªºª¬ªp¥¼¨ÓOS¥X¨Ó, ¸û¹ï·Ó²Õ¨Î, HR´¶´¶OK, ¦ýPÈ¥¼¹F¼Ð., ³o¼Ë¥i¯à·|¦p¦ó»{©w ? ´Á«Ý±zªºÆ[ÂI. ¦P®ÉÀµ½ÐCliff¤j, ¦Ñ¥v¤jµ¥ª©¤W¥ý¶i¬O§_¯à´N±z̪º»{ª¾«ü¾É¤@¤G ? |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/11/6 ¤W¤È 11:08:27²Ä 2845 ½g¦^À³
|
³\¤j ¬JµM«ù¦³´N¦w¤ß@¤ßµ¥«Ý¤½¥qªº¶iµ{ ªF°Ý¦è°Ý¥u¬O¬ðÅãµJļ¤§¤ß¡A©ó¨Æ¤]µL¸É ¤£µM´N°h¥X¸¨Ó¦w¤ß¡A¥Í§ÞªÑÁÙ¦³¤£¤Ö¦n¼Ðªº¦Ó¥B·ÀI«Ü§CªºÓªÑ¥i¿ï ¸Û¤ß«Øij¡Aµ´µL¤£·q |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/11/6 ¤W¤È 09:41:52²Ä 2844 ½g¦^À³
|
T¤j: ÁöµM§Ú¤£¬O«ÜÀ´ ¦ýÁÙ¬OÁÂÁ§Aªº¤À¨É. ¤§«e§A¦³´£¨ì 2017¯E¹©¦³«Ü¦hÁ{§É¦P®É¶i¦æ..... ½Ð°Ý³o¦³¯S§O¥Nªí¤°»ò? ¤è«K»¡©ú¶Ü? ÁÂÁÂ! |
|
|
·|û¡Gfun10138468 µoªí®É¶¡:2016/11/6 ¤W¤È 12:36:00²Ä 2843 ½g¦^À³
|
walker¤j: ÁÂÁ§Aªº¸Ñµª¡A§ÚÀ´¤F¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/11/5 ¤U¤È 09:53:16²Ä 2842 ½g¦^À³
|
fun ¤j ¤p§ÌÂû±C¤@¤U IgG 1:40 171¤H ¥|¦~¦s¬¡¾÷²v 77.2% IgG 1:80 148¤H ¥|¦~¦s¬¡¾÷²v 74.8% IgG 1:160 112¤H¥|¦~¦s¬¡¾÷²v 78.1% IgG 1:320 84¤H ¥|¦~¦s¬¡¾÷²v 85.9% IgG 1:640 50¤H ¥|¦~¦s¬¡¾÷²v 91.8 % ½Ð°Ý:IgG 1:40-1:640 Á`¤H¼Æ¶W¹L300¤H¥H¤W¡A¥i¬O¹êÅç²Õ¤H¼Æ¤£¬O¤~240¤H¶Ü¡H³oÂI§Ú«Ü§x´b¡AÀµ½Ð¸Ñµª¡AÁÂÁ§A¡C IgG 1:40 ªº·N«ä¬O IgG ¿@«×¶W¹L 1:40 ªº¤H¼Æ¦³ 171 ¤H, ³o¸Ì¤w¥]§t¿@«× 1:80 ~ 1:640 ©Ò¥HÁ`¤H¼Æ¤£»Ýn¥[°_¨Ó |
|
|
·|û¡Gfun10138468 µoªí®É¶¡:2016/11/5 ¤U¤È 08:20:34²Ä 2841 ½g¦^À³
|
¤p©_¤j¤H¤é¦w: IgG 1:40 171¤H ¥|¦~¦s¬¡¾÷²v 77.2% IgG 1:80 148¤H ¥|¦~¦s¬¡¾÷²v 74.8% IgG 1:160 112¤H¥|¦~¦s¬¡¾÷²v 78.1% IgG 1:320 84¤H ¥|¦~¦s¬¡¾÷²v 85.9% IgG 1:640 50¤H ¥|¦~¦s¬¡¾÷²v 91.8 % ½Ð°Ý:IgG 1:40-1:640 Á`¤H¼Æ¶W¹L300¤H¥H¤W¡A¥i¬O¹êÅç²Õ¤H¼Æ¤£¬O¤~240¤H¶Ü¡H³oÂI§Ú«Ü§x´b¡AÀµ½Ð¸Ñµª¡AÁÂÁ§A¡C |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/11/5 ¤U¤È 08:17:38²Ä 2840 ½g¦^À³
|
ÁÂÁÂT^T¤j¦Ê¦£¤§¤¤¤À¨É±zªº¬Ýªk Àµ½Ð±z¦b¦³ªÅ¤§¾l ¯à¨Ó¥²´Iºô¤À¨É §ÚÌ«Ü´Á«Ý¬Ý±zªº¤å©O !!! ¹ï§Ú¦¬Ã¬«Ü¤j ¯uªº«ÜÁÂÁ ^^ ¦³¤@Ó¤p¤p°ÝÃD,±z´£ªºESMO PPT Slide.9¨º±i¹Ï,§Úªº²z¸Ñ¬O¨º±i¬O¹êÅç²Õ¸ò¹ï³y²Õ¤À§O¦³¥´§¹¤E°wªº±wªÌ©Ò»s¦¨ªº¹Ï ¹êÅç²Õ¦³46%§¹¦¨¤E°w ¹ï³y²Õ¦³52%¤ñ¨Ò§¹¦¨¤E°w ¦n¹³¤£¬O¹ï³y²Õ¬D±¼¤w¸gPROGRESSION¨S¥´§¹9°wªº¯f¤H,¥h©M¥þ³¡¹ï·Ó²Õ¤ñ ÁÙ¬O§Úªº²z¸Ñ¬O¿ùªº?? |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/11/5 ¤U¤È 06:22:34²Ä 2839 ½g¦^À³
|
ÁÂÁ´£¨ÑESMOºtÁ¿ÀÉ¡A¥þµ{³£¦³Å¥§¹¤@¦¸¡A¦³¨Ç¦a¤è¦³¤ÏÂÐÅ¥¡A¤W¶g¨ä¥LºÞ¹D´¿¸gµoªí¹L©å¨£¡A¤Í¤H§iª¾¤£n¨ì¥²´I½×¾Ô¡A³QÂI¦W¤F¤£¦n·N«ä¼g¤@ÂI¤F(«Ü¦h¬O½Æ»s¶K¤Wªº¦rµü) µ²½×: proof of concept ->¨Ì¥Ø«e¤½¥q´£¨Ñªº¸ê°T(¥x¤j¶ÀÂå®v: S8)¡A¦³¥¿¦V¬Ý«Ýªº²z¥Ñ¡A¦ýµ¥«Ý®É¶¡ÃÒ©ú¡C «ÂI¬O§ä¥X¾A¦Xªº±Ú¸s°µp3¡A¦Ó¥B¦¹¬ã¨s®É¶¡¤Óªø¡A¼vÅT¦s¬¡Åܼư£Àù¯gÁÙ¦³¨ä¥L¦]¤l¡A¼Æ¾Ú¤£©ú¤Un¤p¤ß¸ÑŪ¡C ¥x¤j¶ÀÂå®v: s5 ¨È¬w¤H¦û¬ã¨s±Ú¸s¤ñ¨Ò¤Ó°ª,¬ü°êFDA¥²¦³ºÃ¼{ s9 ¬D±¼¤F¤w¸gPROGRESSION¨S¥´§¹9°wªº¯f¤H¡C¥h©M¥þ³¡¹ï·Ó²Õ¤ñ¡A¤@¼Ë¦³¤£¤½¥ªº¦a¤è s15 ¦³ª§Ä³³B ¥´§¹9°w§ÜÅé°ª¡A¬OÃĪ«ªºÃö«Y¡AÁÙ¬O¥»¨Ó³o²Õ¯f¤H¥»¨Ó´N¬O·|°ª§ÜÅé(¦s¬¡¸û¤[¡APFS¸ûªø)¡A¤Ï¹L¨Ó»¡¡A¥´ªº¾¯¶q¶Vµu(¥Nªí·U¦PFS¡A¯f¤HÅé½èÄݧC§ÜÅé¡A¦s¬¡¶Vµu) S17 Àù²ÓM¨S¦³globo H ªº¯f¤H¡AHR³ºµM±µªñ0.5¡A¦pªGP3¬D³oÓ±Ú¸s°µ¸ÕÅç¡A·|¤£·|¤j¤j¦¨¥\? ©Î¬O¬D3+¤]¦æ¡A ¦ý«ç»ò¸ÑÄÀ1+ªº¯f¤H«o¨S¦³Àø®Ä¡C¨ä¹ê³Ì«ápanel discussion¨ä¥LÂå®v¤ñ¸û¸Û¹ê¡A¹ïÀø®Ä³£ªí¥Ü¼Æ¾Ú¦³¡An¦A¬ã¨s!¤]±j½ÕP3«ç»ò¿ï¯f¤Hªº«n! ³¯°|¤h s17 Globo H Ceramide act as immune check point molecule -> inhibit proliferation of T-cell & B-cell s23 Globo H enable tumors to evade the immune system and acts as angiogenics factor ©Ò¥H¹ï¥»¨¨S¿ìªk²£¥Í§ÜÅé±Ú¸s¡Aµ¹¥LGlobo-H·|¤£·|¤Ï¦Ó¦³®`? ¨Ì·Ó«H¿à«OÅ@ì«h¡A©Ò¿×¥ý¥´¤@°w¬Ý¬Ýªº»¡ªk¡A¬O¤£¬O·|®`¨ì³o¤@±Ú¸s¯f¤H!§Ú¤£»{¬°¬O¥i¦æªº! µ²½×: anti-GloboH §ÜÅé²£¥Í©M¯f¤H¦s¬¡§e¥¿¬ÛÃö¡A©Ò¥H¦¹§ÜÅ鬰¹w«á«ü¼Ð¡A¦ýÃĪ«Àø®Ä¤Î¾A¦X±Ú¸s«Ý½T»{¡C·íµMªÑ»ù¤ÏÀ³¦p¦ó§Ú´N¤£ª¾¹D¤F! Á{§É¤W©Ò¦³ÃĪ«³£·|®`¨ì¤Ö¼Æ±Ú¸s¡A¦ý¦pªG¯à§ïµ½¤j¦h¼Æ±Ú¸s¡A¨º»ò³oÓÃĪ«´N¦³¦s¦b»ùÈ¡A¤]´N¬O¦P¤@°_ÂI¡A¬ã¨s«á¥iÃÒ¹êÀø®Ä¡A´Á«ÝS8³Ì«áµ²ªG¬O¥¿±ªº! |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/11/5 ¤U¤È 03:49:25²Ä 2838 ½g¦^À³
|
¹ï¤£°_¡A»~»{QQ¤j¬°·x·x¤j |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/11/5 ¤U¤È 03:25:00²Ä 2837 ½g¦^À³
|
QQ¤j ÁÂÁ±zªº¼ö¤ß¡A³o¨Ç¤j«L¨Ó¥hµLÂÜ¡A´£°Ý¤£¨£±o·|¤Þ°_¥L̪º¦^À³¡A ¸Ñª¼¨´¤µ¤w¹O8Ó¤ë¡A¸ê®ÆÁö¤´Ãø¥H¿s¥þ»ª¡A¦ý¤j¶ÕÀ³¸Ó¤w©w¡AªÑ»ù¤]¨«¶^¦Ü¦¹¡A¦AÃa¤]¦³¤F °O±o¸Î§Ì¦b2012¦~ªì¤p§Ì¶R¤J®É¡A´N£¸ª½¦b½Í±ÂÅvªº°ÝÃD¡Aª½¨ì¤µ¦~2016¦~¤~¦³µÛ¸¨¡A µ¹¤½¥q®É¶¡³Ð³y³Ì¨Îµ²ªG¬O¤p§Ì¥Ø«eªº¤ß¹Ò |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/11/5 ¤U¤È 12:41:38²Ä 2836 ½g¦^À³
|
½Ð±ÐT^T: ±zªºÆ[ÂI¦b9/13²Ä2553½g¤¤´£¤Î: ¡§¦ý¬OOBI 821/822 ªºP2 proof of concept¥Ø«e, ¦A±j½Õ¤@¦¸¬O¥Ø«e, ´N¬OÁÙ¨S(¦¨¥\)½T»{!¡¨ ¯E¹©¦b10/26¤½§i¤F³¡¥÷ESMOªº¸ê®Æ, ÀH§Y¯E¤Í¤p³½(10/30 ²Ä2849½g)¤]´£¨Ñ¤F§¹¾ãªºESMOÁ¿ªÌ¼vµ. ½Ð°Ý¦b³o³Ì·sªºµoªí«á, ±z¤Wzªº¬Ýªk¬O§_¤w¦³§ó·s ? ¦pªG¦³, ½Ð°Ý¬O¦ó¦]¯À³y¦¨ ? ÁÙ¬O³o¤º®e©M±z즳ªº»{ÃÑ¥u¬O¤FµL·s·N ? «D±`´Á«Ý±zªº¨£¸Ñ¤À¨É. ·PÁ |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/11/4 ¤W¤È 11:38:25²Ä 2835 ½g¦^À³
|
ÁÂÁ¤ѩR¤j |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/11/4 ¤W¤È 10:54:35²Ä 2834 ½g¦^À³
|
Æ[¹î«ü¼Ð¦bpµe®Ñ¡A¬O¤£¬O¥u¯à«ü©w¤@Ó¡H |
|
|
·|û¡Gming10140949 µoªí®É¶¡:2016/11/4 ¤W¤È 10:41:24²Ä 2833 ½g¦^À³
|
¤p·s¤j¤j: ¥Ó½Ð«á1Ó¤ë,FDA¨Sij¨£,´Nºâ®Ö¥i! |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/11/4 ¤W¤È 10:29:31²Ä 2832 ½g¦^À³
|
Ó¤Hªº»{ª¾¬O¥un¤T´Á¹êÅç³]p³QFDA®Ö·Ç,Y¤T´Á¹êÅçµ²ªG¦¨¥\,¥i¨Ì¦¹¼Æ¾Ú ¦VFDA¥Ó½ÐÃÄÃÒ §Y¨Ï¬O ¥u¿z¿ïIgG®Ä»ù°ªªº¯f¤H°Ñ»P¡AµLªk¦b²Îp¤WÅã¥Ü¦P¤@°ò¦ªº¤½¥©Ê ªº¤T´Á¹êÅç³]p,¥unFDA®Ö¥i§Y¥i ¤£ª¾¬O§_¦³»~? |
|
|
·|û¡Gªø½u10139882 µoªí®É¶¡:2016/11/4 ¤W¤È 10:21:40²Ä 2831 ½g¦^À³
|
¤j¤j̦n ¤½¥q¦p¦ó¿z¿ï¹êÅç±ø¥ó¡A¥¼¬Ý¨ìpµe®Ñ¡A¤£ª¾!¦ý¤½¥q¸Ì¦³¤@°ï±M®a¡A§Ṳ́j¥i©ñ¤ß§a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/11/4 ¤W¤È 10:12:35²Ä 2830 ½g¦^À³
|
¤Ñ©R¥S §A³o¼Ë·|Åý¯E¤Í»~¥H¬°§Ú»¡¤F¡G ¡u¥u¿z¿ïIgG®Ä»ù°ªªº¯f¤H°Ñ»P¡AµLªk¦b²Îp¤WÅã¥Ü¦P¤@°ò¦ªº¤½¥©Ê¡A¥u¦n¼W¥[¼Ë¥»¼Æ¡C¤~¯à¹F²Îp¤WªºÀË©w¤O¡C¡v ¦pªGBaseline demographic characteristics³£¤£¤@¼Ë¤F¡A¼Ë¥»¦A¦h¤]¨S·N¸q |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/11/4 ¤W¤È 08:54:52²Ä 2829 ½g¦^À³
|
«e½ú¦n ¦pªG¤£¿z¿ï¾Ç¥Í «ÜÃøÃÒ©ú¥x¤j¦Ñ®v¤ñ¸û·|±Ð®Ñ ¦ý¦pªG¯¸¦b°ö¨|¤H¤~ªº¥ß³õ ¿z¿ï¤£¦P©Ê¦Vªº¾Ç¥Íµ¹¤©¤£¦Pªº±Ð¨|¤è¦¡ ³oÓ¤]¬O«D±`ȱoªÖ©wªº§@ªk ©êºp±ß½úJ¨¥¶Ã»y¤F |
|
|
·|û¡GSun10140214 µoªí®É¶¡:2016/11/4 ¤W¤È 01:22:55²Ä 2828 ½g¦^À³
|
New cancer drugs may damage the heart Marilynn Marchione, The Associated Press NBC NEWS www.cnbc.com/2016/11/03/new-cancer-drugs-may-damage-the-heart.html Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer: In rare cases, they may cause potentially fatal heart damage, especially when used together. The problem is, no one has this on their radar, so patients are not routinely checked for it, said Dr. Javid Moslehi, head of a Vanderbilt University clinic specializing in heart risks from cancer therapies. He led a team of experts who reported Wednesday in the New England Journal of Medicine about two patients who died of heart trouble two weeks after receiving their first doses of two Bristol-Myers Squibbdrugs, Opdivo and Yervoy, for the deadly skin cancer melanoma. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/11/3 ¤U¤È 04:13:30²Ä 2827 ½g¦^À³
|
Cliff¤j¡A ¡yÁÙ¦³¨ºÓ¥|¦~¦s¬¡²vªº³¡¥÷¡A¡u¥|¦~¡v«üªºÀ³¸Ó¬O±q¡u²Ä¤@¦ì¡v¨ü¸ÕªÌÀH¾÷¤À°tªº®É¶¡ºâ°_ªº¥|¦~¡A¦Ó«D¡u¨C¤@¦ì¡v¨ü¸ÕªÌ³Q°lÂÜ¥|¦~«áªºµ²ªG¡z Ãö©ó¥|¦~¦s¬¡²v¡A¤½¥qªº¼Æ¾Ú¤£Â_¥X²{¡A¥Î¨Ó¤ñ¸û¨â²Õ¤§¶¡ªºOSÀø®Ä¡C¤p§Ì¥i¯à¤§«e¸ÑÄÀªº¤£²M·¡¡A¥|¦~¦s¬¡²v¨ä¹ê´N¬OASCOªºP17ªºKM¦±½u»PX¶b48Ó¤ë¬Û¥æªº¦s¬¡¾÷²v¡A¦pªG¼Æ¾Ú°÷¦¨¼ô¡A§ÚÌ¥i¥H¬Ý¨ì¦b48Ӥ릳¨¬°÷ªº¼Ë¥»¼Æ³q¹L¤Î¨¬°÷ªº¨Æ¥ó¼Æµo¥Í¡A¨º»ò¦¹®Éªº¥|¦~¦s¬¡²v´N»P³Ì²×ªºOS¤ÀªR©Ò¬Ý¨ìªº¹ê»Ú¥|¦~¦s¬¡²v¬Û·í±µªñ¡C¦ýASCOªºP17©Ò¬Ý¨ìªº¹Ï¡A¾ãÅéÁ{§ÉÆ[¹î®É¶¡¤£°÷¤[¡A28Ӥ몺¦s¬¡²v¦]¬°¤w¦³¤j¬ù57%ªº¤H³q¹L¡A¨ä¥¦43%ªº¤H¤]³£¦b16~28Ó¤ë³~¤¤¡A¦]¦¹¥Ø«eP17¬Ý¨ìªº28Ӥ몺¦s¬¡²v·|»P³Ì²×ªºOS¤ÀªR©Ò¬Ý¨ìªº28Ó¤ë¦s¬¡²v¬Û·í±µªñ¡F¥Ø«eP17¬Ý¨ìªº32Ӥ몺¦s¬¡¾÷²v(78.05%¡B52.99%¡B60.51%)¦]¬°¤w³q¹Lªº¼Ë¥»¤H¼Æµy¶û¤£¨¬¡A¦]¦¹³oÓ78.05%¡B52.99%¡B60.51%»P³Ì²×ªºOS¤ÀªR©Ò¬Ý¨ìªº32Ó¤ë¦s¬¡²v¥i¯à¦³µy¤j¤@ÂIªº»~®t¡A¦ý¦pªG¦¦¬®×»P±ß¦¬®×ªº¦s¬¡ª¬ªp¤£n®t¤Ó¦h¡A«h³Ì²×OS¤ÀªRªº32Ó¤ë¦s¬¡²v»P78.05%¡B52.99%¡B60.51%³»¦h¬O2%¤W¤Uªº®t²§¡C¦Ü©óP17Åã¥Ü4¦~¦s¬¡²v¬°¦ó¤]¬O78.05%¡B52.99%¡B60.51%¡H¨ä¹ê¥HP17ªº¹Ï¨Ó¬Ý¡A¤w¸gÆ[¹î32Ó¤ë¦s¬¡ª¬ªpªº¤H¤Ó¤Ö¡A«ê¥©32Ó¤ë¥H«á¤S¨S¦³¦º¤`¨Æ¥óµo¥Í(¥u¦³§C¤ÏÀ³²Õ¦b33Ӥ릳¤@Өƥó)¡A¦]¦¹32Ó¤ë¥H«áªºKM¦±½unµe¤ô¥½u¡A³o78.05%¡B52.99%¡B60.51%¹ï32Ó¤ë¥H«áªº¦s¬¡²v´yz¨Ó»¡³£¥u¬O¼È®Éªº¥N´À¼Æ¦r¡An»¡40Ӥ몺¦s¬¡¾÷²v¬O78.05%¡B52.99%¡B60.51%¤]¦æ¡An»¡60Ӥ몺¦s¬¡²v¬O78.05%¡B52.99%¡B60.51%¤]¦æ¡A¦]¬°P17¹Ï¤WX¶b¤@©Ô»P¦±½u¬Û¥æªº³£¬O78.05%¡B52.99%¡B60.51%¡A¦ý³o³£¥u¬O¼È®Éªº¥N´À¼Æ¦r¡C ±q2015/10¨ì2016/10¤S¹L¤F12Ó¤ë¡A쥻28Ӥ몺±wªÌ³£Æ[¹î¨ì¤F40Ó¤ë¤F¡AY¦¹®É¥´¶}¬ÝOS¤ÀªR¡A¥i¥H¬Ý¨ì40Ӥ몺¦s¬¡²v»P78.05%¡B52.99%¡B60.51%¤£¤@¼Ë(³£¸û§C)¡A¤T²Õ¦U§O¥H¤£¦Pªº³t«×¤U°¡A¦¹®ÉÆ[¹î¨ìªº40Ó¤ë¦s¬¡²v»P³Ì²×OS¤ÀªRªº¦s¬¡²v·|·¥±µªñ¡A·íµM40Ó¤ë¥H«á¤]·|¦³¤@¨Ç¹s¬Pªº¨Æ¥óµo¥Í¡A¦ý¦]¬°³q¹L40Ó¤ë©Ò¯àÆ[¹î¨ìªº¼Ë¥»¼Æ¤£¨¬¡An»¡40Ó¤ë¥H«áªº¦s¬¡²v¦p¦ó¡Aºë½T«×·|¤ñ¸û®t¡A·íµM¤]¥i¥Hµe¥X4¦~¦s¬¡²v¡A¦ýÁÙ¬O¦³¼Ë¥»¥Nªí¼Æ¤£¨¬ªº°ÝÃD¡A³»¦h¥u¬ã§P¨ì44Ӥ몺¦s¬¡²v¡A©Ò¥H¦pªGn¤ñ¸ûºë½Tªº´yz4¦~¦s¬¡²v¡A¤ñ2016/10¦A¦hÆ[¹î4Ó¤ë¨ì8Ó¤ë·|¤ñ¸û¦n(¦A¦h4Ó¤ë¬O¤ñ¸û¤jÁxªº¬ã§P¡A¦A8Ó¤ë¨äºë½T«×´N»P³Ì²×OS¤ÀªR(¤j³¡¤À±wªÌ³£Æ[¹î5¦~)ªº¹ê»Ú4¦~¦s¬¡²v·¥¬°±µªñ¡C¥u¬O¤p§Ì¤£ª¾¬°¦ó¤½¥qªº¼Æ¾Ú(¥]¬A¤@´Á)³£n¥[µù4¦~¦s¬¡²v¡H ©Ò¥H¡A¤p§ÌÁ¿ªº4¦~¦s¬¡²v´N¬OKM¦±½uªº4¦~¦s¬¡²v¡A¤]´N¬O¥Î¦s¬¡¨ç¼Æ¨Ó¬ã§P©Ò¦³¨ü¸ÕªÌªº4¦~¦s¬¡²v¡A¦ý¦]¬°nµ¥¨ì³Ì«á¤@¦ì¨ü¸ÕªÌ¤]¹F¨ìÆ[¹î4¦~nµ¥«Ü¤[¡A¥un¦³¤j¬ù6¦¨ªº¨ü¸ÕªÌ¤wÆ[¹îº¡4¦~¡A¥Î¦s¬¡¦±½u©Ò¬ã§Pªº4¦~¦s¬¡²v´N·|»P¸Ó¹êÅ窺³Ì²×¹ê»Ú¦s¬¡²v·¥¬°±µªñ¤F¡C Cliff¤j¦³¸Ü»P¤p§Ì»¡¡A¤p§ÌÀH®É¬~¦Õ®¥Å¥¡C |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/11/3 ¤W¤È 12:52:56²Ä 2826 ½g¦^À³
|
¥xÁÞ¤j,¨¯W¤F,ÁÂÁÂ! |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/11/3 ¤W¤È 12:25:48²Ä 2825 ½g¦^À³
|
¥xÁÞ¤j ÁÂÁ±z¡A©ú¥Õ¤F ½ÐÄ~Äò¥[ªo |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/11/2 ¤U¤È 10:15:55²Ä 2824 ½g¦^À³
|
ÁÞ¤j¡A¤½¥q«áÄòªº¨M©w§Ú³£¤ä«ù¡Aµ´¹ï¬Û«H¤½¥qªº±M·~...¤£½×¬O¦b¦X§@¹ï¶H¡A©Î¬O¨M©w±ÂÅvªº®É¾÷¡A¤@¤â¦nµP¡A¬Û«H¤½¥q³£·|¦³³Ì¦nªº¨M©w¡A¤j«×¤s©]§N¡A²y³õ·Án¦h...¤£¾A¦X¥´²y¤F... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/2 ¤U¤È 09:47:47²Ä 2823 ½g¦^À³
|
½n¶¯¤j ±ÂÅvì«h¤½¥q¦³´£¨ì:¯àÅý822¬ãµo³t«×¥[§Ö ¯àÅý²£«~½u§Ö³tÂX¥R ¡C Roche ¦³¨ÅÀùÃĤW¥«¡A§Ú»{¬°¥i¯à©Ê¤ñ¸û§C¡C °ê»Ú¤W±ÂÅv¡Aµ¦²¤Áp·ù¡A¦XÁa³s¾î¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/11/2 ¤U¤È 09:20:17²Ä 2822 ½g¦^À³
|
ÁÞ¤j¡A§A³o¼ËÂI¦WBristol-Myers Squibb¡BMerck¡BRoche¡K¡A¨º¾Õ©ó¦X¨Ö¦¬ÁʪºPfizer ·|«Ü¶Ë¤ß¡A¤H®a¤]¬O«Ü¿n·¥¸ò¶ÀÁ`¦b°Q½×¬ã¨s¡A¤£¹L¯¸¦b¯f¤H¥i¯à»Ýn¦X¨Ö¥ÎÃĪº¥ß³õ¡A¸òBristol-Myers Squibb¡BMerck¡BRoche¥i¯à¬O¤ñ¸û¦nªº¿ï¾Ü¡CPfizer¦b§K¬ÌÀøªk³o¶ô¦n¹³ÁÙ¬OÂù¤âªÅªÅ¡AY¨S¦³¤@Ó¦nªº§ÜÀùÃĪ«¡Aµ¥VIAGRA±M§Q´Á¨ì¤F¡A¥i¯à´N³Ü¦è¥_·¤F¡K.½Ö¥s¥LÂŦâ¤pÃĤY½æ¨º»ò¶Q¡K.¤Ï¹ï¤½¥q±ÂÅvµ¹Pfizer¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/2 ¤U¤È 07:48:30²Ä 2821 ½g¦^À³
|
²´·ú¦Ñªá¶V¨Ó¶V« C §ó¥¿¬°¡A°£¤F¤½§G2016¦~ESMO·sªº¼Æ¾Ú¥~: @ ÄáÅ@¸¢Àùªº¼Æ¾ÚÀ³¸Ó¬O¼ƾڦAESMO¦A«´£¤@¦¸¡A·Pı¦n¹³¬Onªí¹F¨Ï¥Î¾¯¶qªº¥¿½T©Ê |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/2 ¤U¤È 06:56:08²Ä 2820 ½g¦^À³
|
¸É¥R»P§ó¥¿A: A OBI8222¨t¦Cªº»ùȹF¨ì³Ì°ª: ±q¤µ¦~¦~³ø»P9¤ëªk»¡Â²³ø:³W¹º¤¤ªº¦³ªÍÀù GÀù ¤j¸zÀù ¨xÀù ¯ØŦÀù ¥[¤W¨ÅÀù §Z±_Àù ¦@¤CºØ ,OBI8222¨t¦Cªº»ùȹF¨ì³Ì°ªÓ¤H»{¬°¬Opipeline ªºÂX¥R»PÀu²§ªºÁ{§É¼Æ¾Ú,¦w¥þ©Ê»P¥Í¬¡«~½è ,±M§Q«OÅ@ªø«×»P±j«×, ÃÄ ª«»s³yµ¥¬ÛÃöªº Data Rooms ,OBI8222¨t¦C ¾A¥Î16ºØÀù¯g , ¤µ¦~ªÑªF·|¯E¹©¤]¦³´£¨ì¥un¬O¦nªºdeal, ¦nªº±ø¥ó,¯E¹©¤]·|¦Ò¼{¾ãÓOBI8222¨t¦C±ÂÅv,·|¥Î°ê»Ú³W®æ¨Ó½Í(¤jÃļt·|¤£·|¬O¦³¬ãµoÀˬdÂI§í¨î¾¯ PD-1,PD-L1,CTLA-4 ªº¤½¥q???) ¥H¤W¸É¥R ´£¨Ñ¤À¨É»P°Ñ¦Ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/2 ¤U¤È 05:11:53²Ä 2819 ½g¦^À³
|
Sorry ¤p·s¤j ¤~¹ï |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/11/2 ¤U¤È 05:06:36²Ä 2818 ½g¦^À³
|
¤pªY¤j IgG §ÜÅé®Ä»ù 1:40 »P 1:80 ±q·ÀI¤ñ ¥|¦~¦s¬¡²v »P PÈ¨Ó¬Ý ¨ä¹ê¹ïÀ³ªºÁÙºâ²Å¦XÅÞ¿è ²q·Q¤j¤w¸ÑÄÀì¦]¤F ¦h´XӨƥóPÈÅܤƷ|§ïÅÜ ,§Ú¬Û«H²q·Q¤jªº§PÂ_ ( ¤½¥q³Ìªñ¥i¯à¤ñ¸û¦£ ¤£©öÁpô ) ·x¤j D¤j ²³¤j¤j ¤j®a«ÜÃö¤ß¯E¹©¤°»ò®ÉÔ·|µo§G§Q¦h Ó¤H»{¬°¯E¹©¦bµ¥¤@Ó best timimg ¦A¥XµP , ¥H¦X§@±ÂÅv¨Ó»¡ A OBI8222¨t¦Cªº»ùȹF¨ì³Ì°ª:822¥t¥~¾AÀ³¯gªÍÀù GÀù ¤j¸zÀù ¨xÀù ¯ØŦÀù¤G´ÁÁ{§É³W¹º °ê»Ú¤jÃļt¤@©w·|µû¦ô822¦b³o¤CºØÀù¯gªº±ÂÅvÁ`»ùÈ ) B ¬ü°êFDA¹ï¨ÅÀù¤G´Á¦ì¶¥ªº»{©w: ¬O§_µ¹¤©conditional approval ©Î BTD , AA, Á{§É¤H¼Æn¨Dµ¥¤è¦Vªº½T©w ±ÂÅv¤jÃļt¤@©w·|µû¦ô,Ó¤H»{¬°¬ü°êFDA¹ï¨ÅÀù¤G´Á¦ì¶¥ªº»{©w»P¤è¦Vªº½T©w·|¥ýµo¥Í, ¦A¨Ó¤~¬O¬O¦X§@±ÂÅvªºµo¥Í ®É¶¡¤w¶i¤J˼Æp®É C 2016 ESMO ¯E¹©¤½§i·s¼Æ¾Ú ¥[¦{¬¥§üÁF¶ëÁ[º¸.¶ø´µ´Üºî¦XÀù¯g¬ã¨s©Òªº¸~½FÂå¾Ç±M®a§Æ·æ.³Á§Jªü·æÂå¾Ç³Õ¤h¤]´£¨ì¨ä¥LÀù¯g ÄáÅ@¸¢Àù¤@´ÁÁ{§É¦b¤£¦P¾¯¶q¤UIgG IgM §ÜÅé§K¬Ì¤ÏÀ³±¡§Î ¦o¤]¦bP7 ¯S§O´£¨ì¥D°Ê§K¬ÌÀøªk»PÀˬdÂI§í¨î¾¯ªºÁp¦XªvÀø¤Wªº¼ç¤O ±qÅ¥²³¤ÏÀ³½Õ¬d¤¤°ª¹F 94% »{¬° ÀˬdÂI§í¨î¾¯( PD-1 PD-L1 CTLA-4 ) »PÀù¯g¬Ì]Áp¦X¨Ï¥Î¬O¦X²zªºªvÀøµ¦²¤ Ó¤H»{¬°³o¹ïOBI8222¨t¦Cªº»ùȦ³¥[¤À§@¥Î ¤]´£°ª°ê»Ú¤jÃļt±ÂÅv·NÄ@ §K¬ÌÀøªk Àù¯g¯f¤Hªº·s§Æ±æ www.twhealth.org.tw/index.php?option=com_zoo&task=item&item_id=936&Itemid=19 ¸~½F¬Ì]»PT ²ÓM½Õ±± homepage.ntu.edu.tw/~ntucdbrm622/20160601-10.pdf D¤j: ¹ªÀy±ø¤j¦h¥X¨Ó¬°¤j®a¥[ªo¥´®ð, ¥Lªºª©¥DÃD¤]«Ü´Î, §ÚÀ³¤£»Ý¦A¶}Óª©, ÁÂÁ ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/11/2 ¤W¤È 07:47:11²Ä 2817 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±zªº¦A¦¸½T»{¡AÄYÂÔªº¨D¯u»P¹ï¤pªº¨þÅ@·ÓÅU¡AÁö¤Ñ²D¡A¦ý¤pªº«o·x¹M¥þ¨ ³o¼Ë´N¯à¸ÑÄÀ¬Y¨Ç¼Æ¾ÚªºÃþ¦ü¸õ°w²{¹³¡A©Î¤]¯d¤U¨ì©³¬O¦ó¶µ¦]¯À¨ÏµMªº½T»{ªÅ¶¡ §Æ±æ¤½¥q¦¤é¤½§G¬ÛÃö¼Æ¾Ú¡A¥H¸Ñ²³´b ÁÂÁ±z¡A«Ü¸r¼}±z^¤å³o»ò´Î ª¾ÃÑ»P¯à¤O®t¶Z¡A²ª½¤£¯à¥H¥j¦Ñªº¹D¨½p ¦A¤@¦¸·PÁ±zªº¨þÅ@»P«ü¾É ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/11/2 ¤W¤È 01:50:27²Ä 2816 ½g¦^À³
|
Cliff ¤j: ·P¿E±z¸ÔºÉ²M·¡ªº¦^ÂÐ, ÁÂÁ±zªº@¤ß«ü¾É. ¤j·PÁ ! ®M¥Î²q·Q¤jªºÃã·J: ¡§Åý§Ú·P¨ì©¯¹B»P©¯ºÖ¡¨ ·P®¦±zªu¸ô¤Þ»â¶i¤JÁÞª¾ÃѤΥÍÂå¬ÛÃöªº·µ°ó ! ¦V±z·q§ ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/11/2 ¤W¤È 12:05:39²Ä 2815 ½g¦^À³
|
QQ¤j ±zªº´£°Ý·U¨Ó·UÃø¡A¤p§Ì¤O¦³¤£¶e¡A»Ýn¨D±Ð±M®a¡C ¶À¥D¥ô ESMO slide No.16¡G Q.:1) ¡uMean IgM Titer¦b40©P«á´N½w¨B¤U¶^, 56©P«á¶^¦Ü20¥H¤U., 96~104©P³º¥X²{¤Ï¼u., ÁöµMtiter§C, 20¥H¤U, ¦ý¤´¬O¦³, ¸ûªì©l°ª. ¯à±À»¡IgM¤]¦³¦~¥H¤Wªº°O¾Ð¶Ü ?¡v A.¡G±M®aªº¦^µª¡]è¥XÄl¡^¡GELISAªº¤ÀªR·Ç«×¦³¡A®Ä»ù§C©ó20®É¥iµø¬°µ¥¦P©ó¹s¡Aºâ¦b¤£·Ç«×ªº½d³ò¤º¡A°£«D¦³¾÷·|¬Ý¨ì¦A²{©Ê¡A§_«h¤£¥²¶O¤ß¥h·Q²z¥Ñ¡C¡]¦bMean IgG Titer¹Ï¤¤¹ï·Ó²Õ¦bweek 64-96¤]¦³IgG¤W¤ÉªºÃþ¦ü²{¶H¡A¹D²z¬Û¦P¡C¡^¡]µù¡G¦A²{©ÊÀ³¸Ó¬O«üreproducibility¡^ ¥H¤U¬O¤p§Ì§ä¨ìªº¸ê®Æ¨Ñ±z°Ñ¦Ò¡A¶û³Â·Ðªº¸Ü¥un¬Ý¤WzªºµªÂЧY¥i¡C ¤@¯ë»{¬°IgM¬O¦b³Q·P¬Vªºªì´Á·|§Ö³t¤É°ª¡AµM«á®Ä»ùº¥º¥°¤U¨Ó¡A¦A¹J¨ì§Üì¨ë¿E®É¤´·|¤É°ª¡A¦ý¤ñ²Ä¤@¦¸³Ì°ª´T«×¤p±o¦h¡C¤£¦Pªº§Ü줧¶¡¥i¯à¦s¦b¤p®t²§¡A¦ý¤@¯ë«w»{»PIgGªºªø´Á°O¾Ð©Ê©Ò»¤µoªº¡u´T«×¡v¤£¯à¤ñ¡C¦Ü©óduration¦³¦h¤[¡H¤£¦Pªº§Üì¥i¯à¦s¦b®t²§¡A¹³¥xÆW¤Ö¦³ªºµÜ©i¯f¡]Lyme disease¡^¡A¯fìÅé¬O¤@ºØÁ³±ÛÅé¡]¸ò±ö¬rªº¯fìÅé¦PÃþ¡A¤£¬O²Óµß¤]¤£¬O¯f¬r¡^¡A2001¦~¦³¤Hµoªí¬ã¨s³ø§i¡A§â10-20¦~«e´¿·P¬V¹L¦¹¯f¦ý«á¨Ó²¬Â¡ªº±wªÌ¦å²MIgM°µ¤ÀªR¡Aµo²{¹ï³oºØÁ³±ÛÅ餴¦³10%ªº¼Ë¥»IgM¤´§e²{¶§©Ê¡A25%¼Ë¥»¤´¦³IgG¤ÏÀ³¡C¤å¥½ªº°Q½×¤£§â³oºØ²{¶HÂk¦]©ó¦A«×·P¬V¡A¦Ó»{¬°¬O¡upersistence¡v¡Aì¥y¡G¡u¡KAlthough we cannot prove that IgM reactivity was continuously present, we favor the interpretation that these responses were due to persistence, albeit with some diminution, of the original IgM response¡K.¡v¡A¦³¿³½ì¥iŪì¤å¡G¡ucid.oxfordjournals.org/content/33/6/780.full ¡v¡C ¤HÃþ¹ï¶Ç¬V¯fªº¤F¸Ñ¸û¦h¡A¹ïÁÞ§Ü쪺¤F¸Ñ¤Ö¤F«Ü¦h¡A¬Ý¬Ý822¤@´Á¥Î©óÄáÅ@¸¢ÀùªºIgM¹Ï¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC21925/figure/F2/ ¡^¡F¥H¤ÎIgG¹Ï¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC21925/figure/F3/¡^¡F¹Ï¤¤ªºIgM¦n¹³¤]¶Èºû«ù¦b«Ü§CÀɤ£¬OÂk¹s¡C ¦Ó§Ú̲{¦b¦U¦¡ªº¬Ì]¬ãµo©Ònªº¬O¯à²£¥Íªø´Áªº°O¾Ð®ÄÀ³¡A¦bª`®g«á¦A³Q¦P¼Ëªº¯fìÅé§Üì·P¬V®É¡A©Î¬OÀù²ÓM¦A¦¸´_µo®É¡A¨º¼Ëªº°O¾Ð®ÄÀ³¡A¯à²£¥Í¡u¤j´T«×¡vrobust IgG¤ÏÀ³¡A¥H«KÄ~Äòºû«ù°·±dª¬ºA¡A©Ò¥HIgMªº§C¿@«×persistence¡Aì«h¤W¤£³Q»{¬°¬O«ÂI¡C Q.:2) ¡u¯f¤H¦b¤@¶}©l¶i¤JÁ{§É®É, ¬O¨S¦³§ÜÅ骺, ¨ºìÂIÁa¶b¤W¬O¤£¬OÀ³¸Ó¦Û0(¹s)¶}©l ? §ë¼v¤ù¤W¤S¦n¹³¤£¬O ?¡v A.:¦P¤WÃDªº±M®a¦^µª¡C Q.:3) ¡uData lock¨ì²{¦b¤S¬O¤@¦~, 104©P«áªºtiterª¬ªp¤£²M·¡, ¥Ø«e¦bOS¤ºªº¯f¤HÅ餺¬O§_ÁÙ¦³§ÜÅé¤]¬O¥¼ª¾. ¦³¥i¯à¯f¤HNED¤F, ¦ý¦bOSÆ[¹î´Á¤º¤S´_µo¶Ü ?¡v A.:è¸Ñª¼ªº¤G´Á¸ÕÅ禳¨S¦³¥i¯à¯f¤HNED¤F, ¦ý¦bOSÆ[¹î´Á¤º¤S´_µo ?³oÓnµ¥¥¼¨Ó¤½¥q¤½¥¬ªº¸ê®Æ¤~ª¾¹D¡C¨º¤@´Á¨ÅÀù¸ÕÅ禳¨S¦³©O¡HˬO¥i¥H®³¨Ó°Ñ¦Ò¤@¤U¡C ¤@´Á¸ÕÅç´Á¶¡¬O1997¦~9¤ë¦Ü1999¦~8¤ë¡A¥´ÃÄ«á°lÂÜ¡A¨ì¤F2002¦~5¤ë®É¡]¾ú¸g4¦~¤S10Ó¤ë¡^¡A·íªì¦¬®×®Éªº27¦ì¡]16¦ì¬ONED¡F11¦ì¬OSD¡F¨S¦¬¶iPRªº¡^¤¤ªº16¦ìNEDªÌ¡A¦³9¦ì¤´ºû«ùNED¡A5¦ìª\¡A2¦ì³Qµo²{¦³Àù²ÓM¡C¨ì¤F2007¦~3¤ë¦Ü¤ÖÁÙ¦³12¦ì¦s¬¡¡]¯f±¡¦ì¶¥¤£²M·¡¡^¡F¨ì¤F2008¦~1¤ëªìÁÙ¦³8¦ì¦s¬¡¡]¯f±¡¦ì¶¥¤£²M·¡¡^¡C¦ýnª`·N¡A¤G´Á»P¤@´ÁªºÃÄ¥i¯à¦³¤p®t²§¡]GH»PKLH³s±µªº±ø¼Æ¡B¤ñ¨Ò¡^¡F¾¯¶q¤£¦P¡]9¾¯vs 5¾¯¡^¡F¦¬®×±ø¥ó¥i¯à¤£¦P¡]¤@´Á¶È¦¬NED»PSD±wªÌ¡A¥¼¦¬PR±wªÌ¡^¡A©Ò¥H¤£¯àµ¥¦P¥hµû¦ô¤ñ¸û¡A¯Â¨Ñ°Ñ¦Ò¡C ¥t¥~¸ò²q·Q¤j¤j°µÓ½T»{¡G ¦b10/31²Ä 2857 ½g¦^À³ùظò±z´£¨ìªº¡uIgG specific to GH¡vªº½T»P¡uIgG specific to GH series¡v¤£¦P¡AµMIn the slides we see now is all about the analysis of¡uIgG specific to GH¡vonly¡Anot¡uIgG specific to GH series¡v. But the total efficacy of 822 should be attributed by IgG specific to GH series¡Anot only by IgG specific to GH. ÁÙ¦³¨ºÓ¥|¦~¦s¬¡²vªº³¡¥÷¡A¡u¥|¦~¡v«üªºÀ³¸Ó¬O±q¡u²Ä¤@¦ì¡v¨ü¸ÕªÌÀH¾÷¤À°tªº®É¶¡ºâ°_ªº¥|¦~¡A¦Ó«D¡u¨C¤@¦ì¡v¨ü¸ÕªÌ³Q°lÂÜ¥|¦~«áªºµ²ªG¡A³o¼Ë¥hŪ¤p©_¤jªº¤ÀªR´N®e©ö¤F¡C ¤p©_¤j¡A·PÁ±zªº²Ó¿°¤ÀªR¡C ¦³¸Ü¸ò±z»¡¡A§ï¤Ñ§i¶D±z¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/11/1 ¤W¤È 12:54:41²Ä 2814 ½g¦^À³
|
Cliff¤j: ·PÁ±zªº»¡©ú. ¤@ª½¦bµ¥EOP2ªº®ø®§, ©¡®É¥i¯à´N¦p±z©Ò»¡ªº, «Ü¦hªº¶i«×´N³£·|§ó©ú®Ô¤F., ¯u´Á«Ý°Ú. ¹ï©ó¶À«T¤ÉÁ`PIªº§ë¼v¤ù¤¤²Ä16¶¤¤, ²£¥Í¤F¦p¤UºÃ´b, ¦V±z½Ð±Ð: 1) Mean IgM Titer¦b40©P«á´N½w¨B¤U¶^, 56©P«á¶^¦Ü20¥H¤U., 96~104©P³º¥X²{¤Ï¼u., ÁöµMtiter§C, 20¥H¤U, ¦ý¤´¬O¦³, ¸ûªì©l°ª. ¯à±À»¡IgM¤]¦³¦~¥H¤Wªº°O¾Ð¶Ü ? 2) ¯f¤H¦b¤@¶}©l¶i¤JÁ{§É®É, ¬O¨S¦³§ÜÅ骺, ¨ºìÂIÁa¶b¤W¬O¤£¬OÀ³¸Ó¦Û0(¹s)¶}©l ? §ë¼v¤ù¤W¤S¦n¹³¤£¬O ? 3) Data lock¨ì²{¦b¤S¬O¤@¦~, 104©P«áªºtiterª¬ªp¤£²M·¡, ¥Ø«e¦bOS¤ºªº¯f¤HÅ餺¬O§_ÁÙ¦³§ÜÅé¤]¬O¥¼ª¾. ¦³¥i¯à¯f¤HNED¤F, ¦ý¦bOSÆ[¹î´Á¤º¤S´_µo¶Ü ? ¦pªG¤è«K, Àµ½Ð«ü¾É, ÁÂÁ±z. ¤p³½¤j: ·PÁ±z´£¨Ñªº¸ê®Æ, ¤Ó´Î¤F, Æg!Æg!Æg! |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/31 ¤U¤È 10:35:28²Ä 2813 ½g¦^À³
|
Ãö©ó±ÂÅv, ·Q½Ð±Ð¤@¤U, ¦pªG¹³¤¤¸Î¨º¼ËÂ÷¦¨¥\«Üªñªº·sÃÄ, ¬°¦ó¤´¥u±ÂÅv¤@®a¤p¤½¥q? ¤j¤½¥q¹ï¤¤¸ÎªºÃĨS¿³½ì? ÁÙ¬O±ø¥ó¤Ó®t? |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/10/31 ¤U¤È 10:28:53²Ä 2812 ½g¦^À³
|
«Ó¥v¤j¡G «D±`¦P·N±z»¡ªº¡G±ÂÅv¬O³Ì§Ö¥i¥H®³¨ÓÃÒ©ú822»ùÈ¡C §Ú·Q¤º¦æªº°ê»Ú¤jÃļt¹ï¬ð¯}©Êªº·sÃĤ£¥i¯à¨S¿³½ì¡A°£«D³oÓ·sÃļç¤O¦³¡C ¦L¶H¤¤¡A«nÁú¦³¤@Áû·sÃĦbASCO µoªíÁ{§É³ø§i¡A·í¦~11¤ë¤~§¹¦¨±ÂÅv½Í§P¡A©Ò¥H§ÚÓ¤H»{¬°¦~©³«e¤]ºâ¥¿±`¡C ¦ýY¤Ó¤[¨S®ø®§¡A©Î³\·|¼vÅT§Úªº«H¤ß¡C·íµM§Ú§¹¥þ¤£ª¾²{¦b¬O§_¦³»P¥ô¦ó¤½¥q¦b±µÄ²/½Í§P¤¤¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/10/31 ¤U¤È 09:58:58²Ä 2811 ½g¦^À³
|
¤£¦n·N«ä¡A¦³¤@Ӳ°ÝÃDn½Ð±Ð¡G «Ó¥v¤jªºPO¤åªº ¤è®×¤@¡G¹êÅç²Õ¥ý¥´¤@°w¬Ý¦³µL§ÜÅé¤ÏÀ³¡A¦¬¤J1:40¥H¤WªÌ¡A¹ï·Ó²Õ«h¤£ºÞ¦³µL§ÜÅé¤ÏÀ³³£¦¬¡A³o¼Ë¦³¬DÄå®ç¤§¶û¡AFDA·|¦P·N¶Ü¡H §Úªº°ÝÃD¬O¡G ¤½¥q¤£¥i¥H±N¥¦³]¦¨¬O³oÓÃĪ«³sÄò¬IÃĪºcondition ¶Ü¡H ¦pªG FDA ¥uµ¹§Úconditional approval ¤]¥i¥H¡C ¬JµM¥i¯à±Ïªñ¤K¦¨ªº±wªÌ¡AFDA ¤£¦P·Nªº²z¥Ñ¤S¬O¤°»ò©O¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/31 ¤U¤È 08:27:24²Ä 2810 ½g¦^À³
|
¥m¾´¤j ÁÂÁ±zªº½Ì¸Ñ©M¹ªÀy ¤j®a³£«Ü¨¯W ´Á«Ý¯E¹©»°§Ö¨«¥XªdÕï Â\²æ³Q¿äÆnªº¤é¤l ·PÁ±z¡I |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/10/31 ¤U¤È 07:54:54²Ä 2809 ½g¦^À³
|
²q·Q¤j¡A±z¨¯W¤F |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/31 ¤U¤È 12:25:26²Ä 2808 ½g¦^À³
|
¥xÁÞ¤j¡A ¡u§ÜÅé®Ä»ù¤À5Óthreshold ìHÈ IgG 1:40 171¤H ¥|¦~¦s¬¡¾÷²v 77.2% IgG 1:80 148¤H ¥|¦~¦s¬¡¾÷²v 74.8% IgG 1:160 112¤H¥|¦~¦s¬¡¾÷²v 78.1% IgG 1:320 84¤H ¥|¦~¦s¬¡¾÷²v 85.9% IgG 1:640 50¤H ¥|¦~¦s¬¡¾÷²v 91.8 % IgG 1:40 , IgG 1:80 ,IgG 1:160 ¥|¦~¦s¬¡¾÷²v ®t¶Z¤£¤j ³oÓ·sData ¹ï P13 MOS ·|²£¥Í¦óºØ¼vÅT ?¡v ¥|¦~¦s¬¡²v¡AÁöµM§ë¼v¤ù³o¼Ë¼g¡A¦ý¨º¬O¦]¬°Æ[¹îªº®É¶¡¤£°÷¤[¡A32Ó¤ë¥H«áªº¼Æ¾Ú¥u¦³§C¤ÏÀ³²Õ¦b33Ӥ릳¤@Өƥóµo¥Í¡A§_«h32Ó¤ë¥H«áªº¦b¥Ø«e©Òª¾³£¥u¬O³]¸ê®Æ¡A¦]¦¹¯u¥¿ªº¥|¦~¦s¬¡²v¨C¤@²Õ³£¤£·|³o»ò°ª¡C IgG < 1:160ªº§C¤ÏÀ³²Õ¡A¥Ø«e¬Ý¨ìªº¨Æ¥ó´N¬O29¤H¡AESMOªº¸ê®Æ¥u¬O§i¶D§ÚÌ¡A29¤H¤¤¥i¯à¦³¤@¥b¥H¤Wªº¨Æ¥óÂkÃþ¦bIgG < 1:40¡A³o¤£·|§ïÅÜP13¦b16Ó¤ë¥H«eªº¦s¬¡¦±½u¡A§C¤ÏÀ³²Õ³o¤TÓ²Ó¤À²Õ¡A¥L̦@¦P¦X§@¡A¦b16~32Ӥ몺´Á¶¡¡A§C¤ÏÀ³²Õ±N¦s¬¡²v±q¸¨«á¹ï·Ó²Õ°l¦¨»P¹ï·Ó²Õ®t¤£¦h¡A¥H¨C¥|Ӥ밧C¦s¬¡²v¤j¬ù5%ªº³t«×(¹ï·Ó²Õ¦b¦¹°Ï¶¡¨C¥|Ó¤ë¤j¬ù°§C6%)¡A¨ä¤¤¥HIgG 1:40 ~ 1:80³o¤@²Õ°^Äm«×³Ì¤j¡AIgG 1:80 ~ 1:160³o¤@²Õ°^Äm«×¦¸¤§¡A©Ò¥H§C¤ÏÀ³²Õ¤¤ªºIgG > 1:40ÁÙ¬O¦³Àø®Äªº¡C ¦P²z¡A°ª¤ÏÀ³²Õªº¤T²Õ¦@¦P¦X§@¡A¦b¦b16~32Ӥ몺´Á¶¡¡A°ª¤ÏÀ³²Õ±N¦s¬¡²v±q쥻»â¥ý¹ï·Ó²Õ4%ÂX¤j¨ì»â¥ý¹ï·Ó²Õ17.5%¡A¦b³o¬q°Ï¶¡¡A°ª¤ÏÀ³²Õ¥H¤j¬ù¨C¥|Ó¤ë¤U°2.5%ªº¦s¬¡²v¶i¦æµÛ¡A¨ä¤¤IgG > 1:640³o¤@²Õ°^Äm«×³Ì¤j¡AIgG 1:320 ~1:640³o¤@²Õ°^Äm«×¦¸¤§¡AIgG 1:160 ~ 1:320³o¤@²Õ°^Äm«×¦A¦¸¤§¡C ±q³oÓªí¤¤±oª¾¡A°ª¤ÏÀ³²Õ¶i¤J32Ó¤ë¥H«áªº±wªÌ¡A¥HIgG > 1:640©MIgG 1:320 ~1:640³o¨â²Õ¦û¤ñ³Ì¦h¡A¥Ø«eªº¦s¬¡ª¬ªp¤´¦b¶i¦æ¤¤¡Aȱo§ÚÌ«ø¥Ø¥H«Ý¡C ¦Ü©ó¯Ç¤JIgG 1:40 ~ 1:80»PIgG 1:80 ~ 1:160§ó¦hªº¤H³ºµM¦s¬¡¾÷²v»PIgG 1:160®t¶Z¤£¤j¡A³o¥u¬OÓ°²¶H¡A·sData¥u§i¶D§Ú̧C¤ÏÀ³²Õ¤¤ªº29Өƥ󦳤ñ¹w´ÁÁÙ¦hªº¨Æ¥ó¬OÂkÃþ¦bIgG < 1:40³o¤@²Õ¤W¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/31 ¤W¤È 11:54:12²Ä 2807 ½g¦^À³
|
¤p©_¤j¤j ÁÂÁ±zªº¸Ñ»¡ ¤p§Ì¤£¤~¡@¨¬¨¬¬Ý¤F¢²¢¯¤ÀÄÁ¤~²¤²¤ÁA¸Ñ±zªºªí¹F ¦³±zÅ޿誺¥\¤O¡@ÁÙ¦³²Ó½oªº«ä¦Ò¤ÀªR¯à¤O ´N¸ò¢Ñliff¤j®¦¼w¤@¼Ë ¥O¤p§Ì·P¨ì©¯¹B»P©¯ºÖ ·PÁ±z! ¦P®É ¤p§Ì¤]¦b°ø±æ §Æ±æ¤½¥q¯à±N¨CӰѤ©¸ÕÅçªÌªº¸ê®Æ ¦p°ò¥»±¡ªp(CR PR SD ¥´´X°w IgG IgM®Ä»ù) »P¨Æ¥óµo¥Í®É¶¡°µ³sµ² Åý§Ú̹ï822ªºÀø®Ä°µ¾ãÅé©Êªº¤F¸Ñ «¢!¤p§Ì¤w¸g·Q±o«Ü²Ö°Õ¡@ ¦A¦¸·PÁÂ! ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/31 ¤W¤È 10:51:37²Ä 2806 ½g¦^À³
|
·PÁÂCliff¤jªº«ü¾É¡I ²q·Q¤j¡A °£¤FCliff¤j©Ò¸ÑÄÀ¤§¥~¡A ¤p§Ì¤]¦³¥H¤U´XÂI²q·Q¡G (§â¨CӮĻù½d³ò¡A¦ô¥X¤j¬ù¨Æ¥ó¼Æ¡A¯u¤£®e©ö°Ú¡I) 1.®Ä»ùIgG < 1:40»P®Ä»ùIgG 1:40 ~ 1:80¬O¹j¾À¾F©~¡A¦¦´NPD©Îdrou outªº±wªÌ¡A¥un¦b¸Ó±wªÌ¦¦´NPD©Îdrou out¤§«e´ú¤£¨ìIgG > 1:40¡A´N³QÂk¨ìIgG < 1:40¤F¡A¦pªG³oÃþ±wªÌ«ùÄò«Ý¦bÁ{§ÉÆ[¹î¡A¤£¯à±Æ°£¨ä¤¤©Î³\¦³³¡¤À¬O¥i¯à´ú¨ìIgG > 1:40(¥»¨Ó¥i¯à¬OIgG 1:40 ~ 1:80³o¤@²Õªº¡A¤Ó¦PD©Îdrou out¡A¥Ã»·¨S¦³¾÷·|°µ½T»{¤F)¡A³o´N¬Oimmortal biosªº¼vÅT¡C 2.¯Å¼Æ¤£¦P¡CIgG 1:40 ~ 1:80»PIgG 1:80 ~ 1:160®Ä»ù®t²§¨ä¹ê¨S¦³¨º»ò¤j¡A»PIgG 1:320 ~1:640©MIgG > 1:640¤ñ°_¨Óªº¸Ü¡A©Ò¥H¤p§Ìı±o¡A§C¤ÏÀ³²Õ¤¤¦³¤ÏÀ³ªºIgG 1:40 ~ 1:80»PIgG 1:80 ~ 1:160ˬO¥i¥H¦X¨Ö°_¨Ó¤@°_¬Ý¡C 3.drou outªº¼vÅT¡CIgG 1:160 ~ 1:320»PIgG 1:320 ~1:640¤ÎIgG > 1:640¦@¤T²Õ¡AOSªºdrou outÁ`¦@¤j¬ù5¤H¡A§C¤ÏÀ³ªº¤T²Õ¡AOSªºdrou outÁ`¦@¤j¬ù25¤H¡A¦¦ªºdrou out±wªÌ¨ä¹ê¦b¬YÓ¨¤«×¥i¥Hµø¬°¬O¨Æ¥óªºµo¥Í¡A©ÎªÌºë½T¤@ÂI»¡¡Adrou out¦û¤ñ¸û°ªªº²Õ§O¡A¨ä¨CӨƥóµo¥Í¹ï¦º¤`²vªº¤U°¼vÅT¬O¤ñ¸û¤jªº¡CASCOªºP17¡A§C¤ÏÀ³²Õªº¨Æ¥ó¼Æ¤ñ=25.89%¡A§C©ó¹ï·Ó²Õªº¨Æ¥ó¼Æ¤ñ=28.23%¡A¨Æ¥ó¼Æ¤ñ²v¸û§C¡A²zÀ³¦s¬¡²v¸û°ª¡A¦ý§C¤ÏÀ³²Õªº¦s¬¡²v¦b¥iÆ[¹î¨ìªº®É¶¡«o²¤§C©ó¹ï·Ó²Õ¡A³o´N¬Odrou out¦û¤ñªº¼vÅT¡C 4.ÁÙ¦³¤@ÂI¡AIgG 1:160 ~ 1:320¨Æ¥ó¼Æ©úÅã°¾°ª¡A¤½¥q¬O¥HIgG 1:160 ·í§@°ª§C¤ÏÀ³²Õªº¤À¬É½u¡A¤£ºÞ¬O¥HIgG 1:160©ÎIgG 1:120©ÎIgG 1:200·í¤À¬É½u¡A±qASCOªºP13¤¤¥i¥H¬Ý¥X¡A822¹ï16Ó¤ë¥H«e´N¦º¤`ªº±wªÌ¬OµL®Äªº(»P¹ï·Ó²Õªº¦±½u¤À¤£¶})¡AP17¬Ý¨ì°ª¤ÏÀ³²Õ»P¹ï·Ó²Õ¤À¶}¡A¨ä¹ê¬Oimmortal bios»P¡u¬ÛÃö©Ê¡vªºµ²ªG¡A¦ý¼vÅTªºµ{«×¨S¦³¤Ó¤j¡C¤]´N¬O»¡¡AIgG > 1:160ªº°ª¤ÏÀ³²Õªº112¤H¡AÁöµM®Ä»ù¤w¸g»·°ª©ó§C¤ÏÀ³²Õªº¦U²Õ¡A¦ý¹ï©ó¦¬®×±ø¥ó¬OCR¡BPR¡BSDªº±wªÌ¡A¨ä¤¤¥i¯à¦³¨Ç¤£¬Ostaleªºª¬ºA¡A¸~½F¤´¦b¶i®i¤¤¡A§Y¨Ï822¦b°ª¤ÏÀ³²Õ¤w¸g²£¥Í¤F»·»·ªº°ª®Ä»ù¡A¦ý°ª¤ÏÀ³²Õ112¤H¤¤ÁÙ¬O¦³13¤H¦b16Ó¤ë¥H«e¦º¤`¤F¡A822ªº°ª®Ä»ù¹ï©ó¯e¯f¤´¥¼Ã©wªº¤HÁÙ¬OµL®Äªº(²qªº)¡A³o13¤H¤¤¡A¤j³¡¤À¥X²{¦bIgG 1:160 ~ 1:320³o¤@²Õ¡A¥i¯à¤]¦³¤Ö³¡¤À¥X²{¦bIgG 1:320 ~1:640³o¤@²Õ¡AIgG > 1:640³o¤@²Õ¥i¯à¤@өΨS¦³¡C¦Ü©ó§C¤ÏÀ³²Õªº±¡ªpÃþ¦ü¡A¤p§Ì²q·Q16Ó¤ë¥H«e´N¦º¤`ªº§C¤ÏÀ³²Õ¦@18¤H¤¤¡A¤j³¡¤ÀÀ³¸Ó³QÂk¦b¦bIgG < 1:40³o¤@²Õ¤¤(¥L̪ºPFS¤@©w«Ü®t)¡C ¤£ºÞ«ç»ò¸ÑÄÀ¡AIgG 1:40 ~ 1:80³o¤@²Õ¥Ø«eÆ[¹î¨ìªº¸ê®Æ¡A¨ä¦s¬¡±¡ªp¤ñ¸ûÀu¬O¤@Өƹê¡AOS¸ê®Æ32Ó¤ë¥H«áªºªí²{¤£±o¦Óª¾¡A«áÄòµ¥¤½¥q¶i¤@¨Bªº¸ê®Æ¤½¥¬¦A¨Ó½T»{¡C ¥H¤W¬O¤p§Ìªº²q·Q¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/31 ¤W¤È 06:45:02²Ä 2805 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±zªº«ü¾É¡AÅý¤pªº°gÃúº¥¶}¡A°ß¤½¥q¤´¥¼´£¨Ñ¬ÛÃö¸ê®Æ¡A®í¬°¥i±¤ ¥Ñ¤½¥q¾ã²zªº¸ê®Æ¨Ó±À´ú ±Ë±ó¤p©ó1:40ªº¤£p¨Ó¤ñ¸û¡A´N¦p¦Ñ¥v¤j¤j©ÒµûªR¡A¤£¨ã¤½¤¹·N¸q ¦ý¤pªº±À´ú¡A¤½¥q©Î³\¦b§i¶D§ÚÌ¡A ¤£p¤p©ó1:40ªº³¡¤À¡A¼Æ¾Ú«Ü¤£¿ù¡A1:40¦³¥i¯à¬°¤T´Áªº¿z¿ï¼Ð·Ç ¡]¶Ã²qªº¡^ ¥t¥~¡A±zOSªº°T®§¡A¤pªº¦¬¨ì¤F ¨C¦¸Å¥±z¨¥¡AÁ`¦³º¡º¡ªº¦¬Ã¬¡A¦³±z¯u©¯¹B¡A¤ß¸Ì¤]©¯ºÖ ¦A¦¸·PÁ±z¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/31 ¤W¤È 12:44:33²Ä 2804 ½g¦^À³
|
²q·Q¤j¡A ±zªººÃ°Ý¡A§Úªº¬ÝªkIgG¡Ù160ªº¤ÀªR¼Æ¾Ú¡A©Ò«üªº§ÜÅé¬OIgG to GH ¡]µù1¡^¡FµM¦Ó«ö·Ó¾Ç²z±À½×¡A¾ãÓÀø®ÄÀ³¸Ó¬O¡uIgG to GH¡v+¡uIgG to SSEA-3¡v+¡uIgG to SSEA-4¡v¤TªÌ¦@¦Pªº§@¥Î¦¨ªG¡A©Ò¥HY¯à¥H¡uIgG to GH series¡v¨Óø¹Ï©Î¤ÀªR¡AÓ¤H»{¬°¡u©Î³\¡v¥i¥H±o¨ì§ó½u©Ê¦Ó¶K¤Áªºµ²ªG¡C¥i±¤¨´¤µ¥¼¨£¨ì¡uIgG to SSEA-3¡v»P¡uIgG to SSEA-4¡vªº®Ä»ù¤ÀªR¡C ¥t¥~³¯¹a¬z°|¤hªºSlide No.21¥k¤U¤è²Ä¤TÂI¡G¥y¥½ªº¡u¡Kto an IgG response6,7¡C¡v6,7¬O¤W¼Ðªº¼Æ¦r¡Aªí¥Ü³o¬q±Ôzªº¥X³B¨Ó¦Û°Ñ¦Ò¸ê®ÆNo.6&7¡A©¹¤U¤è²Ó¤pªº´X±Æ¦r¤¤¥i§ä¥XNo.6&7¨â½g½×¤å¡A¤]´N¬Occc¤j¦b²Ä 2830 ½g¦^À³ùØ´£¨ìªº¨â½g¤å³¹¡A¤@¬°2015¦~¡F¤@¬°2013¦~¡A¬Ò¬O°Êª«¸ÕÅç¼Æ¾Ú¡A¦Ó«D²{¤µª©ªº833ªºphase I ¸ê®Æ´¦ÅS¡Cªp¥B¦o´£¨ìªº¬OGH-DT/C34¡A¤£¬O²{¤µª©ªº833¡C QQ¤j¡A Ó¤Hı±o¤p³½¤j´£¨Ñªº¥þµ{ª©¥»¡AY§Ú̧âIgG¡Ù1:40®Ä»ù¬°¹º¤À¬É½u¡A¥i¥H¬°±i¸³¦b¸Ñª¼¤§ªì©Ò»¡ªº¡u¦³²£¥Í§ÜÅ骺´N¦³Àø®Ä¡v´£¨Ñ¤ä«ùÃÒ¾Ú¡F¥H¤ÎIgG¡Ù1:40®Ä»ùªÌ¦û¤F¹êÅç²Õ76%¡A¤]¬°°|ªø©Ò¨¥ªº¤K¦¨¦³®Ä´£¨Ñ¤ä«ùÃÒ¾Ú¡C ¤£¹L¹ï©ó¥¼¨Ó¡AÓ¤H¤´»{¬°·s¤T´Á¦p¦ó³W¹º¤~¬O«ÂI¡Fconditional approval¦³§Æ±æ¡A¦ý¥±`¤ß¡]¦]¬°mOS¦¨¼ô¶i«×¡u¥i¯à¡v¤ñ±`¤H¹w¦ô¬°ºC¡^¡A§Æ±æ¦~©³ªþªñ¯à¥ý¶}§¹EOP2¡A¤T´Áªº¤è¦V´N·|¥X¨Ó¡ABTD¦³¨S¦³§Æ±æ¤]·|§ó²M·¡¡KÂå¾Ç·|¡K´N¦A¬Ý¬Ý¡K µù¡G 1.¡uwww.obipharma.com/index.aspx?lang=chi&fn=news_content&no=76 ¡v¡G¡u¡KGlobo H¯S©wIgG¤ÏÀ³¡K¡v¡F ¡uwww.obipharma.com/index.aspx?lang=eng&fn=news_content&no=26 ¡v¡G¡u¡KGlobo H specific IgG response¡K¡v¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/30 ¤U¤È 03:24:48²Ä 2803 ½g¦^À³
|
__®Ä»ù½d³ò________¤H¼Æ (¥e¤ñ%)______¬ù¦ô¨Æ¥ó¼Æ IgG < 1:40_______53 ( 23.66% )______17 ( 32.1 % ) IgG 1:40 ~ 1:80______23 ( 10.27% )______ 2 ( 8.7 % ) IgG 1:80 ~ 1:160_____36 ( 16.07% )______10 ( 27.8 % ) IgG 1:160 ~ 1:320____28 ( 12.50% )______10 ( 35.7 % ) IgG 1:320 ~1:640 ____34 ( 15.18% )______ 7 ( 20.6 % ) IgG > 1:640______50 ( 22.32% )______ 4 ( 8.0 % ) 822²Õ¥´°w¼Æ¤ÎIgG > 1:160ªº¤H¼Æ¤ñ¨Ò 1 ~ 5 °w ( n = 52 ) 28.8% ¡÷ 15¤H ( 13.39 % ) 6 ~ 8 °w ( n = 68 ) 41.2% ¡÷ 28¤H ( 25.00 % ) §¹¦¨9°w( n = 104 ) 66.3% ¡÷ 69¤H ( 61.61 % ) ¹ï¤£°_! ¤p§Ì¨Ó§ó¥¿¤@¤U¬Q¤éªºµ²½× ¥Ñ¤Wªí¥i¥H¬Ý¥X ¬ù¦ô¨Æ¥ó¼Æ(¸Õºâªí¼ÒÀÀ¦Ó±o)ªº¥e¤ñ , ¨Ã¥¼¦p4¦~¦s¬¡²v³W«ß ·íµM¨Æ¥óªº²£¥Í¤£¥þµM¥ÑIgG´x±± , IgM©M¨ä¥L¦]¯À(¨Ò¦p:¬O§_§¹¦¨9°w)¤]¯A¤Î¨ä¤¤ ¦³½Ðþ¦ì¤j¤j«ü¾É¤@¤U, °ÝÃD¥i¯àªº©Ò¦b? ¤£³Ó·P¿E ¤S¬Ý¤FPFSªº²Îp ¦ü¥G¥HPFS·í«ü¼Ð , ¨Ã¤£¨º»ò¦X¾A ¦Ñ¥v¤j¤j¬Q¤éÁ¿ªºÁ{§É¤T´Á°ÝÃDÂI¤¤, ¦ü¥G¦s¦b¤£©ö¥hµûÂ_¨â²Õ°Ñ¤©ªÌªº¦P½è©Ê ¤T´Á·|¤£·|§ï±Ä¶}©ñ¦¡¸ÕÅç? §K¥h¨â²Õ¦³µL¦P½è©Êªº§xÂZ , ¤]¥i¥[§Ö¦¬®×³t«× , ¤S¯àª½±µÆ[¹î¸ÕÅçªÌªºÀø®Ä¤ÏÀ³ ¶À¥D¥ô¦bºtÁ¿¤¤¤]³zÅS , ¦³§K¬Ì¤ÏÀ³ªÌÄ~ÄòªvÀø ¯u¶Ë¸£µ¬ ÁÂÁ¤p³½¤j¤j´£¨Ñ§¹¾ãªº¬ã°Q·|¼v±a , ®ø«Ú¤½¥q³Q¥~¬É¸á¯f , °ê¤º¥~¤£¦P¨Bªº½èºÃ ·q½Ð«ü¥¿«ü¾É ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G½²1110143354 µoªí®É¶¡:2016/10/30 ¤U¤È 02:10:46²Ä 2802 ½g¦^À³
|
²³¤j¤j ¥~¦æ¤H½Ð±Ð 2016 ASCO P14 ¥´§¹¤E°w104¤H VS 64¤H ¨º¤@±i§ë¼v¤ù ¬OPFS PÈ0.0566¡A¦pªG¬OOS¡Aµ²ªG·|¦p¦ó? ¦³·N¸q?³o¼Ë ¨â²ÕPK¼Æ¾Ú¡A¤½¤¹? |
|
|
·|û¡GµL¹Ð10141268 µoªí®É¶¡:2016/10/30 ¤W¤È 11:34:13²Ä 2801 ½g¦^À³
|
³Ìªñ¤@ª½¦b·j´M¹L¥h¦U4174¦Uª©ªº¤å³¹,¦³¤ß¤HÁÙ¯u¦h,¦ý³Ì«á¥u¬O´«±b¸¹¥X²{,«Ü¦h²£·~³£¦]¬°¦³«¤j¬ð¯},³Ì«á³y¦¨¥«³õ«¤À°t,¦ý¤@©w·|¦³¤H¥¢¦³¤H±o,¼Ú³°±j°ê¦³¥L̾A¦Xµo®iªº²£·~,¦Ó¥B¥i¥HÂX±i¤S®Â½Ã¦Û¤vªº°Ó·~§Q¯q,¦ý¥xÆW´N³o»ò¤p,·í§½¯à§ä¬Æ²£·~¨Ó±j§§³o¤p®q,´N¬O¯à¥´¶i¥þ²y¥«³õªº²£·~,¦Ó¥B¦³±M§Q«Ì»Ù«OÅ@ªº,¦bɨ÷¾lÃB¦±½u»PªÑ»ù¤ë½uªº¥æ¤eÂI,±N·|¬O¬üÄR»P«s·Tªº¤À¤ôÀ. |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/30 ¤W¤È 11:02:51²Ä 2800 ½g¦^À³
|
ÁA¸Ñ, ·PÁ²³¤jªº¸ê°T¤À¨É, ·P®¦! |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/10/30 ¤W¤È 10:40:37²Ä 2799 ½g¦^À³
|
Walker¤j,¶ÀÂå®v¦b¤ùÀY¦³»¡¤F¡A§e²{»PRugo¦bASCOµoªíªº¬Û¦ü¤º®e¡A¦ý¤]¼W¥[¤F¦bASCO«á¤ÀªRªº¼Æ¾Ú... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/30 ¤W¤È 10:25:09²Ä 2798 ½g¦^À³
|
ÁÂÁ¤p³½¤j´£¨Ñªº«n¸ê°T |
|
|
·|û¡G¤p³½10141408 µoªí®É¶¡:2016/10/30 ¤W¤È 10:08:48²Ä 2797 ½g¦^À³
|
¶ÀÂå®v¸û§¹¾ãªººtÁ¿¤º®ewww.dinkcs.co.uk/obipharma/3ChiunShengHuang/ ¨ä¥L¬Ý³owww.dinkcs.co.uk/obipharma/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/30 ¤W¤È 10:08:14²Ä 2796 ½g¦^À³
|
Walker¤j §A´£¨ìªº°ÝÃD·|¤£·|¬O¶ÀÂå®v¤]¦³³ø§iASCO½×¤åµoªíªº¤º®e? ¦]¬°ASCO¤w¸g¤½§i¤F¡A©Ò¥H¥u¤½§i·sµo²{ªº·s¼Æ¾Ú ¡C±Ð¨|¬ã°Q·|´£¨Ñ2016 ASCO ½×¤å¼Æ¾Úµ¹»P·|¤Hû¤]¬O¥i¥H²z¸Ñªº¡C ¥H¤W¦s²q´ú¡Aťť´N¦n¡A¤£n·í¯u¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/30 ¤W¤È 09:54:20²Ä 2795 ½g¦^À³
|
§ó¥¿:¬ã¨s¤Hû ¹ï¯E¹©³oÁû¨ÅÀùÃÄ«O«ù§C½Õ¼f·V¼ÖÆ[ªººA«×¨Ó±¹ï¬O«Ü¦nªºµ¦²¤¡A¤½¥q¦p¦¹¡AªÑªF¤]À³¾Ç²ß¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/30 ¤W¤È 09:27:21²Ä 2794 ½g¦^À³
|
Walker¤j ªÑªF¤j·|¯E¹©¦³»¡·|¤£Â_ªº§â¦n®ø®§§i¶DªÑªF §Æ±æªÑªF¦h¨Ç@¤ß¡A¥Ø«eÁÙ¨S¦³¤½§iªº³¡¥÷Ó¤H»{¬°·|¦b°ê»Úª¾¦W´Á¥Zµoªí¡A¥H«Ø¥ßOBI822 Àù¯g¥D°Ê§K¬ÌÀø¬ã§P¤Hûªº¾Ç³N¦a¦ì¡A°ê»Ú´Á¥Z¥÷¶q¥i°Ñ¦Òimpact factor |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/30 ¤W¤È 09:11:11²Ä 2793 ½g¦^À³
|
¥xÁÞ¤j ÁÂÁ±zªº¤À¨É, 쥻¬Ý§¹¤§«áı±o¸ò ASCO Á¿ªº¬O¤@¼ËªºªF¦è, ¤£·|·Q¦A¬Ý²Ä¤G¹M ·Q¤£¨ìÁÙ¦³³oºØ¦^°¨ºj ³o¼Ë´N«Ü¦n©_¤F, ²{¦b´¦ÅS¶ÀÂå®v³ø§iªº³¡¤À¤~¥Î¤F¤¤ÀÄÁ¥ª¥k, ¦Ó¥Lªº®É¬q¦³¤G¤Q¤ÀÄÁ ³Ñ¤U¨S©ñ¤Wºô¸ôªº³¡¤À¤SÁ¿¤F¬Æ»ò©O? ³£¦bÁ¿ summary ªº well tolerated, with only grade 1-2 injection site TEAEs and pyrexia.... ³o³¡¤À¶Ü? |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/10/30 ¤W¤È 08:52:51²Ä 2792 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤jªº¼Æ¾Ú¤À¨É¡C Leo¤j§ë¼v¤ù¦b¼vµÀɸ̱¡A¥i¯à»Ýn¹q¸£¬Ý¤ñ¸û¬yºZ¡C ¤Ñ§N¤F¡A²³¤jª`·N«O·x |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/10/30 ¤W¤È 04:34:04²Ä 2791 ½g¦^À³
|
¦n°s¨IÂ|©³,¤é¤[¨£¤H¤ß.. «D±`·PÁ¤j®aªº±M·~¤À¨É.. °ò¥»±,¤½¥qªº§V¤O»P©Ó¿Õ,²×±N·|¨£¨ì¾¤©ú«eÀÆ¥ú,¦Ó·|ºCºCªº®i¶}¦°¤éªFª@,²×±N´¶·Ó¤j¦a,´þ¼íªø¾i¥Í©R.. º©ªø®É¶¡µ¥«Ý,«D±`¥¿½T¦Óȱo.. ¤@¸ô¨«¨Ó,¬Û«H¤½¥qªº«H©À»P§V¤O,±q¥¼§ïÅÜ.. ¥¿¦p¦Ñ¥v¤j©Ò¨¥.. ¯E¤ÍÌ,¤´»Ý¥H²z©Ê¦Ó§NÀRªº@¤ßµ¥«Ý, n¥´°ê»ÚÁÉ,³o¬O¥²¸gªº¨½µ{.. ¨ÌµM¦³«H¤ßªº°í«ùµ¥«Ý¤U¥h,¤£ºÞ¦³¤ß¤Hªº¦p¦ó§N¼J¼ö¿Ø,¦Ê¯ë¦¾öG.. ®É¶¡²×·|ÃÒ©úªº... |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/30 ¤W¤È 02:53:17²Ä 2790 ½g¦^À³
|
¦Ñ¥v¤j: ·PÁ±z¤¤ªÖªºµûªR, ¨C¦¸¬Ý±zªº¤å³£¨ü¯qê²L. ¤j·PÁÂ. ¤T´Áªº³]p, ¦L¶H¤¤¥Í§Þ®i®É¿à³Õ»¡¹L¦~©³«e·|¦³®ø®§, ¦pªG¨SÅÜ°Ê, ¤]¥u¦³¨âÓ¦h¤ë¤F, ¨ì®É§Æ±æ·|¦³®ø®§¥X¨Ó. ±µÄ²¨ì¥t¤@®a¥Í§Þ¤½¥qªºÃĪ«, ³Q±ÂÅvªº¹ï¶H¬O¬ü°ê¥À¤½¥qªº¥t¤@®a¤l¤½¥q, ±q¤½¥qµo¨¥³æ¦ì±oª¾¤]¬O±q¦~ªì´N¶}©l½Í, ¤@ª½¨ì¥Ø«e¤~è½T»{¨S¦h¤[. ¤]¥u¬O³æ¯Âªº£¸Áû¦b¥xÆW§¹¦¨¤G´ÁªºÃĦӤw., 822Áö¤w¸Ñª¼8Ó¤ë, ¦ý±qdata pool¤¤±ÄÄq¶·n¨Ç®É¶¡, ¥i¯à¤£¦Pªº±ÂÅv¹ï¶H·Q¬Ýªº¼Æ¾Ú¤]¤£ºÉ¬Û¦P., Y±ÂÅv½Í§Pªº°ò¦¬°³o¨Ç¼Æ¾Ú, ¨º¥i¯à¤£¤[«e¤~è¶}©l®i¶}¹ê½èªº½Í§P§a? ¤S¥H822ªº½ÆÂø©Ê, ¥i¯à®É¶¡¬Û¹ï¤]¸ûªø. ¦ý¯u§Æ±æ¤½¥q¯à¥[§Ö¸}¨B, ´N¸Û¦p±z©Ò¨¥ª½±µ¨Ó¦Û°ê»Ú¤jÃļtªº¥[«ù¤~¬O²{¶¥¬qÃÒ©ú822»ùȳ̦³¤OªºÃÒ¾Ú. ¬Ý¬Ý°ê»Ú¤jÃļt§K¬ÌÀøªkªº¶i«×, ¯u¬O¥O¤HµÛ«æ ! Cliff¤j: ¤æÁx½Ð±z¬O§_¤]¥i®Ú¾Ú³Ì·s³o¼Æ¾Ú»¡»¡±zªº¬Ýªk ? ¦n´Á«Ý¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 10:25:00²Ä 2789 ½g¦^À³
|
ÁÂÁ¦ѥv¤j§ó¼e¼sµø³¥ªº½×z»P¤À¨É¡C ¤p·s¤j§Ú¬P´Á¤@¦A°Ý°Ý¬Ý¡A²q·Q¤j¤w¦³´£¥X¬Ýªk¡AÀ³¸Ó¬O¤£·|¿ù¡C Faith¤j ²×©ó¥X²{¤F¡A³ÌªñÁÙ¦n¶Ü? «ÜÃh©À¨º¨Ç¦´Á¦@¦P¤À¨É¯E¹©ªº®É¥ú·³¤ë¡A¤w¥¢Âܫܤ[ªº¯E¤Í ¤F¡A«ÜÃh©À |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/29 ¤U¤È 10:04:29²Ä 2788 ½g¦^À³
|
ÁÂÁ¤j®aªº¤ß±o ¦Ñ¥v¤j¤j§NÀR¤£¿E±¡ªºµûªR¡A§ó¥O¤H°Ê®e »¡¦Ñ¹ê¸Ü¡A¤p§Ìªì¬Ý¼Æ¾Úªº·í¤U¡A²ª½¿³¾Ä²ö¦W¡A¤ñ¤p§Ì©Ò·Q¹³ªº¦n¤W¤Ó¦h ¤×¨ä1:40ªº4¦~¦s¬¡²v¡A´X¥G»P1:160ªÌ»ô¥ Åã¥Ü¥X1:40¥H¤UªÌªº¨Æ¥ó¼Æ¡A©Ô¤U¹êÅç²Õ¾ãÅ骺ªí²{ ¥çÅçÃÒ¦³§ÜÅéªÌ´N¦³Àø®Ä¡A§ÜÅé¶q¶V°ª¡AÀø®Ä´N¶V¦nªº»¡ªk ¦Ü©ó¦³¤j¤jªº»~´Ó¤§»¡¡A¤p§Ì»{¬°À³¤£¦Ü©ó ¥Dn¬O¸Óµ¥¼Æ¾Ú¬OÓ§O²Õ¦Xºâ¥X¨Óªº ¤]´N¬O ®Ä»ù1:40¥H¤WªÌ¡A¥Î171¤H¨Ópºâ4¦~¦s¬¡²v¡A¦MÀI¤ñ¤ÎpÈ ®Ä»ù1:80¥H¤WªÌ¡A¥Î148¤H¨Ópºâ4¦~¦s¬¡²vµ¥¼Æ¾Ú ¥H¤UÃþ±À ·|·Pı©_©Ç¡A¥i¯à¥u¬O¦b1:80 ¡ã 1:160¶¡¡A¦h¤F´XӨƥó¼Æ¦Ó¤w ³o¬O¤p§Ìªº±À´ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/10/29 ¤U¤È 08:43:58²Ä 2787 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j´£¨Ñ«D±`Ä_¶Qªº¸ê°T 1:40/171/76%/77.2%/0.58/0.0294 1:80/148/66%/74.8%/0.66/0.0939 1:160/112/50%/78.1%/0.57/0.0399 1:320/84/38%/85.9%/0.38/0.0049 1:640/50/22%/91.8%/0.21/0.0028 ,¦ýŲ©ó¤§«e¦³µo¥ÍESMO ²³ø¸ê®Æ¦³»~´Óªº²{¶H, ÅÞ½r¤W,¼Æ¾Úªº pÈ, 1:40À³n¤ñ1:80¤j,¦³¥i¯à1:80 ¼Æ¾ÚKey¿ù,©ÎªÌ1:40 ªº¼Æ¾ÚKey¿ù(©È¬O1:40 ¬° 0.294 key ¦¨ 0.0294),¦pªGÁÞ®v¦³³sµ¸¨ì¤½¥q¥i§_¥N¤j®a°Ý¤@¤U½T¥ß³o¨âӼƾÚ(1:40©M 1:80 )¬O§_¥¿½T ÁÂÁÂ. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/10/29 ¤U¤È 08:40:26²Ä 2786 ½g¦^À³
|
«Ó¥v¤jô ÆgÆgÆg¡I10000ÓÆg¡I ¡u±ÂÅv¬O³Ì§Ö¥i¥H®³¨ÓÃÒ©ú822»ùÈ¡B¦P®É¤]¬OÀ°¯E¹©¥¤Ïªº°Ó·~¤â¬q¡v«D±`ÃÙ¦P¡I «áÄò¡A¤@©w±o¦b¥xÆW°µ¶Ü¡H¥xÆW¡A©Î³\¨S·Q¹³ªº®t¡A¦ý¬Y¨Ç§ë¸ê¤ô¥¡Bµo®iÀô¹Ò¤´¨S·Q¹³ªº¦n¡I ¬°¤F¯f±w¡Bªì°J¡A«Ü¦h¨Æ±¡À³¸Ó«O«ù¼u©Ê¡I ¿Ë¤Í¡Bline¸s¤Í¼g¤F«Ü¦h«Hµ¹¤½¥q¡A§Æ±æ°ª¼h¯à¬Ý¨£¡BÅ¥¨£ªÑªF¡B¯f±w®aÄݪº¤ßÁn¡I ³Ì«áÁÙ¬O§Æ±æ¤½¥q¡A¯à±N¤â¤WªºµP¦n¦n¥´¡B¾Ô¾Ô¹¸¹¸¡B§¶§¶Í}Í}ªº¥´¡A¥[ªo§r¡I |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/10/29 ¤U¤È 08:30:28²Ä 2785 ½g¦^À³
|
衆¤j®v¦n¡G1¡G64O¦³5O¤H¡D¤p§Ì²q·Q¥þ¡ªº¤H¬O§_´N¦b𥚃±©O¡H |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/10/29 ¤U¤È 08:17:13²Ä 2784 ½g¦^À³
|
®Ä»ù/¤H¼Æ/¤ñ²v/4¦~¦s¬¡²v/¹ï·Ó²Õ/HR/PÈ 1:40/171/76%/77.2%/0.58/0.0294 1:80/148/66%/74.8%/0.66/0.0939 1:160/112/50%/78.1%/0.57/0.0399 1:320/84/38%/85.9%/0.38/0.0049 1:640/50/22%/91.8%/0.21/0.0028 ¥H¤W4¦~¦s¬¡²vªº¼Æ¦r¡A¤p§ÌÃhºÃ1:80³o²Õ¼Æ¾Ú¬O¤£¬O¹q¸£°µªí®æ®É§Û¿ù©ÎºV¿ù¤F¡A©M1:40³o²Õ¼Æ¾Ú©úÅã°Â¤£¥X¦X²z©Ê¡C ¦pªG¤W±ªº¼Æ¦rµL»~¡A¨º»ò¡A1:40¡ã1:79.99³o°Ï¶¡ªº23¤H¤Ó±j¤F¡A¤ñ>=1:640ªº50¤HÁÙ±j¡AÅãµM¤£¦X²z¡C ¤p§Ì¦pªG²z¸Ñ¦³»~¡A½Ð¤j¤jÌ«ü¥¿¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/10/29 ¤U¤È 08:08:26²Ä 2783 ½g¦^À³
|
1.¨â²Õn¤½¤¹¦aPK¼Æ¾Ú¡A«Ü«nªº«e´£´N¬O¨â²Õªº±ø¥ó¥²¶·µLÅãµÛ®t²§¡C1:640¦û22%¡A¦pªG¬O©M¹ï·Ó²Õªí²{«e22%ªº¬Û¤ñ©O¡HPÈÁÙ·|³o¼Ë¶Ü¡H1:320¦û38%¡A¦pªG¬O©M¹ï·Ó²Õªí²{«e38%ªº¬Û¤ñ©O¡HPÈÁÙ·|³o¼Ë¶Ü¡H³o¬O¤T´ÁÁ{§É¥²¶·±¹ïªº°ÝÃD¡A¤è®×¤@¡G¹êÅç²Õ¥ý¥´¤@°w¬Ý¦³µL§ÜÅé¤ÏÀ³¡A¦¬¤J1:40¥H¤WªÌ¡A¹ï·Ó²Õ«h¤£ºÞ¦³µL§ÜÅé¤ÏÀ³³£¦¬¡A³o¼Ë¦³¬DÄå®ç¤§¶û¡AFDA·|¦P·N¶Ü¡H¤è®×¤G¡G©Ò¦³¤H³£¥ý¥´¤@°w¡A1:40¥H¤W¤~¦¬¤JÁ{§É¡AµM«áÀH¾÷¤À¤J¹êÅç²Õ¹ï·Ó²Õ¡A¨â²Õ¨ü¸ÕªÌ±ø¥ó¬Û¦P¡A³£ÄÝ©ó¨Åéµy·L°·±d¤@ÂIªº¡A³o¼ËÀ³¸Ó¤£·|³QFDA¥´ºj¡C°ÝÃD¨Ó¤F¡A¤è®×¤Gªº¹ï·Ó²Õ¤ñ¤G´Áªº¹ï·Ó²Õ°·±d¡A¤è®×¤Gªº¹êÅç²Õ¥i¯à¤ñ¤G´ÁªºResponder²Õ¤£¨º»ò°·±d¡A¦pªG¨ä¥L±ø¥ó¤£ÅÜ¡A«h¤T´Áªº¼Æ¦rÁÙ·|¬O¤µ¤Ñ©Ò¬Ý¨ìªº¼Æ¦r¶Ü¡H¨â²Õªº®t²§·|ÁY¤p§a¡C 2.ASCO²Ä13¶¤£¤À²ÕªºOSÁͶէi¶D§Ú¡A¹êÅç²Õ»P¹ï·Ó²ÕªºPÈÀ³¸Ó«Ü¦³¾÷·|¤p©ó0.05¡A©Ò¥H¦pªG¤T´ÁÁ{§Éªº¹êÅç²Õ»P¹ï·Ó²Õªº¦¬®×±ø¥ó³£¬Û¦P¬O1:40¥H¤W¡A§Ú¤]«ÜÄ@·N¬Û«H¤T´Á³Ì²×OSªºPȫܦ³¾÷·|¤p©ó0.05¡C§Ú¥u¬O·Q´£¿ô¤j®a¡AµL¶·¬°¤FESMOªº·s¸ê®Æ¦Ó¹L«×¼ÖÆ[¡A²¦³º¨º¬O¦b¨â²Õ±ø¥ó¦³®t²§ªº±¡ªp¤UPK¡A³o¬O¦bPost-hoc¡u¶EÂ_¯f¤H¡v¡A§Ú»{¬°¤£°÷«ÈÆ[¡C´N¦n¹³¤@´Áªº¦¬®×¯f¤H´N©úÅã¤ñ¤G´Á±j¤Ó¦h¡A§Ṳ́£¸Ó¥H¤@´Á¼Æ¾Ú¨Ó¹w´ú¤G´Á¡C·íµM¡A¦pªG¤T´Á¯à´î¤Ö»~§PPD¤ñ¨Ò¡A¯à´£°ª¥´§¹¤E°w¤ñ¨Ò¡]Keytruda¦³´XÓÁ{§É¬OÁ{§É¤W©úÅãPD¤~°±¤îªvÀø¡^¡A«h²z½×¤W¼Æ¾Ú·|¤ñASCO²Ä13¶¦A¦n¤@¨Ç 3.¸ê¥»¥«³õ·Q¬Ý¨ìªº¬O¬Æ»ò¡H§ÚÌ»¡±o¦A¶}¤ß¤]¤ñ¤£¤W°ê»Ú¤j¼t¥[«ù¨Ó±o¯u¤Á¡A1:320»P1:640ªº¼Æ¾Ú¤]¤ñ¤£¤WBTDÅ@Åé¨Ó±o°í©w¡An¥´°ê»ÚÁÉ´N¬On¥ý¨ú±o°ê»Ú±M®aªº»{¦P¡CConditional approval»PBTD¾Þ¤§¦bFDA¤â¤W¡A«æ¤£±o¡A¦Ó¥Bnµ¥¼Æ¦r¦¨¼ô¡A¦ý±ÂÅv¬O³Ì§Ö¥i¥H®³¨ÓÃÒ©ú822»ùÈ¡B¦P®É¤]¬OÀ°¯E¹©¥¤Ïªº°Ó·~¤â¬q¡A¸Ñª¼¦Ü¤µ¤KÓ¤ë¤F¡A¸ê¥»¥«³õÄ@·Nµ¥¯E¹©¦h¤[¡H¬Ý°_¨Ó¤£¤Ö¤H¤£@·Ð¤F¡C¶¶¹D¤@´£¡A¤é¥»¤j¶ï»sÃĬO¥þ²y±Æ¦b¤G¤T¤Q¦Wªº¤jÃļt¡AAbilify¦b¬ü°ê³Ð¤U¦~¾P75»õ¬üª÷¡A¥þ²y¦~¾P9x»õ¬üª÷ªº¬ö¿ý¡A¥L¦b¬ü°ê¦³¦Û«Ø¦æ¾P¹Î¶¤¶Ü¡H¨S¦³¡A¬O©M¥²ªv§´¦X§@¦@¦P¦æ¾P¡C |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/10/29 ¤U¤È 07:49:02²Ä 2782 ½g¦^À³
|
C®v¡DÁÞ®v¡D¤Ñ©R®v¤Î衆®v¤½¥q¦n¹³¨SÄF¤H¡D讃ÁÞ®v¹q¤OÅå¤H¡D |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 07:14:08²Ä 2781 ½g¦^À³
|
¦P¤@Ó°ÝÃD¦A«ä¦Ò¤@¤U:¦pªG¨Ï¥Î¦b¤¤¦´Á¨ÅÀù¯f±w¨¤W¤¤¦ì¼ÆÁ`¦s¬¡´Á·|¦p¦ó? ¤]¬O¨S¦³µª®× |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 06:20:49²Ä 2780 ½g¦^À³
|
ÁÂÁ²q·Q¤j§â¨âÓ·s¤½§iªº§ë¼v¤ù¾ã¦X¬°¤@¡A ¦s¬¡¾÷²v»P§ÜÅé®Ä»ù¦¨¥¿¬ÛÃö¡A¦Ó¥B1:40°_´N¦³¬Ý¨ìÀø®Ä¡C ¥t¥~©ß¤@Ó°ÝÃDµ¹²³¤j¤j«ä¦Ò¡A¨S¦³µª®×: ¦pªG¦w¥þ©Ê¡A¥Í¬¡«~½è»P§óªø´Áªº¦s¬¡¬O¯f±w»P®aÄÝnªº¨¤«×¨Ó¬Ý¡A¥þ²y¤T´Á¸g¹L¿z¿ï¦³§K¬Ì¤ÏÀ³¯à²£¥Í¨¬°÷§ÜÅ骺¯f±w+¥´§¹¤E°w©Î§ó¦h°w¦¸¡A¤¤¦ì¼ÆÁ`¦s¬¡´Á·|¦p¦ó ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 05:43:30²Ä 2779 ½g¦^À³
|
ÁÂÁÂCCC¤j´£¨Ñ¸ê°T¡A§Ú»P²q·Q¤j¤w°Q½×¹L¤F¡A¬P´Á¤@¦A°Ý°Ý¬Ý¡A¬O§_¬°¶i¦æ¤¤ªº833¡A ±q§ë¼v¤ù¤å¦r½×z«Ü®e©ö»~¸Ñ¡A¯u¬O¶Ë¸£µ¬ |
|
|
·|û¡Gccc10136060 µoªí®É¶¡:2016/10/29 ¤U¤È 05:15:30²Ä 2778 ½g¦^À³
|
10/28 ¤W¤È09:35:58 ,²Ä16349½g¦^À³: ¥t¥~³¯¹a¬z°|¤h¦b±Ð¨|¬ã°Q·|¤¤´£¨ìªº¤j³¡¥÷¬O¤j®a¤w¸g¼ô±xªº¡A¤ñ¸û¯S§Oªº¬O¦o¦³³zÅS¦b¶i¦æ¤¤ªº833¤HÅéÁ{§É¤¤¦³µo²{¨ì¨Ï¥Î¤£¦P¸üÅé³J¥ÕCRM197 »P¦õ¾¯ C34 ¯àÅýIgM Âà´«¦¨ IgG¡A³o¬O²Ä¤@¦¸¦b¤HÅéÆ[¹î¨ìªº³ø§i¡AOBI833¤]¬O«Ü¦³¼ç¤Oªº ³oÓÀ³¸Ó¬O«ü³¯¹a¬z°|¤h¦bESMO ²³øªºslide No. 21 ¥Ñ¤U¨¤ªº¤@¬q±Ôz: Investigations underway using different carrier and adjuvant (DT CRM -197 & c34 ) show a significant class switch from an IgM response to an IgG response. ³o¤@¬qì¤åªº±Ôz¡A ´`½u¬d¤U¥h·|§ä¥X2ӰѦҤåÄm: --¬O2015¦~Danishefsky»P¨ä¥L¤T¦ì¦@¥|¥¨ÀY¼gªº¨º¤@½g¤å³¹¡C --¬O2013¦~ªº¯»¶ê½×¤å¡C ¨â½g©Ò¨¥¨ä¹ê¬Û¦P¡A ³£¬O«üGH/DT-C34ªº¡¨°Êª«¸ÕÅçµ²ªG¡¨¡A ¤£¬O²{¦b¯E¹©ªº833¡A ¤£¬O¤HÅé¸ÕÅç¸ê®Æ¡C ¤]¤£¬O833 phase Iªº¸ê®Æ´¦ÅS¡C ¤jÁx°²³] ,¤p¤ß¨DÃÒ ¬ì¾Ç®aªººë¯« µL½aªº·Q¹³¤O, ¶}±ÒÃÀ³Nªº³Ð³y ¯E¹©ªº822 ¬Oª¾ÃѪº¬ì¾Ç ÁÙ¬OÃÀ³Nªº·Q¹³¤O©O? |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/10/29 ¤U¤È 02:52:14²Ä 2777 ½g¦^À³
|
§ä¨ì¤F ¦]¬°¥Î¤â¾÷¬Ý ·|¸õ¨ì¼v¤ù ¬Ý¤£¨ì§ë¼v¤ù «Øij¸ò¤½¥q¤ÏÀ³¤@¤U ³o¼Ëªº¦n®ø®§À³¸ÓÅý¤j®a§ó®e©öª¾¹D |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/29 ¤U¤È 02:51:54²Ä 2776 ½g¦^À³
|
Leo ¤j ¦bºtÁ¿¸Ì±§Û¿ýªº ¤½¥q²Ä¤@¦¸ªº¼v±a¦ü¥G¤ñ¸ûµu ¤p§Ì°O±o¦n¹³¬O21±i , 12¤À¦hÄÁ ¦p¤µÅܬ°25±i , 14¤À55¬í ¶À¥D¥ôªº¨º¨â±i¼Æ¾Ú , ¦ü¥G¬O«á¨Ó¥[ªº , ¥HP§ÚÌ©¿²¤¤F ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/29 ¤U¤È 02:41:57²Ä 2775 ½g¦^À³
|
Leo ¤j ¤½¥qªººô¯¸´N¦³¤F |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/10/29 ¤U¤È 02:35:23²Ä 2774 ½g¦^À³
|
½Ð°Ý©xºô¨ºÃ䦳§ë¼v¤ù ¤p§Ì·M¹y ÁÙ¨S§ä¨ì³sµ² ¦³¨º¦ì¤j¤j¥i¥H¶K³sµ²¶Ü |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/29 ¤U¤È 02:29:16²Ä 2773 ½g¦^À³
|
OBI 822 Á{§É¹êÅç²Îp ®Ä»ù_______¤ÏÀ³¤H¼Æ______PFS______¦MÀI¤ñ ( 95% CI )___PÈ__4 Year Survival( %)__¦MÀI¤ñ ( 95% CI )__ PÈ gG 1:40____171 ( 76% )___11.1 ( 9.2 )___0.79 ( 0.60~1.04 )___0.0909___77.2 ( 60.5 )_____0.58 ( 0.36~0.95 ) ___0.0294 IgG 1:80___148 ( 66% )___11.1 ( 9.2 )___0.77 ( 0.58~1.03 )___0.0778___74.8 ( 60.5 )_____0.66 ( 0.41~1.07 ) ___0.0939 IgG 1:160__112 ( 50% ) ___11.1 ( 9.2 )___0.71 ( 0.52~0.97 )___0.0295___78.1 ( 60.5 )_____0.57 ( 0.33~0.97 ) ___0.0399 IgG 1:320___84 ( 38% ) ___11.2 ( 9.2 )___0.70 ( 0.50~0.98 )___0.0373___85.9 ( 60.5 )_____0.38 ( 0.19~0.74 ) ___0.0049 IgG 1:640___50 ( 22% ) ___17.6 ( 9.2 )___0.61 ( 0.41~0.91 )___0.0165___91.8 ( 60.5 )_____0.21 ( 0.07~0.58 )___0.0028 ¥xÁÞ¤j¤j Ä_ÂóQ±z«õ¥X¨Ó¤F ÁÂÁ±z! ¶g¤@ ±z°Ý¤½¥q833ªº°ÝÃD®É , ½Ð±z¥[°Ý833ªº§ÜÅé®Ä»ù¬O§_¤ñ822¨Ó±oÀu? °Ú«¢! ¨ä¹ê²Ó¬Ý¤½¥qªººô¯¸ , ¦´N¦³¥ñµ§ , Á٥άõ¦â¦rÅé¥[±j¿ô¥Ø®ÄªG , ¤j®a©Î³\³£©¿²¤¤F ¡§ On Slide 11 of Dr CS Huang¡¦s presentation, the data table on the right is mislabeled as "weeks" instead of "months". We regret any confusion this may have caused. µù¡B±z¥i§Q¥Î¼v¤ù¿Ã¹õ¤U¤èªº¾Þ§@«öÁä¡A¿ï¾Ü¡B©ñ¤j©Î¬OÁY¤p§ë¼v¤ù¤ÎºtÁ¿ªÌµe± ¡§ ¦Ü©ó³o¥÷¼Æ¾Ú¦n¤£¦n ´N¯d«Ý¤j®a¦Û¦æ¸ÑŪ ¤]³\¤Ñ©R¤j¤j¤w»¡¤F¤£¤Ö ¤p§Ì¤ü¼LÁÙ¬O¦R¤£¥X¶H¤ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/10/29 ¤U¤È 02:19:55²Ä 2772 ½g¦^À³
|
±i¸³»¡¦³§ÜÅé´N¦³Àø®Äªº¼Æ¾Ú²×©ó¥X²{ ÁÂÁÂ¥xÁÞ¤j |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 01:48:50²Ä 2771 ½g¦^À³
|
Lin¤j ³o¬O¹êÅç²Õ¤£¦P§ÜÅé®Ä»ù»P¥|¦~¦s¬¡¾÷²vªº¤ÀªR¡A¬Û·í¸Ô²Ó¡A¹ï·Ó²Õ¦]¬°³£¬O60.5%¡A¦³Äæ¦ì¥i¬O§Ú¨S¦³¥´¶i¥h¡A§A¥i¥H§â³o¤²Õ¤£¦P®Ä»ù¥|¦~¦s¬¡¾÷²v¤À§O´î¥h60.5 ´N·|¬Ý¥X¨â²Õ¦b¤£¦P§ÜÅé®Ä»ùªº®t¶Z¡C °ò¶©ÁöµM¤UÂI«B¥i¬OPM2.5¥u¦³9¡AªÅ®ð«~½è¬Û·í¦n¡A¤j¥x¥_¤µ¤Ñ¤]ÁÙ¦n³£¦bºñ¦â°Ï¡A¬Q¤Ñ¬O¶À¦âĵ§Ù°Ï¡C |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/10/29 ¤U¤È 01:32:52²Ä 2770 ½g¦^À³
|
ÁÂÁÂÁÞ®v¡G±z¤Sn¥h¥R¹q¤F⋯⋯ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤U¤È 12:44:31²Ä 2769 ½g¦^À³
|
Walker¤j¡A Lin¤j ¦b©xºô¤½§i2016 ESMO §ë¼v¤ù20,21´N§ä±o¨ì¡A§ÜÅé®Ä»ù»P¦s¬¡²v¦¨¥¿¬ÛÃö¡A§ÜÅé®Ä»ù¶V¤j¨â²Õ®t²§¶V¤j¡A³oÓ¤£¬O§ó·s¸ê®Æ¬Oª½±µ¤½§i·s¼Æ¾Ú¡A¯E¹©¬Û·í§C½Õ¡A¤µ¤Ñ¦³ÂI·N¥~µo²{¨ì¡A·PÁ¤ѧa! ¥¼¨Ó¿z¿ï¯f±w¦A¤j¤E°w©Î«ùÄò¬I¤j¡AÀø®Ä¦Û¤v¥h¬ã§P! |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/29 ¤U¤È 12:19:22²Ä 2768 ½g¦^À³
|
³o¹êÅçµ²ªG¡AÀ˽լO¤£¬O¸ÓÁÙ¤H®a²M¥Õ¤F¡H |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/29 ¤U¤È 12:11:02²Ä 2767 ½g¦^À³
|
¥xÁÞ¤j ½Ð±Ð¤@¤U¡A±z¦bþÃä¬Ý¨ì³o¸ê®Æªº? |
|
|
·|û¡GµL¹Ð10141268 µoªí®É¶¡:2016/10/29 ¤W¤È 11:00:29²Ä 2766 ½g¦^À³
|
¥@¬É½Ã¥Í²Õ´¡]WHO¡^µo§G³ø§iºÙ¡A¥þ²yÀù¯g±wªÌ¤H¼Æ«æ³t¼W¥[¡A¨C¦~·s¼WÀù¯g±wªÌ¤H¼Æ¦h¹F1200¸U¡A¨ì2035¦~¦³¥i¯à¼W¥[¨ì2400¸U¡F¦b¹L¥h10¦~¶¡¡A¥þ²yÀù¯g±wªÌ¼W¥[20%¡C ³ø§i¯S§O«ü¥X¡AÀù¯g°òª÷·|ªº½Õ¬d¸ê®ÆÅã¥Ü¡A¥@¬É¦U°êªÍÀù³Ì¬°ÄY«¡A¦b¥þ²yÀù¯g±wªÌ¤¤ªÍÀù±wªÌ¥e¤F85%¡A¨ä¦¸¬O¤k©Êªº¨Å¸¢Àù¡A¥e¤FÀù¯gÁ`¤H¼Æªº25%¡C ¥@¬É½Ã¥Í²Õ´ªº³ø§iªí¥Ü¡A¨C¦~·s±wÀù¯g¯f¤H60%¶°¤¤¦b«D¬w¡B¨È¬w©M¤¤«n¬ü¬w¡A¦]Àù¯g¦º¤`ªÌ70%¤]¶°¤¤¦b¤Wz¦a°Ï¡C³ø§i©IÆ~¦U°ê±Ä¨ú¤Á¹ê¦æ°Ê¹w¨¾Àù¯g¡C¡]°ê»Ú¤¤¤ß¡þºî¦X¥~¹q³ø¾É¡^ |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/10/29 ¤W¤È 10:58:05²Ä 2765 ½g¦^À³
|
ÁÞ®v¬°¦ó¬O対·Ó²Õ¡D³o¼Ë¬O〇K¶Ü¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤W¤È 10:49:37²Ä 2764 ½g¦^À³
|
®Ä»ù1:80 PÈ0.0939 ¥t¥~ÁÙ¦³¤@±i®Ä»ù¤j¤p»PPFSªºÃö«Y¤]¦³´£¨Ñ¡A§Ún»P®a¤H¥h°ò¶©ª±¡AµLªk¦A¥´¦r¤F! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤W¤È 10:29:32²Ä 2763 ½g¦^À³
|
¹ï·Ó²Õ¥|¦~¦s¬¡²v60.5% ¥´1-5°w52¤H¡A ¥´ 6-8°w68¤H ¡A¥´ 9°w104¤H¡C ¥´1-5°w»P ¥´9°w¤ñ¸ûPÈ<0.0001 ¥´6-8°w»P¥´9°w¬Û¤ñPÈ0.0013 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤W¤È 10:21:19²Ä 2762 ½g¦^À³
|
²³¤j¤j ¶À«T¤ÉÂå®v³ø§i³¡¥÷¡A¸ê®Æ§ó·s«Ü¤j ®Ä»ù/¤H¼Æ/¤ñ²v/4¦~¦s¬¡²v/¹ï·Ó²Õ/HR/PÈ 1:40/171/76%/77.2%/0.58/0.0294 1:80/148/66%/74.8%/0.66/0.0xxx 1:160/112/50%/78.1%/0.57/0.03999 1:320/84/38%/85.9%/0.38/0.0049 1:640/50/22%/91.8%/0.21/0.0028 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/29 ¤W¤È 09:14:25²Ä 2761 ½g¦^À³
|
²q·Q¤j ³o¯uªº¬O¶Ë¸£µ¬¡A±q§ë¼v¤ù¨Ó¬Ý¬O833 ¤G¥N ¦Ó¥B´£¨ì¶i¦æ¤¤ªº¬ã¨s¡A¬P´Á¤@§Ú¦A°Ý¤½¥q¬Ý¬Ý¡A·|¤£·|¤w¸g´£¥X§ïÅܦõ¾¯¥Ó½Ð¨Ã¥B¤w¦¬®×Æ[¹î¨ìªº? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/29 ¤W¤È 08:06:41²Ä 2760 ½g¦^À³
|
¹ï¤£°_ ¤p§Ì¥i¯à±i«a§õÀ¹¤F DT CRM -197 & c34 ¬O833²Ä¤G¥N©|¥¼Á{§É ²{¦b³B©ó¤@´ÁÁ{§Éªº¬O833²Ä¤@¥N ¬O DT CRM -197 & QS-21 ¦ý¬OºÙ³¯°|¤h»¡ªº¬OÁ{§É¤@´Áªº¤HÅé¼Æ¾Ú? ÁÙ¬O¹«Å骺¼Æ¾Ú? °Ú¡I ¶Ë¸£µ¬ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/28 ¤U¤È 07:54:40²Ä 2759 ½g¦^À³
|
³¯°|¤h§ë¼v¤ù©Ò³zÅS833 Á{§Éªº°T®§ Investigations underway using different carrier and adjuvant (DT CRM -197 & c34 ) show a significant class switch from an IgM response to an IgG response. ªþµù¡GºK¦Û¦¨¤j¾¤·ØÄ£ ±Ð±Âªº§K¬Ì¾ÇÁ¿¸q ¡] http://www.ncku.edu.tw/~microbio/course/teacher/lei/lei2.htm ¡^ a. IgM¦û¦å²M¤¤§ÜÊ^§t¶qªº10¢H¡A¥Dn¦b¦åºÞ¤º¡A¥Ñ¤Ó¤À¤l²Õ¦¨¤»E¦Xª« ¡@¡@¡@¡@(pentamer)¡A¦]¦¹¦³10Ó§Üìµ²¦X¦ì(binding site)¡A¥¦ªº§ÜÊ^¿Ë§Üì©Ê ¡@¡@¡@¡@(avidity)¤j¡A¦b·P¬V®É¬O³Ì¦¥X²{ªº§ÜÅé¡A¦]¦¹±`³Q¥Î¨Ó·í°µ·P¬Vªº¶EÂ_¡A ¡@¡@¡@¡@¦pªG¦³IgMÃþ§Oªº§ÜÅé¥X²{¡Aªí¥Ü·P¬V¬O³Ìªñªº¡CIgM ¯à¬¡¤Æ¸ÉÅé¡C ¡@¡@ b. IgG¡A¬O¦å²M¤¤¥Dnªº§K¬Ì²y³J¥Õ¡A¦û¥þ³¡§ÜÊ^§t¶qªº70¡ã75¢H¡A¥¦ªº¿@«× ¡@¡@¡@¡@¥i¹F10 mg/ml¡A¥¦¦b¦åºÞ¤º(intravascular pool)©Î¦åºÞ¥~(extravascular ¡@¡@¡@¡@pool)¥§¡¤À§G¡A¥¦¬O¤G¦¸¤ÏÀ³(secondary response)²£¥Íªº¥Dn§ÜÅé¡A§Ü¬r¯À ¡@¡@¡@¡@§ÜÊ^(anti-toxin Ab)°ò¥»¤W¬Ò¬O IgG¡C±qIgMÂàÅܦ¨IgGºÙ§@§ÜÊ^ºØÃþÂಾ ¡@¡@¡@¡@(class switch)¡A³oÓ¹Lµ{¶·nTh-²ÓMªºÀ°¦£¡AIgGªº¿Ë©M¤O(affinity)¦]¬° ¡@¡@¡@¡@¦³§ÜÊ^¦¨¼ô(maturation)¹Lµ{¡A¤]¤ñIgM°ª¡AIgG¬O°ß¤@¯à³z¹LL½L¡A¥Ñ¥À¿Ë ¡@¡@¡@¡@¶Ç»¼µ¹L¨àªº§ÜÅé¡A¤]´£¨Ñ·s¥Í¨àªì´Áªº«OÅ@¤O¡CIgG·|¬¡¤Æ¸ÉÅé¡A©M§]¾½ ¡@¡@¡@¡@²ÓM(phagocyte)¦@¦P¶i¦æ½Õ²z§@¥Î(opsonization)¡A§]¾½²Óµß¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/28 ¤W¤È 11:10:29²Ä 2758 ½g¦^À³
|
¤p§ÌÁn©ú ¤p§Ìªº¬Ýªk ¤]¥u¬O¤p§Ìªº¬Ýªk ¨ä¥L¤°»ò³£¤£¬O ¤p§Ì¨S¦³¹ª§j¤j®a¶R¶i «ù¦³ªº·N«ä ¤j®a¥²µM³£¦³¦Û¤vªº¬Ýªk ½Ð±z¨Ì¦Û¤vªº·Qªk¶i¥X ÁÂÁ¤j®a! |
|
|
·|û¡G¿³Âd¤p¦y§L10138540 µoªí®É¶¡:2016/10/28 ¤W¤È 11:00:46²Ä 2757 ½g¦^À³
|
¯f¬r¼Æ¶q¤£¨¬®É¤HÅé¤]¤£·|¦³¯gª¬µo¥Í¡A822§ÜÅ餣¨¬¤]«ÜÃø²£¥Í®ÄªG¡C822+cyclophosphamide·|¬O¤@ºØ¿ï¾Ü¡AÁ{§É®ÄªG¤]·|¦]¤H¦Ó²§¡A¦³¨Ç¤H¥i¥H¤£¥[§Y²£¥Í¨¬¶q§ÜÅé¡A¦³¨Ç¤H¥[¤F¤]¨S¥Î¡C©Ò¥H±i¸³»¡¡A¥´¤@°w¤U¥h´Nª¾¹D¡C ¥«±¤W¦UºØ¬Ì]«Ü¦h¡A¦³¤£¤Öª`®g«á¥X²{§ÜÅé¶q¤£¨¬¡A¸ò¤Hªº§K¬Ì¨t²Î»P°ò¦]¦h¼Ë©Ê¦³Ãö«Y¡A¦ý¬O³o¨Ç¬Ì]²×¨sÀ°§U¤F¤£¤Ö¤H¡A¦b´_§@¥Î¤£¤jªº±¡§Î¤U¡Aªu¥Î¦Ü¤µ¡C³o¨Ç¦ÑÃÄÂå¥Í¥Îªº«Ü¶¶¤â¡C·sÃÄ®³¨úÃÄÃÒ«á´Nn¶i¤J¥«³õ¡Aº¥ý´N¬O¨ã¦³³B¤èÅvªºÂå¥Í¡A¦Ó¤£¬O±i¸³©Î¬O¯Î°|ªø¡C822«e³~¦p¦ó§Ú¤]¤£ª¾¹D¡A¤j®an§ë¸ên·V«¡C |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/10/28 ¤W¤È 10:52:19²Ä 2756 ½g¦^À³
|
5619 ¤j... ±zı±on³ø§iªº¤H·|¨S¦³¬Ý¹L§ë¼v¤ù? ¤p§Ìı±o¥i¯à¬O¥D¿ì³æ¦ìªº¤uŪ¥Í©ñ¿ùÀɮת©¥»¤F... XDDD |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/28 ¤W¤È 10:31:17²Ä 2755 ½g¦^À³
|
¦³«í¤j¤j ÁÂÁ±zªº»¡©ú , Åý¤p§Ì©ú¥Õ¤½¥q¦³¦bª`·N³o¥ó¨Æ , ³o´N¤ß¦w¤F ²{¦b ¤p§Ì¹Á¸Õ§â³o¨â¤T¤Ñªº©å¤å , »P822°µ¤@·Q¹³¦¡ªº³sµ² §Æ·æ.³Á§Jªü·æ³Õ¤h´£¤Î . Vaccine-based therapies may induce T-cell infiltration into the tumor . Increased T-cell infiltration improve response to immune checkpoint inhibitors ¦ý¬Ì]¥²¶·²£¥Í¤j¶q§ÜÅé , ¤~¯à°õ¦æ³o¶µ¤u§@ ¡§ T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy ¡¨ ¦b³o½g¤å³¹ªº¤l¼ÐÃD ¡¨HOW TO MODIFY T-CELL INFILTRATION TO HELP IMMUNOTHERAPY ¡§ ²Ä¤ÂI§i¶D§ÚÌ ¡K¡K (5) suppressor cells can be depleted by specific chemotherapy drugs such as cyclophosphamide (for Tregs) or gemcitabine (for MDSCs); ³o¬O¤p§Ì»{¬° , Y¨S¥[§C¾¯¶qcyclophosphamide , ·|¤£·|¦³²£¥Í§ÜÅé¶q°¾¤ÖªººÃ¼{? ¥D°Ê¦¡§K¬ÌÃöÁäÂI´N¦b¤Þµo¨¬°÷ªº§ÜÅé , ²£¥ÍTIL( Tumor-infiltrating lymphocytes ) ²{¶H¨Óªv¯f , ©Ò¥H«Ü«n ¤p§Ì¤£ª¾¹D¤½¥q¤ÀªRªºµ²ªG? µMÓ¤H»{¬° , ÁÙ¬O¥H²K¥[¬°©y §Ú̦A¬Ý§Æ·æ.³Á§Jªü·æ³Õ¤hÁ¿ªº induce T-cell infiltration into the tumor , ³oÀ³¬O±þ¼Ä ¦Ó°£¤F±þ¼Ä¥~ , ¤]¥i¥Himprove response to immune checkpoint inhibitors (Áp¦XªvÀø , 1+1 > 3 ? ) ¥t¥~ T-CELL INFILTRATION IS IMPORTANT FOR OVERALL SURVIVAL ©Îªí¥Ü T-cell infiltration ¦³§U©ó OS ªº¾ãÅéªí²{ ? ÁÙ¦³ Next-generation cancer immunotherapy should harness the trafficking of immune cells to malignant tissue to achieve superior cancer therapies. 822 , 833 ÁÙ¬O 888 ¦³¨S¸ê®æ ?! Jo»ò¦h , ¥u¦b»¡©ú¤p§ÌÓ¤HªºÁp·Q , µLÃö¨Æ¹ê ½Ð¤j¤jÌ«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/10/28 ¤W¤È 09:32:04²Ä 2754 ½g¦^À³
|
ESMO ªº¿ù»~«ÜÂ÷ÃСA¦Ó¥B¤£¬O²Ä¤@¦¸¤F¡C¶À³Õ¤hªºÁ¿ºt¥O¤H¬°¥Lºò±i¡C¹ï©ó¯E¹©ªºÀù¯g§K¬ÌÀøªk©MÁÞ§Þ³N¤´µM²`¨ã«H¤ß¡A¥u¬O¨ºÓ¤½¥qªv²z¡A°Ý¸¹¡C©Z¥Õ»¡¡A¯uªºÃhºÃ±i¸³¶ÀÁ`¦³µL¼f¾\¹LESMOªºPPT¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/27 ¤U¤È 08:54:25²Ä 2753 ½g¦^À³
|
¦ü¥G¨S¥[§C¾¯¶qªºCyclophosphamide ü... ¦pªG¬O¥xÆWªº¯f±w, ¤K¦¨¨p©³¤U³£§]¤FÆFªÛµ¥ÆF¤¦§®ÃĤ]»¡¤£©w Á@Á@ÆFªÛªº¼s§iµü, ¬O¤£¬O«Ü¦n¥Î? ¢°¡D¬¡¤Æ§K¬Ì¡A´î½w§K¬Ì¨t²Î¦Ñ¤Æ §K¬Ì¨t²Î·|ÀHµÛ¦~¬ö¼Wªø¦Ó³vº¥°I°h¡AÅýªøªÌ§ó®e©ö¿©±w·P«_¡A¤£¦ý»Ýn§óªø®É¶¡«ì´_¡A¤]®e©ö¤ÞµoªÍª¢µ¥ÄY«¨Öµo¯g ¦Ó¦b°I¦Ñªº§K¬Ì¨t²Î¤¤¡A¥Dnªº§K¬Ì²ÓM¦pT²ÓM¤ÎB²ÓM¤]·|ÅܱoÃø¥H¤À¿ë¼Ä§Ú¡AÅý²Óµß¯f¬r§ó®e©ö¦b¨ÅéÁc´Þ¡A§ó¥i ©Èªº¬OÁÙ¥i¯à§ðÀ»¦Û¨²Õ´¡A§Î¦¨¦ÛÅé§K¬Ì¯e¯f ¦ÓÆFªÛ¦b¬ã¨s¤¤¤w³QÃҹ꦳¥H¤U½Õ¸`§K¬Ì®ÄªG¡A¯à´î½w§K¬Ì¦Ñ¤Æ¡A¹F¨ì¨¾¯f¥\®Ä 1. ¼W¶i§K¬Ì²ÓMªº¥\¯à¡A¹³¬O¡]¦ÛµM±þ¤â²ÓMnatural killer cells¡B»s³y§ÜÅ骺 B ²ÓM¥H¤Ît³d§Ö³t¤ÏÀ³¤Î°O¾Ð§Ü쪺T ²ÓM¡^ 2. °©Åè¬O»s³y¦å²G¤Î§K¬Ì²ÓMªº«n¾¹©x¡A¦ÓÆFªÛ¯à´î¤Ö¤ÆÀø³y¦¨ªº¡u°©Åè§í¨î¡v¡A ¬¡¤Æ°©Åè¥\¯à 3. ÆFªÛ¯à´£¤É¥¨¾½细M¤Î¾ð¬ð²ÓMªº¥\¯à¡A´£¤É¨Åé¹ï¦UºØ¥~¨Óª«¡B¬Ì]¬Æ¦Ü¬OÀù¯gªº¹ï§Ü¤O |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/27 ¤U¤È 03:54:28²Ä 2752 ½g¦^À³
|
°¨°ºÂå°|¥D¾Éªº822¥Î©óOvarian CancerªºÁ{§É¤G´Á ¦ü¥G¨S¥[§C¾¯¶qªºCyclophosphamide https://clinicaltrials.gov/ct2/show/NCT02132988?term=OPT-822&rank=2 ³o¼Ëªº®ÄªG·|¤£·|¥´§é§r?! ¥¼¨Ó822ÂX¤j¾AÀ³¯gªº¤G´ÁÁ{§É ¬O§_¤]n¦Ò¼{¥[¤J§C¾¯¶qªºCyclophosphamide , ¨Ó¼W¶i±wªÌªº§K¬Ì®ÄÀ³ ¤½¥q¬O¤£¬O¦³¬ÛÃö²Îp , ¦A°µ¨Mµ¦©O ? ³o¬O¤p§Ì«¬Ý " T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy " ¤å ©Ò°µªºÁp·Q ????????? |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/10/27 ¤W¤È 11:02:05²Ä 2751 ½g¦^À³
|
ºô¸ô¸ê®Æ¡A¯u¹ê±¡ªp¡AÁÙ¬O±o°Ý¤@¤U§õ²Õªø...¤£¹L¡A¨º¤]¤£«n¤F «¢ |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/10/27 ¤W¤È 10:42:52²Ä 2750 ½g¦^À³
|
§d½n¶¯¤j... ESMO ªº¿ù»~½T¹ê«Ü±¼º£... ASCO ½×¤å¼f¬dÀ³¸Ó¬OÄY®æªº¡A¦Ü¤Ö¼f½Z©eûÀ³¸Ó§âÃö... ºKn¦¤½§G¤F...·|¦b«e¤@¤Ñ³Q®³±¼...§õ²Õªø·|ı±o®×±¡¨Ã¤£³æ¯Â |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/10/27 ¤W¤È 10:27:45²Ä 2749 ½g¦^À³
|
¤µ¦~ASCO, Immunomedics¦bASCO¤j·|¶}¹õªº«e¤@¤Ñ¡A¨ä¤T³±¨Å¸¢ÀùÃĪ«IMMU-132ªº¬ã¨sµ²ªG³Q±qASCO¤j·|ºKn¶°¤¤§R°£¡Aì¦]¬OImmunomedics§â¤§«e¤w¸g¤½¶}¹Lªºµ²ªG·í°µ·sªºµ²ªG´£¥æµ¹ASCO²Õ©e·|¡A´N³Q¥´ºj¤F¡K¡K¤½¥q¥H«á¤]·|¥Ç³oºØ§C¯Å¿ù»~¹À¡H |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/27 ¤W¤È 10:12:29²Ä 2748 ½g¦^À³
|
Cliff ¤j¤j: ·PÁ±zªº¦^ÂÐ. §Ú·|¦³³oºÃ°Ý, 昰¦]¬°ÃĦW昰¤G´Á¸Ñª¼«á¤~¦³ªº(?)., ¦P±i§ë¼v¤ù,¥k¤W´£¨ìªº昰¨ÅÀù, ¥k¤U¤Þ¥Îªº昰II´Áªº¸ê®Æ, ©Ò¥H¨Ã¦Cªº¥ª¤U, ª½Æ[¤WÀ³¼gªº昰 II ¦Ó«DI., §Y¨Ï¼gI, ¤]À³¦³ÓÃþ¦ü¡¨¦P¼Ëªºµ²ªG¤]¥X²{¦bII´Á¨ÅÀùÁ{§É¡¨ªº »¡©ú. ¦b¥Ø«e¨S¦³¥ô¦ó¦³ÃöFDAªº¶i¤@¨B®ø®§«e, ¬JµM¤½¥q¤w¿ï¾Ü½pÀq, ¨º nµoªíªºªF¦è´NÀ³¸Ó§ó¥[¼f·V, ¥LÌn±¹ïªº¤£¥u昰²{³õªº¹Å»«§ó¦³¼s¤jªº§ë¸ê¤H, ¥ô¦ó¦³¥i¯à³y¦¨±Ò¤HºÃÄu©ÎÅý¤H¨£Á_´¡°wªº¥ô¦ó¶Ç¹F, ³£À³¼f·V³q½L«ä¦Ò. ¤½¥q¦b¬ì¾Çªº»y¨¥¥~, »P¥«³õ·¾³qªº¯à¤O¯uªºÀ³¸Ó¦n¦n¥[±j, §_«h¥Ã»·§e²{¤@Өƥó¦U¤è¤£¦P¸ÑŪªºª¬ªp, ªø´Á¤U¨Ó, ¹ï¤½¥q¸Û«Hªº²Ö¿nµ´«D¥¿±. ¤£¬O¥u¦³µ¥¼Æ¾Ú¨Ó»¡¸Ü, ¼Æ¾Ú»¡ªº¸Ü, ¤H«ç»ò»¡ ? ³o¬q®É¶¡, ¥«³õªº¶Ç¨¥Å¥¨ìªº³£¥u¬Ot±, ©TµM¥i¯à¬O¦³¤ß¤H³yÁÁ©Î¤£©úÁAªº ¤H»~¸Ñ., ¦ý³oºØ¦ü昰¦Ó«Dªº¨¥½×, ³£¤ù±¤Þ¥Î¤F³¡¥÷¤½¥qªº¼Æ¾Ú©Î»¡ªk, ©Ò¥H³y¦¨·¥¤jªº¶Ë®`. ³o¶Ë®`¹ï¤½¥qªº¼vÅT«D±`¥¨¤j, Ä´¦p²{¼W., Ä´¦pªÑ»ù. ¸Ü¦h¤S¦ü¥GÂ÷ÃD¤F. ¦A¦¸·PÁ±z. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/27 ¤W¤È 08:48:51²Ä 2747 ½g¦^À³
|
QQ¤j¡G ³oÓSlide¤º®e¥X¿ùªº½T¬O¤£¸Ó¦³ªº¤H¬°¦]¯À¡A©ú©úקïmPFSªº¼ÆȤF¡A«ç·|¤£¥hקï³æ¦ì¡H¦Ó¥B¥uקï¤F¥´§¹¤E¾¯ªº¨º±islide¡K¡K¡C ¡u¨º±i¥ª¤U¨¤ ¡§Adagloxad simolenin was safe and well tolerated in Phase 1 trials¡¨ ¬°¦ó¼gPhase I ¦Ó«D Phase II ©O ?¡v ¨º¤@±i¥ª¤U¨¤¬O´£¨ì822¦´Á°µÄáÅ@¸¢Àù»P¨ÅÀù¤@´ÁÁ{§É¸ÕÅ窺¨Æ±¡¡A©Ò¥H¤~»¡¡uwell tolerated in Phase 1 trials¡v¡A·sÃĬãµo¦w¥þ©Ê/@¨ü©Ê©l²×¬O¨üÃöª`ªº¡A¤@¯ë³£·|´£¨ì¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/27 ¤W¤È 08:42:28²Ä 2746 ½g¦^À³
|
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142435/ ³o½g¤å³¹ªº¨â¥y¸Ü ´£¨Ñ¤j®a°Ñ¦Ò .T-CELL INFILTRATION IS IMPORTANT FOR OVERALL SURVIVAL (¼ÐÃD) .Next-generation cancer immunotherapy should harness the trafficking of immune cells to malignant tissue to achieve superior cancer therapies.(µ²»y³Ì«á¤@¥y) |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/10/27 ¤W¤È 04:38:59²Ä 2745 ½g¦^À³
|
½T¹ê«Ü´Á«Ý¦X¨Ö anti-PD1ªº®ÄªG¡I§Æ±æ¤½¥q¿n·¥¤@ÂI¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/27 ¤W¤È 02:00:25²Ä 2744 ½g¦^À³
|
¹ê¦b§Ô¤£¦í·Q°á¤@¤U¡K. «ç»ò¨C¦¸ªº§ë¼v¤ù³£·|¥X¿ù ?! ¤w¸g¦³¤Ó¦h¦¸¥X¿ùªº¸gÅç¤F, ¬°¤°»ò²Ó¸`³BÁÙ¬O³£¤£¯d·N ? ¦b³oºØ°ê»Ú³õ¦X¤@¦A¬Ý¨ì¤½¥qªv²zªº¤£°÷ÄYÂÔ, ³o¬O¥Ø¼Ð¦¨¬°°ê»Ú¯Å¤½¥qÀ³¦³ªºªí²{¶Ü ? ü! Cliff ¤j¤j: ½Ð±Ð±z : P.20 ¨º±i¥ª¤U¨¤ ¡§Adagloxad simolenin was safe and well tolerated in Phase 1 trials¡¨ ¬°¦ó¼gPhase I ¦Ó«D Phase II ©O ? ¦³¯S§Oªºì¦]¶Ü ? |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/27 ¤W¤È 12:03:49²Ä 2743 ½g¦^À³
|
Ãö©ó³¯³Õ¤h©Ò»¡¥´°w¤@Ó¤ë«á´Nª¾¹D¦³¨S¦³§ÜÅé.................... ½Ð¬Ý¼v¤ù13¤À³B,±i¸³©ó2/22¸Ñª¼ªk»¡¦³´£¨ì! www.youtube.com/watch?v=Lp2cOFUz2X4 |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/26 ¤U¤È 11:50:29²Ä 2742 ½g¦^À³
|
±q2/21¯Î°|ªøªº½Í¸Ü,2/22¯E¹©¸Ñª¼»¡©ú·|,6¤ë°Ñ¥[ASCO,8¤ëRugo¨Ó¥x«á,10¤ë³¯¨}³Õ°|¤h±M³X,¦Ü10¤ëESMO¬ã°Q·|! µ²½×:¹ï¥¼¨Ó¤T´Áªº¬Ýªk«Ü¤@P!(¬Ý°_¨ÓRugo8¤ë¥÷¨Ó¥x«á¹ïÁ{§Éªº²q·Q¬O¦h¼{¤F!²¦³º10¤ë¬Ý¨ìªº³ø§i¤´µMºû«ù¤½¥q¤@Pªº»¡ªk! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/26 ¤U¤È 11:37:15²Ä 2741 ½g¦^À³
|
©Ò¥H¨S¦³·sData¡A»PASCO¬Û¦P¡C 1.»~ȳæ¦ì¡C¡]¶À¥D¥ô¤]¸òµÛ°á¿ù¡^ 2.¥[¤F¤@±i»Pcheckpoint inhibitor¦X¨ÖªvÀøªº±´°Q¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/26 ¤U¤È 11:06:59²Ä 2740 ½g¦^À³
|
®É¶¡³æ¦ì¤£¤@¼Ë§a ESMO ¦³ÂIµ§»~ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/26 ¤U¤È 11:05:48²Ä 2739 ½g¦^À³
|
§ó¥¿¡G §Ú§Ë¿ù³æ¦ì¡A¦ý§Úµo²{²{³õ©xª©ESMO slide¤]¬O¿ùªº¡]§ÜÅé®Ä»ù1¡G160ªºmPFSªº³æ¦ì¡^ ASCO¡GNo.14¥´§¹¤E¾¯ªºmPFS¡]weeks¡^:822¡GPlacebo=90.1¡]80.4-NA¡^¡G72.6¡]58.0-97.1¡^ ESMO¡GNo.9¥´§¹¤E¾¯ªºmPFS¡]months¡^:822¡GPlacebo=20.7¡]18.5-NA¡^¡G16.7¡]13.3-22.3¡^ ASCO¡GNo.16§ÜÅé®Ä»ù1¡G160ªºmPFS¡]weeks¡^:Responder¡GNon-responder¡GPlacebo=48.4¡]40.3-76.4¡^¡G23.9¡]16.3-24.4¡^¡G40.0¡]31.6-49.1¡^ ESMO¡GNo.14§ÜÅé®Ä»ù1¡G160ªºmPFS¡]weeks**¡^:Responder¡GNon-responder¡GPlacebo=11.1¡]9.3-17.6¡^¡G5.5¡]3.7-5.6¡^¡G9.2¡]7.3-11.3¡^ **¡G³oùØ©xª©À³¸Ón§ï¬°months¤~¹ï¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/26 ¤U¤È 10:50:24²Ä 2738 ½g¦^À³
|
ESMO Slide Data ¦³§ó·s³á¡I¥J²Ó¬Ý. ASCO¡GNo.14¥´§¹¤E¾¯ªºmPFS¡]months¡^:822¡GPlacebo=90.1¡]80.4-NA¡^¡G72.6¡]58.0-97.1¡^ ESMO¡GNo.9¥´§¹¤E¾¯ªºmPFS¡]months¡^:822¡GPlacebo=20.7¡]18.5-NA¡^¡G16.7¡]13.3-22.3¡^ HR¨SÅÜ¡C ASCO¡GNo.16§ÜÅé®Ä»ù1¡G160ªºmPFS¡]months¡^:Responder¡GNon-responder¡GPlacebo=48.4¡]40.3-76.4¡^¡G23.9¡]16.3-24.4¡^¡G40.0¡]31.6-49.1¡^ ESMO¡GNo.14§ÜÅé®Ä»ù1¡G160ªºmPFS¡]months¡^:Responder¡GNon-responder¡GPlacebo=11.1¡]9.3-17.6¡^¡G5.5¡]3.7-5.6¡^¡G9.2¡]7.3-11.3¡^ HR¨SÅÜ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/26 ¤U¤È 09:11:37²Ä 2737 ½g¦^À³
|
§Æ·æ.³Á§Jªü·æ³Õ¤h»¡ªºCombination therapy . Vaccine-based therapies may induce T-cell infiltration into the tumor . Increased T-cell infiltration improve response to immune checkpoint inhibitors ½Ð°Ñ¦Ò T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142435/ |
|
|
·|û¡GµL¹Ð10141268 µoªí®É¶¡:2016/10/26 ¤U¤È 07:59:11²Ä 2736 ½g¦^À³
|
³¯°|¤hÁ¿ªº¸ò²Ä3ÂI¤@¼Ò¤@¼Ë¡A¥u¬O³¯¯S§O±j½Õ¤px´Á¡A¦pªG§Aµo´§·Q¹³¤O¡A¬°¦ón¥´À£¡A¬°¦ónÀ~´²¤á¡A¬°¦ó¥~¸ê«ùªÑ«ùÄò¼W¥[¡A½T¦³°OªÌ»¡¥L¤£§ë¸ê¨Ï¥¢±Ñªº¤½¥q |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/26 ¤U¤È 07:26:11²Ä 2735 ½g¦^À³
|
§ë¼v¤ù P-20¶ ¤U¥b³¡ Future direction .Future trials planned based on the efficacy and and safety seen in this study .Future clinical trials will assess the effect: .In patients who generate an immune response who continue on treatment |
|
|
·|û¡Gccc10136060 µoªí®É¶¡:2016/10/26 ¤U¤È 06:46:27²Ä 2734 ½g¦^À³
|
¯E¹©¦b¼Ú¬w¸~½FÂå¾Ç¦~·|¡]ESMO¡^Á|¿ìªº±Ð¨|¬ã°Q·|¦¨¥\µ²§ô¡A¨Ã«Ü°ª¿³¯à´£¨Ñ¦¹©ó2016¦~10¤ë10¤é¬P´Á¤@¡B¦b¤¦³Áô¥»«¢®ÚÁ|¿ìªº¬ã°Q·|¼v¤ùºëµØ¡C ¦b¦¹¤@¥DÃD¬°¡u°w¹ïGlobo ¨t¦CÁÞªº¹ñ·sÀù¯g¥D°Ê§K¬ÌÀøªkAdagloxad Simolenin¡vªº¬ã°Q·|¤¤¡A»P·|¾ÇªÌ±´°Q¤F¶}µo¤¤ªº¥D°Ê§K¬ÌÀøªkAdagloxad Simolenin¡]OBI-822¡^¡A¨ä°w¹ï Globo ¨t¦C§Üì¦bªvÀøÂಾ©Ê¨ÅÀù»P¨ä¥¦Àù¯gªº¼Æ¾Ú¡A¨ÃÀ˵ø¦¹Àù¯g¥D°Ê§K¬ÌÀøªkªº¥¼¨ÓÀ³¥Î¡C ¬ã°Q·|¥Ñ¬Ó®a°¨´µµnNHS«H°U°òª÷·|©MÛ´°Àù¯g¬ã¨s©Òªº¨ÅÀùÂå¾Ç¡B¸~½F¤º¬ì±Ð±Â¡A¦P®É¬O^°ê¬Ó®a¤º¬ìÂå¾Ç°|ºaÅA·|ûªº´µ¸¦ªâ¡P¬ù¿«´µ¹yÂå¾Ç³Õ¤h¥D«ù¡C»P·|°ê»Ú¾ÇªÌ¥]¬AªL¤fªø©°¬ö©ÀÂå°|·F²ÓM»PÂàĶÀù¯g¬ã¨s©Òªº¯S¸uÁ¿®y±Ð±Â³¯¹a¬zÂå¾Ç³Õ¤h¡F¥[¦{¬¥§üÁF¶ëÁ[º¸.¶ø´µ´Üºî¦XÀù¯g¬ã¨s©Òªº¸~½FÂå¾Ç±M®a§Æ·æ.³Á§Jªü·æÂå¾Ç³Õ¤hº[¤½½ÃºÓ¤h ¡A¥H¤Î¥x¤jÂå¾Ç°|¥~¬ì±Ð±Â¡B¥x¤jÂå°|¨Å©ÐÂå¾Ç¤¤¤ß¥D¥ô¶À«T¤ÉÂå¾Ç³Õ¤h¡C ¬ã°Q·|ºëµØ¼v¤ù¥i³z¹L¥H¤U³sµ²Æ[¬Ý: www.dinkcs.co.uk/obipharma/highlights/ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/10/26 ¤U¤È 02:07:22²Ä 2733 ½g¦^À³
|
·PÁÂCliff¤j¤j ¤p§Ì¨SÔ£±M·~ ¤£¹L¦´N¦³¦P·P |
|
|
·|û¡Gdennislu10137962 µoªí®É¶¡:2016/10/26 ¤W¤È 11:30:01²Ä 2732 ½g¦^À³
|
·PÁÂCliff¤j¤j¡A§Æ±æ§A¦h¦hµo¤å¡A·PÁ¡B·PÁ¡B¦A·PÁÂ!! |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/26 ¤W¤È 11:27:25²Ä 2731 ½g¦^À³
|
°ò¨È·s¼t¸¨¦¨¡A³¯°ÆÁ`²Î¯¸¥x |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/10/26 ¤W¤È 11:27:22²Ä 2730 ½g¦^À³
|
ì¨Ó¬O³oÓ... 105¦~10¤ë26¤é Á`²Î¬¡°Ê¦æµ{ µL¤½¶}¦æµ{ °ÆÁ`²Î¬¡°Ê¦æµ{ 10¡G00 °Ñ³X¡u°ò¨È¬Ì]¦Ë¥_¼t¡v Á`²Î©²¬¡°Ê 09:00¡ã11:30 Á`²Î©²¶}©ñ°ÑÆ[(¤J¤f³ø¨ì³B¡G³Õ·R¸ô¡BÄ_¼y¸ô¤f) |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/10/26 ¤W¤È 11:21:44²Ä 2729 ½g¦^À³
|
¥xÁÞ¤j¨¯W¤F ¤µ¤Ñ¸g¹L¦Ë¥_¥ÍÂå¶é°Ï ¬Ý¨£¸ô¤f³\¦h¥æºÞĵ¹î §Æ±æ¬F©²¤j¤j«ùÄò¬°¥Í§Þ¤½¥q¥´®ð ¤]´Á«Ý±`±`Å¥¨ì¯E¹©ªº¦n®ø®§ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/26 ¤W¤È 11:06:12²Ä 2728 ½g¦^À³
|
¤j³¡¤Àªº¯E¤Í³£¯à±µ¨ü¬ì¾Çªºµ²ªG ¦Ó¤£¬O¥u¦³±¡·Pªº¤ä«ù 1 ¥»ºô¯¸¶K¤å¤U±¤w§iª¾ : ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u! 2 ¬Ý¦h¬ÝªÅ³£À³¥]®e´L« ¤U±³o¨Ç¾ÇªÌ, ±M®a, ¥Í§Þ¤½¥q, §ë¸ê¾÷ºc, ¸~½FÂå¾Ç·|, ¬F©²³æ¦ìµ¥¤]¬Ý¦n¬Ý¦h, ¬°¦ó¥i¤ñ§Ô ¨ü¥L̬ݦn¬Ý¦h? ¤£§«¥ý¶KÓ¤å±q a ¨ì I ÄY¥[§å§P¬°¤°»ò¥L̹ï¥xÆW¦Û¤v¬ãµoªºÃÄ¥i¥H¬Ý¦n¬Ý¦h, ¨ºùؤ£¹ï, ¥un¥ß½×¦³ ¾Ú,¤j®a³£Åwªï (¬Ý¦hªº²³¤j¤j¸ê°T¤]¬O±q¤¤Àò±o) a ¯E¹©¥Í§Þ¤½¥q: ¸Ñª¼«á¤]»{¬°¬O¦¨¥\ªºÁ{§É¹êÅç, ±µ¨ü¬Ì]ª`®g¥BªvÀø´Á¶¡´¿¥X²{¹ïOPT-822²£¥ÍIgG§ÜÅé®Ä»ù >=1:160 ªº¯f±w¡A¨äPFS¤Î´Á¤¤OS©úÅãÀu©ó¦w¼¢¾¯²Õ¤Î¥¼²£¥Í§K¬Ì¤ÏÀ³ªº¯f±w,´Á¤¤OS ¨ã§ïµ½ÁͶÕ,µ²ªG¥O¤H¿³¾Ä, Á{§É¶i ®i³W¹º¥þ±¥[³t,¦n¸ê®Æ¯d¦bª¾¦W´Á¥Zµoªí b ¯Î°|ªø:¤]»{¬°³o¦¸¥xÆW¤T´Á¬O¬ì¾Ç¤Wªº¦¨¥\ c 2013¦~ĬÃh¤¯³Õ¤h: ²Ä¤TÓ¦a¥½u¥@¥NªºÁÞ¤À¤l·sÃÄ¡A¥xÆW«h«Ü¦³¾÷·|²æ¿o¦Ó¥X¡C d ³¯¨}³Õ°|¤h¬Æ¦Üª½±µªí¹FÁÞ¤À¤l·sÃĤw¸g¦¨¥\ ,¦³²£¥Í¾aÅ骺±Ú¸s¬O¥þÂS¥´, ¬ü°êFDA ·QÀ°§U¯E¹© e MSCI ¤]¬Ý¦h F ¥Ñ¬ü°êÁ{§É¸~½FÂå¾Ç·|: Âå¾Ç³q°T¡A¯S§O¤¶²Ð¨ã®i±æ©Êªº¨ÅÀù·sÀøªk¡F¥xÆW¯E¹©(4174)©Ò´£¥XªºOPT-822/ OPT-821²Ä¤G/¤T ´ÁÁ{§É¸ÕÅ禨ªG¡A¥ç¦b¸Ó¥Z³ø¾Éªº¤TºØ¨ÅÀù·sÀøªk¤§¦C G ¸gÀÙ³¡:2012¦~12¤ë¥xÆW¯E¹©¥Í§ÞOPT-822/821ªvÀøÂಾ©Ê¨ÅÀùPhaseII/IIIÁ{§É¸ÕÅç¶}µopµe(²Ä¤G¶¥¬q)Àò¸gÀÙ³¡¸É§U7,512¸U8,000¤¸ H ¥Íª«²£·~µo®i¨ó·|:¥xÆW¯E¹©ºaÀò2013³Ç¥X¥Í§Þ²£·~¼ú¼ç¤O·s¨q¼ú,¯E¹©±q¹êÃҺ믫¥Xµo¡A«i©ó¬D¾ÔÃøªv¯e¯f¡An¬°¯fWªÌ§ä´M©ú¤Ñ§Æ±æ I Hope Rugo,MD:³o¶µ¬ã¨sÅã¥Ü¡A¹ï¦³§K¬Ì¤ÏÀ³ªí²{ªÌ¤w¹F¨ì¥DnÀø®Ä«ü¼Ð¡A¦P®Éµý¹ê¥H§K¬ÌÀøªkªvÀø¨ÅÀù±wªÌªº¦³®Ä©Ê¡C ¥x¤jÂå¾Ç°|¥~¬ì±Ð±ÂOBI-822 ¦h°ê¦h¤¤¤ßÁ{§É¸ÕÅçpµeÁ`¥D«ù¤H¶À«T¤É¸ÕÅçµ²ªGÅã¥Ü¡AOBI-822¯àÅý²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌÀò ±o©úÅã®Ä¯q¡C |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/10/26 ¤W¤È 09:45:09²Ä 2727 ½g¦^À³
|
·PÁÂCliff¤j¤j¡A±zªº¤å³¹Åã²{¼ö¤ß±M·~ÄYÂÔ»Pµ½¨}¡A¥O¤H´Ü¨Ø¡C |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2016/10/26 ¤W¤È 09:14:58²Ä 2726 ½g¦^À³
|
ÁÂÁÂcliff¤j,«Ü¤¤ªÖ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/26 ¤W¤È 09:13:07²Ä 2725 ½g¦^À³
|
ÁÂÁÂCliff ¤j¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/26 ¤W¤È 08:30:12²Ä 2724 ½g¦^À³
|
·PÁ Cliff ¤j®¦¼w ¤pªº·P¨ü¨ì±zªºªÍµÆ¥mÀ{ ±zªº¤j¤å ¹ï¤pªº¦Ó¨¥ µÛ¹ê¦nÃø¾\Ū °£¤Fª¾ÃÑ©Ê¥~ ÁÙ¦³Áô³ë©Êªº·t¥Ü ¥²¶·±ÀºV¦A¤T «ÜºF·\ ¤pªº°£µLªk´x´¤±z¨¥¥~¤§·N ¬Æ¥B³s¤ä«ù©ÊÀøªk³£¼Ò¼Ò½k½k¡@ ¦óªp»P822§@³sµ² ¤pªº·Q ¤j³¡¤Àªº¯E¤Í³£¯à±µ¨ü¬ì¾Çªºµ²ªG ¦Ó¤£¬O¥u¦³±¡·Pªº¤ä«ù ¤pªº¥H«á·|ÂÔ¨¥·V¦æ ¤£°µ¤Ó¸Ø±iªº±À´ú ÁÂÁ±z! ¦³¤@½g¤¶²Ð¤ä«ù©ÊÀøªk ´£½Ð¤j®a°Ñ¦Ò ÁÂÁ¤j®a! Understanding Maintenance Therapy http://www.cancer.net/navigating-cancer-care/how-cancer-treated/understanding-maintenance-therapy |
|
|
·|û¡Gºô¸ô¥@¬É10141607 µoªí®É¶¡:2016/10/26 ¤W¤È 08:01:11²Ä 2723 ½g¦^À³
|
·¥¬°»{¦Pcliff¤jªº¬Ýªk ³oùتº°Q½×¥»¨Ó´N·|³Q«Ü¦hªº¤H·í°µ¶R½æªÑ²¼ªº°Ñ¦Ò¸ê°T ¤£µM´²¤á¬On±qþ¸Ì±o¨ì³o»ò¦hªº¤½¥q¸ê°T ¦Ó±q³oùرo¨ì¤F³o»ò¦hªº¼ÖÆ[¸ê°T ¤Sn³Q§åµû¦¨ªÑ²¼ªº¶R½æ¬O¦Û¤vªº¨Mµ¦ ·íµM¬O¦Û¤v®Ú¾Ú¤Ó¼ÖÆ[ªº¨¥½×ª^³ò°µ¤F¿ù»~ªº§ë¸ê¨Mµ¦ ²{¦b§Ú¤]»{¦Pcilff¤jªº°Q½×´N¬O¹ê¨Æ¨D¬O Ó¤Hªº©Òªþ¥[ªº±À´ú©Î¬O´Á³\¹L¥h¤w¸g¤Ó¦h¤F ¤°»òªÑ»ù¸ò¤§«e¤j¥ß¥ú¨«ªkÃþ¤ñµ¥µ¥ªº´N¤£¥²¤F ½×¾Â¤w¸g¤£¯Ê®M¨cºG«ªº´²¤á¤F |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/26 ¤W¤È 07:24:13²Ä 2722 ½g¦^À³
|
¦pªG¬I¥´ Cyclophosphamide ¤]¯à²£¥Í§ÜÅé, ©Ò¥H¹ï·Ó²Õ¤]¦³¬Û·íÀø®Ä ¤£ª¾¹D³o¥ó¨Æ¦b Cyclophosphamide Á{§É¹êÅç®É, ¬O§_¦³³Qµo²{? ¤£ª¾¹D Cyclophosphamide Á{§É¹êÅç®É, ¦s¬¡²vª¬ªp¦p¦ó? ¬O§_©M OBI ³o¦¸ªºµ²ªG¦³¬Û¦üªºÁͶÕ? |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/10/26 ¤W¤È 01:34:35²Ä 2721 ½g¦^À³
|
·PÁÂcliff¤jÄYÂÔ¡A¹ê¨Æ¨D¬OªººA«×¡A¨ü±Ð! |
|
|
|